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SUMMARY
Endogenous opioid peptides have a profound inhibitory 
influence on the secretion of luteinizing hormone. Recently, 
it has been proposed that a reduction in the activity of 
these peptides in the hypothalamus may be the initial neural 
stimulus for the generation of the preovulatory luteinizing 
hormone surge which induces ovulation. Furthermore/ this 
action may involve alterations in the activity of 
monoaminergic neurones which synapse on the luteinizing 
hormone-releasing hormone neurones in the hypothalamus. This 
investigation was undertaken to determine the effects of 
exogenous agonists of various opioid receptor subtypes on,
(i) the magnitude of the preovulatory luteinizing hormone 
surge, and (ii) the activity of monoaminergic 
neurotransmitters in the hypothalamic areas which contain 
luteinizing hormone-releasing hormone neurones at the time 
when the surge is initiated.
First, agonists of n-, k -  and a-opioid receptors, and an 
opioid antagonist, were administered intraperitoneally to 
pro-oestrous rats at 12.30h. The animals were decapitated at 
either 14.3Oh or 18.0Oh on the same day. Trunk blood was 
collected, and the hypothalamic areas were microdissected.
In the second set of experiments, the minimum dose of each of 
the agonists which reduced the surge were co-administered (as 
above) with the minimum dose of the antagonist which
XV
increased the surge. The rats were subsequently treated as in 
the first set of experiments.
The third set of experiments involved intraperitoneal 
injection of the opiates at 12.30h on pro-oestrus, and the 
rats being returned to the Animal Unit for daily vaginal 
lavages.
Finally, rats were injected, as in the second set of 
experiments, anaesthetized and serial blood samples collected 
throughout the late afternoon and early evening of pro­
oestrus .
It was found that all three agonists could reduce the 
magnitude of the preovulatory surge. However, the o-agonist
failed to do so significantly. Prevention of the surge on 
pro-oestrus by administration of the agonists did not result 
in the surge being delayed by 24 hours. The antagonist 
markedly increase the surge amplitude, and this was inhibited 
by each of the agonists.
Inhibition of the luteinizing hormone surge was consistently 
associated with elevated noradrenaline activity in the medial 
preoptic area and the median eminence at 14.30h. Enhancement 
of the surge amplitude by the antagonist occurred in 
association with increased serotonin activity in the same two 
areas, and, on some occasions, with increased dopamine 
activity in the medial preoptic area.
XVI
In conclusion, there is a heterogeneous population of 
receptors which, when activated, suppress the secretion of 
luteinizing hormone-releasing hormone. It appears that this 
inhibition may involve alterations of the activity of 
noradrenaline projections to the luteinizing hormone- 
releasing hormone neurones in the medial preoptic area and 
median eminence. Furthermore, opioid antagonist enhancement 
of the surge may be mediated by serotonin projections to 
these neurones in the same two areas.
INTRODUCTION
2OESTROUS CYCLE OF THE RAT
As in the human, the rat is a spontaneous ovulator, but has a
very short oestrous cycle of four or five days. This is
comprised of two or three days of dioestrus and one each of
pro-oestrus and oestrus (Long and Evans, 1922).
Throughout early dioestrus plasma oestradiol-17(5 (E2) 
secretion from the Graafian follicle is low, and increases 
slowly during late dioestrus. On the morning of pro-oestrus, 
E2 reaches its peak circulating levels. This is the primary 
stimulus for the preovulatory luteinizing hormone (LH) surge 
from the anterior pituitary on the afternoon of pro-oestrus. 
The causal relationship between E2 levels and the LH surge 
has been clearly demonstrated by the ability of antiserum to 
E2 to abolish the surge (Ferin et al, 1970). The LH surge 
itself stimulates ovulation, which occurs soon after midnight 
between pro-oestrus and oestrus.
The profiles of secretion of LH, E2 and progesterone (P) 
during the oestrous cycle are illustrated in Figure 1.
In general, follicle stimulating hormone (FSH) is secreted at 
low levels throughout the oestrous cycle, except for a marked 
increase which occurs around the time of ovulation. This FSH 
surge accelerates the development of follicles for the 
succeeding cycle.
If mating does not occur, the corpora lutea do not become 
functional and only a small amount of P is secreted. No 
luteal phase occurs and new follicles are ovulated as soon as 
they are sufficiently mature.
Luteinizing Hormone Secretion Profile During the 
Oestrous Cycle
There are two patterns of LH release that typify the 
secretion of this hormone over the oestrous cycle: basal (or 
episodic) and surge (or phasic) release. LH is not secreted 
at a steady rate, but rather as a series of ultradian pulses. 
The frequency and amplitude of these pulses depend upon the 
time of day (circadian) and the stage of the oestrous cycle 
(cyclic) (Leipheimer et al, 1985).
When rats are kept in a lighting schedule of 14 hours light 
and 10 hours dark, the frequency and amplitude of the LH 
pulses increases on pro-oestrus. This initiates a slow rise 
in plasma LH concentrations approximately seven hours after 
the onset of the light. The increase in plasma LH levels 
continues and accelerates to a plateau some two to four hours 
later (Blake, 1976). This is the characteristic preovulatory 
LH surge.
4The Steroid-Primed Ovariectomized Rat as a Model for 
the Preovulatory LH Surge
Ovariectomy removes the gonadal steroid feedback to the 
hypothalamus and anterior pituitary and results in the loss 
of oestrous cycles. However, the administration of E2 (and P) 
to ovariectomized (OVX) rats can stimulate a preovulatory- 
type LH surge, which can be timed more reliably than the 
spontaneous surge of intact animals. The E2 + P-primed OVX 
model has been used extensively in investigations of the 
control of surge release of LH.
CENTRAL REGULATION OF LUTEINIZING HORMONE SECRETION
Neural regulation of anterior pituitary hormone secretion was 
first demonstrated by the ability of coitus to induce 
ovualtion in rabbits (Brook, 1938). Although the existence of 
a portal circulation between the hypothalamus and pituitary 
had earlier been demonstrated (Popa and Fielding, 1930), it 
was not until 1947 that the existence of a neurovascular link 
between the two was postulated (Green and Harris, 1947).
The involvement of a neural signal in the control of the rat 
LH surge was first demonstrated by pharmacological 
manipulation on the afternoon of pro-oestrus. The LH surge 
was delayed by 24 hours (Everett et al, 1949), but only if 
the drugs were injected during a particular time period. Thus 
the existence of a 'critical period' was postulated, during 
which the neural stimulus for the surge occurred. After this
time, the surge was found to be resistant to pharmacological 
blockade.
It has since become clear that the anatomical site of this 
neural stimulus lies within the hypothalamus. In 1955, the 
first demonstrations of hypothalamic releasing factors were 
reported, with the isolation of a peptide which could 
stimulate the release of adrenocorticotrophic hormone (ACTH) 
from the anterior pituitary (Guillemin, 1955; Saffran and 
Schally, 1955). Later, the existence of a hypothalamic 
peptide with a similar releasing action on LH was determined 
(Guillemin et al, 1963; Schally and Bowers, 1964).
The Hypothalamus
The hypothalamus consists of neural tissue situated beneath 
the thalamus and is composed of two major areas: the medial 
and lateral areas (Raisman and Field, 1971).
The medial area is itself subdivided into three groups
(i) an anterior group of nuclei consisting of the anterior 
hypothalamic area (AHA), medial preoptic area (MPO), 
paraventricular nucleus (PVN), suprachiasmatic nucleus (SCH) 
and the supraoptic nucleus (SON),
(ii) a tuberal group of nuclei comprised of the ventromedial 
nucleus (VMN), dorsomedial nucleus (DMN), periventricular
6nucleus (PeVN), arcuate nucleus (ARN) and the lateral tuberal 
nuclei.
(iii) a posterior group of nuclei formed by the posterior 
hypothalamic nucleus , the supramammillary and 
tuberomammillary nuclei and the periventricular system.
The lateral hypothalamic area forms the lateral border of the 
hypothalamus and is the site at which the medial forebrain 
bundle enters the hypothalamus. This nerve tract contains the 
projections between the hypothalamus and the rest of the 
brain.
The median eminence (ME) lies directly below the ARN in the 
hypothalamus and is the final common pathway through which 
the neural control of LH secretion is exercised (and that of 
the other anterior pituitary hormones). The nature of this 
control is addressed in detail below.
Figure 2 illustrates the anatomical relationship of the 
hypothalamus and the anterior pituitary.
Luteinizing Hormone-Releasing Hormone
The direct stimulus for the secretion of LH from the anterior 
pituitary, including the preovulatory surge, is luteinizing 
hormone-releasing hormone (LHRH or gonadotrophin-releasing 
hormone; GnRH) since immunoneutralization of LHRH results in 
abolition of the rat ovulatory cycle (Fraser et al, 1978).
7Ovulation Ovulation
<1)
>Q)
Q)
Cop
CO
Pro-oestrus Oestrus Early Late Pro-oestrus Oestrus
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Figure 1. Schematic representation of the hormone changes in 
the systemic circulation of the rat throughout the oestrous 
cycle* From: Short, 1972.
Hypophyseal 
portal veins 
(long portal veins)
Prim ary plexus 
in median eminence
A rteria l supply
Secondary plexus 
in pars distalis
Venous drainage
Figure 2. Diagram of the anatomical basis of the neuro- 
humoral relationship between the hypothalamus and the 
anterior pituitary (pars distalis). From: Perry, 1971.
8LHRH is released from the ME into the primary plexus of the 
hypophyseal portal blood system, where it is transported 
through portal veins to a second capillary bed in the 
anterior pituitary. Here it enters the anterior pituitary and 
stimulates the release of both LH and FSH from gonadotrophs.
The peptide sequence of LHRH was first determined from 
porcine hypothalami (Schally et al, 1971) and, soon 
afterwards, from ovine hypothalami (Burgess et al, 1971) as 
the decapeptide: pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly- 
NH2 • To date only one molecular form of mammalian LHRH has 
been isolated, despite the characterization of several 
molecular forms from non-mammalian vertebrates (King et al,
1988).
In the rat, high numbers of perikarya and fibres containing 
LHRH have been visualized in the MPO and high concentrations 
of LHRH itself have been found in the ARN, SCH and ME; in the 
latter two areas the LHRH was restricted to fibres alone 
(Palkovits et al, 1974; Shivers et al, 1983a; Witkin et al, 
1982).
LHRH levels in portal blood have been measured and correlated 
to the LH surge in anaesthetized (Sarkar et al, 1976) and 
conscious rats using the push-pull perfusion technique 
(Levine and Ramirez, 1982). These experiments demonstrate 
clearly that LHRH release is increased on the afternoon of 
pro-oestrus and that this increase precedes the LH surge.
9A luteinizing hormone-release inhibiting factor has been 
isolated from rat hypothalamus and shown to prevent LHRH- 
stimulated LH release (Hwan and Freeman, 1987), It is 
postulated that progesterone (P) may increase the amplitude 
of the LH surge by freeing the pituitary gonadotrophs from 
tonic restraint of the release-inhibiting factor. However, 
administration of a P antagonist has been shown to enhance 
the activation of LHRH neurones on the afternoon of pro­
oestrus (Lee et al, 1990). It would appear that P increases 
the amplitude of the E2-elicited surge by enhancing LHRH 
neurone response to E2 and, perhaps, also by reducing the 
outflow of an LH-release inhibiting factor.
In addition to its effects at the hypothalamic level, E2 also 
increases pituitary responsiveness to the LHRH signal at the 
time of the preovulatory LH surge. This is achieved by 
increasing LHRH receptor numbers, at least partially, by 
increasing the number of LHRH-receptive cells (Lloyd and 
Childs, 1988).
NEUROTRANSMITTERS CONTROLLING LHRH SECRETION
According to one theory, the LHRH neurones intrinsically 
release LHRH and the profile of secretion is modified by 
external influences (Estes et al, 1982). However, much 
evidence now points to basal and surge release of LHRH being 
orchestrated by inputs from other neurones.
10
LHRH neurones concentrate neither E2 (Shivers et al, 1983b) 
nor P (Fox et al, 1990) and so the influence of these 
steroids must be indirect. E2 excites some non- 
tuberoinfundibular neurones in the ARN (Nishihara and Kimura,
1989) and spontaneous electrical activity in the ARN is 
increased on the afternoon of pro-oestrus (Yeoman and 
Jenkins, 1989). Presumably, the ARN is the site of 
interneurones which are responsible for the monitoring, and 
transmitting of information on the steroid milieu to the LHRH 
neurones.
Noradrenaline
A large volume of evidence suggests that noradrenaline (NA) 
may be the major neurotransmitter which directly stimulates 
LHRH neurones to initiate the LH surge.
Three major NA systems project to the hypothalamus; the locus 
coeruleus (LC), an ascending NA tract with projections to the 
MPO and ME via the dorsal noradrenergic bundle (Jones and 
Moore, 1977), and the dorsal and lateral tegmental systems 
which innervate many areas of the hypothalamus including the 
SCH, MPO, ME and ARN through the ventral noradrenergic bundle 
(VNAB; see Figure 3).
There is close apposition of NA nerve terminals and LHRH 
cells in the MPO and to a lesser extent in the ME and ARN 
(McNeill and Sladek, 1978), and catecholaminergic neurones 
innervate LHRH neurones in the MPO (Watanabe and Nakai,
1987). Thus, it appears that there are direct functional
cortex hippocampus dorsal bundle
11
cerebellum
nucleus 
tractus solitarius
hypothalamus
stria terminalis
medial 
forebrain bundle ventral bundle
locus coenieus to spinal cord 
Figure 3 (a). Saggital section showing the noradrenergic
projections in the rat brain. From: Rang and Dale, 1987.
frontal cortex
anterior 
limbic cortex
corpus striatum nigrostriatal pathway
median eminence
substrantia nigra
nucleus accumbens
olfactory tubercle
arcuate nucleus mesolimbic pathway
Figure 3 (b). Saggital section showing the dopaminergic 
projections in the rat brain. The main groups of perikarya 
and fibre tracts are shown in black. Grey areas show the 
location of axon terminals. From; Rang and Dale, 1987.
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connections between the two systems. Receptors for NA are 
divided into two major classes, a- and p-adrenoreceptors,
based on the relative affinities of various adrenergic 
agonists and antagonists for each. These are further 
subdivided into ai- and <22- and pi- and p2-adrenoreceptors on
the same basis. All four of the above classes of
adrenoreceptors have been visualized in the hypothalamus
(Leibowitz et al, 1982). Both types of a-adrenoreceptor were
found in highest concentrations in the MPO, ME and ARN while 
P-adrenoreceptors (predominantly P2) were most common in the
MPO.
NA activity in discrete hypothalamic nuclei was first 
investigated by Crowley and co-workers (Crowley et al, 1978). 
Later, it was shown that, during the E2-induced LH surge in 
OVX rats, increased NA turnover in the SCH, MPO, ME and ARN 
was associated with rising or peak levels of circulating LH 
(Wise et al, 1981). This relationship was subsequently found 
to hold for NA turnover in the ME and the preovulatory LH 
surge, while in the MPO increased NA turnover was associated 
with peak but not rising LH levels (Ranee et al, 1981). 
Furthermore, prevention of increased NA turnover using 
phenobarbital was shown to be associated with failure of the 
LH surge on pro-oestrus (Ranee and Barraclough, 1981).
There are also reports of inhibitory effects of NA on the LH 
surge. Electrochemical stimulation of the locus coeruleus 
(LC), on pro-oestrus blocked the LH surge (Dotti and 
Taleisnik, 1982); an effect which could be prevented by
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administration of a p-adrenergic antagonist (Dotti and 
Taleisnik, 1984),
Similar work later showed that the release of LHRH induced by 
direct stimulation of the MPO could be enhanced by LC 
electrical stimulation (Gitler and Barraclough, 1987) and 
that this could be prevented by a- but not p-adrenoreceptor
antagonists (Gitler and Barraclough, 1988). Furthermore, a 
stimulatory p-adrenergic component has been identified in the
control of the LH surge (Al-Hamood et al, 1985). It would 
appear that NA can influence LHRH secretion in both a 
positive and a negative fashion, the former action being 
mediated by a- and p-, and the latter by p-adrenoreceptors.
The current consensus is that NA is stimulatory to LHRH 
secretion in the presence of E2 but inhibitory in its absence 
(for review see Ramirez et al, 1984).
Our understanding of synaptic transmission cannot explain 
this change in NA actions on LHRH secretion since excitatory 
synapses cannot become inhibitory and vice versa. Therefore, 
other influences must be postulated to explain the complex 
behaviour of NA in the control of LHRH secretion; these will 
be reviewed later in the Introduction.
While there can be little doubt of the influence of NA on 
LHRH secretion, it is difficult to reconcile the temporal 
relationship between increasing NA turnover in hypothalamic 
nuclei containing LHRH neurones with the premise that this is 
the initial neural stimulus for the preovulatory LH surge.
Depolarization
Transmitter 
precursor / Precursor
Degradation 
products j
v- Inactivated transmitter
Figure 4. The main processes involved in synthesis, storage 
and release of the aminergic neurotransmitters (including NA, 
DA and 5HT): (1) Uptake of transmitter precursor by nerve 
terminals, (2) Synthesis of transmitter in nerve terminals, 
(3) Storage of transmitter in releasable form, (4) 
Degradation of surplus transmitter within nerve terminals,
(5) Depolarization of nerve terminal by propagated action 
potential, (6 ) Influx of Ca2+ ions in response to 
depolarization, (7) Release of transmitter, (8 ) Diffusion of 
transmitter to post-synaptic receptors, (9) Interaction with 
receptors and production of post-synaptic effect, (1 0) 
Inactivation of transmitter within synaptic cleft, (11) 
Reuptake of transmitter or of degradation product by nerve 
terminals, (12) Interaction of transmitter with pre-synaptic 
receptors. From: Rang and Dale, 1987.
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Figure 5. Biosynthetic pathway of the catecholamines showing 
some drug manipulations that can alter their synthesis or 
action. From: Ramirez et al, 1984.
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Figure 6 (a). The main pathways of NA metabolism in the 
brain and periphery. From Rang and Dale, 1987.
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Figure 6 (b). The main pathways of DA metabolism in the 
brain. From: Rang and Dale, 1987.
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Dopamine
Neurones of the tuberoinfundibular dopamine (DA) system 
originate in the ARN and PeVN, and project to the internal 
and external ME (Lindvall and Bjorklund, 1982). Those that 
terminate in the external layer secrete DA into the 
hypophyseal blood system to inhibit prolactin (PRL) secretion 
from anterior pituitary lactotrophs (MacLeod, 1976). However, 
those terminating in the internal layers appear to be 
involved in controlling the secretion of releasing hormones, 
including LHRH (Sawyer and Clifton, 1980). Ninety per cent, 
of the tyrosine hydroxylase-containing cells of the ARN 
express P receptors (Fox et al, 1990), which suggests that 
these cells may be involved in mediating the feedback effects 
of P to the hypothalamus.
!
I
A second group of DA neurones project to the hypothalamus; 
the incertohypothalamic DA tract. This is of 
extrahypothalamic origin and projects principally to the MPO. 
E2 + P priming has been demonstrated to have a positive 
feedback effect on incertohypothalamic DA neurones (Sanghera 
et al, 1991). Thus both DA systems may be involved in the 
feedback effects of steroids to elicit the LH surge.
Receptors for DA are currently divided into three classes:
Di, D2 and D3. DA receptors have been visualized in the 
hypothalamus (Leibowitz et al, 1982). The ME and ARN were 
found to contain a moderate density of these receptors, while 
the SCH and MPO were only sparsely populated.
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Conflicting evidence has been provided concerning the role of 
DA in the regulation of LHRH secretion, with both stimulatory 
and inhibitory actions being reported (Kalra and Kalra, 1983, 
for review). There appears to be an anatomical basis for the 
differential actions of DA on the release of LHRH. DA is 
stimulatory in the MPO (Kawakami et al, 1975) and zona 
incerta (ZI) (MacKenzie et al, 1988), but inhibitory in the 
ARN and ME (Fuxe et al, 1977). This suggests that the 
incertohypothalamic tract is stimulatory, and the 
tuberoinfundibular tract is inhibitory to LHRH release.
Decreased spontaneous activity of DA neurones has been found 
in the ME on the afternoon of pro-oestrus (Kerdelhue et al,
1989) without administration of drugs altering DA metabolism. 
Furthermore, E2 + P treatment has a positive feedback effect 
on incertohypothalamic neurones (Sanghera et al, 1991). From 
this a physiological role for DA in the control of the LH 
surge can be inferred; a decrease in its inhibitory activity, 
and an increase in its stimulatory activity both contributing 
to the stimulation of the surge.
Serotonin
The hypothalamus is densely innervated by 5HT projections 
from the raphe nuclei (Steinbusch, 1981). Populations of 5HT 
receptors have been visualized in the MPO and ARN in addition 
to several other hypothalamic areas (Biegon et al, 1982), 
including the ME (Villar et al, 1984). 5HT axons terminate on
cortex hippocampus cerebellum
caudate nucleus
thalamus
hypothalamus
medial forebrain bundle
rostral caudal projection
serotonin nuclei serotonin nuclei to spinal cord
Figure 7. Saggital section through the rat brain showing the 
serotoninergic pathways. The main groups of 5HT cell bodies 
and fibre tracts are shown in black. Grey areas show the 
locations of 5HT nerve terminals. From: Rang and Dale, 1987.
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Figure 8 . Metabolic pathways of the biosynthesis and 
breakdown of 5HT. From: Johnston, 1990.
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LHRH neurones in the POA (Kiss and Halasz, 1985). There is 
also evidence of 5HT innervation of tuberoinfundibular 
neurones in the ARN (Willoughby and Blessing, 1987). Thus 5HT 
may have both direct and indirect effects on LHRH neurones.
Inhibition of LH secretion has been reported after injection 
of 5HT into the third ventricle of female rats (Schneider and 
McCann, 1970), and the LH surge has been blocked after 
stimulation of the medial raphe nucleus on pro-oestrus 
(Morello and Taleisnik, 1985); an effect which appears to be 
mediated by GABAergic neurones (Morello et al, 1989).
However, 5HT activity in the ME is increased on the afternoon 
of pro-oestrus (Kerdelhue et al, 1989), and E2 + P treatment 
of ovariectomized (OVX) rats increases 5HT synthesis in the 
MPO (King et al, 1986). This suggests a stimulatory role for 
5HT on LH release. In vitro, P enhancement of the E2-induced
I
[
LH surge in OVX rats can be blocked by 5HT-antagonists (King 
and Kang, 1988). It may be that the progesterone enhancement 
of the LHRH neurone response to E2 is mediated by 5HT.
Endogenous Opioid Peptides
The opium alkaloid, morphine, was first isolated from the 
poppy, Papaver somniferum. by Seturner in 1803 and has long 
been known to have widespread actions on many physiological 
systems (Bernard, 1864).
In the early 1970's a stereospecific binding site for 
morphine was identified (Goldstein et al, 1971) which led to
i
i
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the isolation and characterization of the first endogenous 
opioid peptides (EOP's) discovered, leu- and met-enkephalin 
(Hughes et al, 1975). EOP's have since been extensivley 
investigated and many more have been identified; the major 
classes being roughly divided as endorphins, enkephalins and 
dynorphins/neo-endorphins which are derived from three 
precursors: pro-opiomelanocortin (POMC), pro-enkephalin A and 
pro-enkephalin B (for review see Hollt, 1983).
In addition to the multiplicity of EOP's, there are various 
subtypes of opioid receptor: p,-, k - ,  a-, 6-and e .  There is 
further support for additional divisions of the pi- and k -  
classes (for review, see Dougall, 1988).
The opioid nature of the a-receptor has been brought into
question since cocaine also binds to these receptors (Sharkey 
et al, 1988), and a non-opioid o-receptor has been identified
in the guinea-pig myenteric plexus (Roman et al, 1988). 
However, more recent evidence suggests that a a-opiate 
receptor does exist and is distinct from the non-opioid a- 
receptor (Holtzman, 1989). These opioid (high affinity) a- 
receptors have been visualized in high concentrations in the 
hypothalamus, while PCP-receptors were found to be relatively 
sparse (Largent et al, 1986).
EOP's are ubiquitous neurotransmitters throughout the central 
nervous system (CNS). High concentrations of p-endorphin (P-
END) and leu- and met-enkephalin have been found in the SCH, 
MPO, ME and ARN, as well as in many other hypothalamic and
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Endogenous Ligand K &
p-Endorphin +++ +++ +++
leu-enkephalin + +++ 0
met-enkephalin ++ +++ 0
dynorphin A ++ + +++
Table 1. Affinity of the most common EOPs for the major 
opioid receptor subtypes (highs +++; moderate: ++; lows +; 
none: 0 ).
extrahypothalamic sites. In the SCH and MPO the enkephalins 
were found to be contained in perikarya of EOP neurones 
(Hokfelt et al, 1977; Watson et al, 1982). In the ME, the 
enkephalins (Watson et al, 1982; Williams and Dockray, 1985) 
and p-END (Mezey et al, 1985) were visualized solely in
fibres. Perikarya and fibres of enkephalin- (Hokfelt et al, 
1977; Watson et al, 1982; Williams and Dockray, 1985) and p-
endorphin-containing (Mezey et al, 1985) cells have been 
visualized in the ARN. Several other less common EOPs have 
also been found in these areas (for review see Palkovits, 
1988).
Opioid receptors are widespread in the CNS. High numbers of 
K-receptors have been shown to exist in the preoptic area 
with fewer numbers of fi- and 6-receptors present. In the ME
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CHS Region K 6
Telencephalon
Frontal cortex +++ ++ +
Piriform cortex ++ ++ ++
Entorhinal cortex ++ ++ ++
Amygdala
Central nucleus 0 0 ++
Medial nucleus +++ ++ ++
Lateral nucleus ++++ +++ +++
Hippocampal formation 
Hippocampus +++ ++ +
Dentate gyrus +++ + +
Olfactory tubercle + +++ +++
Nucleus accumbens ++++ ++++ +++
Caudate-putamen ++++ ++++ +++
Globus pallidus + + +
Medial septum +++ + +
Bed nucleus stria terminalis ++ ++ +++
Preoptic area + + ++++
Diencephalon
Hypothalamus
Supraoptic nucleus 0 0 ++
Paraventricular nucleus 0 0 ++
Arcuate nucleus 0 0 ++
Ventromedial nucleus 0 + +++
Dorsamedial nucleus + 0 +++
Lateral hypothalamic area - + 0 ++
Thalamus
Periventricular area 0 0 +++
Central-medial nucleus ++++ + ++
Reuniens nucleus ++++ + ++
Medial habenula +++ + +++
Mesenencephalon
Interpeduncular nucleus ++++ +++ +++
Substantia nigra 
Pars compacts +++ 0 0
Pars reticulata ++ + +
Ventral tegmental area ++ 0 +
Periaqueductal grey + 0 ++
Superior/Inferior colliculi ++++ + ++
Dorsal raphe nucleus ++ 0 ++
Pons/medulla
Parabrachial nucleus +++ 0 ++
Nucleus raphe magnus ++ 0 +
Nuc. retie, gigantocellularis + 0 +
Nucleus tractus solitarius ++++ + +++
Lateral reticular nucleus + 0 +
Spinal trigeminal nucleus +++ 0 ++
Spinal Cord
Substantia gelatinosa
+++ + ++
Table 2. Regional distribution of opioid receptors in the 
rat brain (very dense: ++++; dense: +++; moderate: ++; low: 
+; undetectable;0). From: Mansour, 1988.
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and ARN only K-receptors have been found (Mansour, 1988). P 
treatment in the presence of E2 increases pi-receptor numbers 
in the MPO 27 hours after its administration (Mateo et al, 
1992). Thus the increase in opioid receptor numbers on 
oestrous may result from the action of gonadal steroids and 
so enhance the inhibitory influence of EOPs on oestrus.
EOP perikarya in the ARN concentrate E2 (Jirikowski et al,
1986) and synaptic connections exist between EOP neurones 
projecting from the ARN and LHRH neurones in the MPO (Leranth 
et al, 1988). Thus, EOP neurones could provide the functional 
link between circulating E2 and LHRH neurones. p-END is one
of the most biologically active EOP's and inhibits LHRH 
secretion from the ME (Bicknell, 1985). Morphine prevents 
release of LHRH but does not alter the hypothalamic content 
of LHRH (Mehmanesh et al, 1988). Both morphine and p-END are
able to block the preovulatory LH surge when administered on 
the morning of pro-oestrus (Leadem and Kalra, 1985). The 
ability of the opiate antagonist, naloxone, to advance the 
surge when administered on the morning of pro-oestrus led to 
the postulation that a decrease in EOP tone may be the 
initial neural stimulus for the preovulatory LH surge (Allen 
and Kalra, 1986).
Large variations in hypophyseal p-END levels occur over the
rat oestrous cycle (Sarkar and Yen, 1985). Fluctuations are 
also evident in the p-END concentrations in the MPO, ME and
ARN; its levels being minimal on the morning and afternoon of 
pro-oestrus (Parnet et al, 1990). These fluctuations are
dependent on the gonadal steroid milieu since they are 
eliminated by ovariectomy and reinstituted following E2 
administration (Genazzani et al, 1990). Specific implantation 
of E2 in the MPO of dioestrous rats increases the p-END
levels in the ARN-ME region (Sturzebecher et al, 1988). Thus 
there is a large volume of evidence suggesting that a 
decrease in EOP tone in response to high circulating E2 may 
indeed be the initial neural stimulus for the preovulatory LH 
surge. There is also evidence that this reduction in EOP tone 
may be partly attributable to a decline in the responsiveness 
of the opiate receptor mechanism during the E2-induced LH 
surge (Berglund et al, 1988).
Much work has been carried out concerning opiate effects on 
LHRH secretion, but relatively little has been published 
which attempts to identify the receptor subtypes involved. 
This can be attributed to the lack of specific agonists and 
antagonists available until recently. K-agonists increase
prolactin (PRL) secretion and reduce LH secretion when 
administered centrally, but the latter effect could be 
blocked by a specific ji-antagonist and so was attributed to
cross-specificity of the agonist employed (Pfeiffer et al,
1987). However, more recently, the highly specific K-agonist,
Tifluadom, has been shown to be as effective as morphine in 
reducing plasma LH concentrations on the early afternoon of 
pro-oestrus (Gopalan et al, 1989), which indicates that k -
receptors may indeed be involved in opioid suppression of LH 
release.
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Although direct connections between EOP and LHRH neurones 
have been established (Leranth et al, 1988), there is 
extensive evidence that EOP effects on LHRH secretion may be 
indirect. Naloxone stimulation of LH release can be blocked 
by a-adrenoreceptor antagonists (Van Vugt et al, 1981) and 
inhibitors of dopamine-p-hydroxylase (Kalra and Crowley,
1982). Further, a-adrenergic agonists are able to elicit LH 
release when administered centrally to morphine-treated rats 
(Kalra and Gallo, 1983). The amount of LH released in 
response to naloxone has been directly related to the 
turnover of NA in the SCH, MPO and ME of OVX, E2-injected 
rats at the time of treatment; the responses being least when 
NA turnover is at its lowest (Akabori and Barraclough, 1986). 
Ionotophoretically applied naloxone enhances the response of 
neurones in the MPO to stimulation of the ventral NA bundle 
(VNAB) (Dyer and Grossman, 1988). Since opioid peptides 
inhibit release of NA from the MPO (Diez-Guerra et al, 1987) 
it would appear that some NA axon terminals in the MPO are 
pre-synaptically inhibited by EOP's. However, a small 
proportion of MPO cells increased their firing rate on 
application of ionotophoretic naloxone, but did not respond 
to electrical stimulation of the VNAB (Dyer and Grossman, 
1988). Thus some EOP neurones make functional synapses 
directly upon cells of the MPO to inhibit their activity.
Tyrosine hydroxylase and met-enkephalin have been co­
localized in many neurones of the Al NA cell group which 
project to the MPO (Ceccatelli et al, 1989). This leads to 
the intriguing possibility that the pre-synaptic opiate
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receptors on NA terminals in the MPO may be autoreceptors on 
neurones that contain NA and EOP as co-transmitters; the 
principal site of action of NA being post-synaptic and of 
EOP's being pre-synaptic.
Recent work has indicated that \i~, but not k -  nor 6- 
receptors, mediate the inhibitory regulation of NA release 
from the cortical, cerebellar and hippocampal projections of 
the rat LC (Werling et al, 1987). This indicates that there 
may be specific subpopulations of opiate receptors involved 
in the modulation of NA release.
In addition to their many effects on NA neurochemistry within 
the hypothalamus, opiates also alter that of DA. Morphine 
reduces the turnover of DA in the ME of male rats (Deyo et 
al, 1979). Recently, k -  and ^-agonists have been shown to
inhibit DA release from the MBH in vitro while leaving the 
outflow of NA unaffected (Heijna et al, 1991), and 
tuberoinfundibular neurones are tonically inhibited in 
dioestrus by k -  but not n-receptor mediated mechanisms
(Manzanares et al, 1992). These effects on tuberoinfundibular 
DA neurones are likely to be involved in the regulation of 
PRL secretion, but would also provide for K-stimulation of LH
secretion should some of these DA neurones be involved in 
control of LHRH rather than PRL.
Morphine activates incertohypothalamic neurones projecting to 
the SCH and MPO in the male rat, as evidenced by its ability 
to increase the concentration of the DA metabolite, 3,4-
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dihydroxyphenylacetic acid (DOPAC) in these regions 
(Lookingland and Moore, 1985). This again, may provide for 
opioid stimulation of LHRH if a similar action results in the 
female.
In the dorsal raphe nucleus, activation of k- but not \i- 
receptors reduces the response of 5HT-sensitive neurones to 
electrical stimulation (Pinnock, 1992) suggesting that, here, 
EOPs are presynaptic inhibitors at 5HT terminals.
Thus it appears that the effects of EOPs on LHRH secretion 
may be mediated in large part by NA, DA and 5HT neurones.
a-adrenergic activation stimulates accumulation of met- 
enkephalin in the ME (George et al, 1990) and long term DA 
agonist treatment reduces EOP immunoreactivity in the MBH and 
ME of male rats (Locatelli et al, 1983), suggesting that 
there may be a reciprocal relationship between catecholamine 
and EOP systems in the hypothalamus.
Other Aminergic Neurotransmitters
(i) Adrenaline (ADR)
ADR administered intracerebroventricularly (ICV) stimulates 
LH release (Vijayan and McCann, 1978), while inhibitors of 
phenylethanolamine-N-methyltransferase (PNMT) block both the 
steroid-induced surge in OVX rats (Crowley and Terry, 1981) 
and the spontaneous LH surge in intact rats (Coen and Coombs,
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1983). This would point to an essential stimulatory role for 
ADR in the regulation of the LH surge. However, the very 
existence of ADR as a classical neurotransmitter in the rat 
CNS has recently been called into question with the claim 
that PNMT-containing neurones are not necessarily ADRergic 
(Sved, 1989). Evidence now seems to favour the view that the
appearance of ADR in the rat CNS is either as a co­
transmitter with NA or as a post-synaptic product of NA 
catabolism (Mefford, 1987). The effects of ADRergic drugs on 
the LH surge may be a result of activating receptors in NA 
neuronal systems or by altering the metabolism of NA itself.
(ii) Acetylcholine (ACH)
ACH muscarinic receptor numbers in the POA vary over the 
oestrous cycle, being highest at pro-oestrus (Olsen et al,
1988) and administration of muscarinic agonists increase 
hypothalamic E2 binding (Lauber and Whalen, 1988). However, 
an ACH effect on LH secretion has not been established, 
whereas an E2-mediated effect on lordotic behaviour has been
demonstrated (Dohanich and Clemens, 1981). Thus ACH may be of
importance in the behavioural aspects of the oestrous cycle, 
but have little or no involvement in the central regulation 
of the LH surge.
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(iii) Histamine (HA)
HA stimulates LHRH release from the steroid-primed rat MBH in 
vitro (Miyake et al, 1987); an action which is independent of 
NA stimulation of the surge (Ohtsuka et al, 1989). Thus HA 
may have a facilitatory role in the induction of the LH 
surge. Blockade of the LH surge by centrally administered HA 
antagonists or synthesis blockers has not been demonstrated; 
therefore the physiological relevance of HA in the control of 
the surge may be minimal.
Other Peptide Neurotransmitters
(i) Neuropeptide Y (NPY)
NPY inhibits LH secretion when injected ICV into OVX rats 
(McDonald et al, 1989). However, the opposite is the case in 
steroid-primed rats, where stimulation occurs (Kalra and 
Crowley, 1984). In vitro, NPY stimulates release of LHRH from 
the MBH of steroid-primed rats (Crowley and Kalra, 1987) and 
ICV administration of antiserum to NPY blocks the LH surge in 
steroid-primed rats (Wehrenberg et al, 1989). These results 
indicate that NPY may be important in the stimulation of the 
LH surge on pro-oestrus. Indeed, NPY levels in the ME, but 
not SCH, MPO nor ARN, peak approximately one hour prior to 
the LH surge on pro-oestrus (Sahu et al, 1989), lending 
support to a physiological role for this neuropeptide in the 
control of ovulation.
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There is evidence to suggest that NPY may act on the LHRH 
neurones as a co-transmitter with NA (Everitt et al, 1984), 
and/or as an independent transmitter on which NA neurones 
make direct appositions (Guy and Pelletier, 1988) to alter LH 
secretion (Allen and Kalra, 1987).
(ii) Substance P (SP)
SP may be involved in the neural circuitry regulating LHRH 
secretion since its levels in the ME vary throughout the 
oestrous cycle (Antonowicz et al, 1982), and it elicits LHRH 
secretion from the MBH in vitro (Ohtsuka et al, 1987). 
Furthermore, SP innervation of LHRH neurones in the POA of 
rats has recently been reported (Tsuruo et al, 1991).
Again, however, very little work has been carried out to 
elucidate the involvement of this neuropeptide in the 
regulation of LH secretion and its participation may only be 
of marginal importance.
(3) Vasoactive Intestinal Peptide (VIP)
VIP administered centrally reduces the magnitude of the 
steroid-induced LH surge in OVX rats (Weick et al, 1992).
Thus this neuropeptide curtails LHRH secretion during the LH 
surge. However, the physiological significance of its ability 
to do so has yet to be assessed.
Excitatory Amino Acids
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Glutamate, aspartic and cysteic acid all stimulate LH release 
following ICV infusion (Ondo et al, 1976; Ondo, 1981;
Scheibel et al, 1980). Infusion of the specific agonist, N- 
methyl-D-aspartate (NMDA) into discrete hypothalamic areas 
identified the MPO as the sole site of action of the 
excitatory amino acids (Ondo et al, 1988). NMDA stimulation 
of LH secretion is markedly increased by E2 + P pre-treatment 
of OVX rats (Carbone et al, 1992) suggesting that the 
excitatory amino acids may have some involvement in the 
transduction of the steroid signal to the LHRH neurones. 
However, the significance of these neurotransmitters in the 
control of the LH surge has yet to be fully determined.
y-Aminobutyric Acid
y-aminobutyric acid (GABA) neurones are extensively 
distributed throughout the hypothalamus (Sakaue et al, 1988), 
and electron microscopy has shown synaptic contacts between 
GABA neurones and LHRH neurones in the MPO (Leranth et al, 
1988b).
GABA is an inhibitory neurotransmitter, but has both 
stimulatory and inhibitory effects on LHRH secretion 
depending on its site of action. In the MPO, GABA is 
inhibitory to LHRH release (Demling et al, 1985). Stimulation 
of NA neurones projecting to the MPO induces release of GABA 
when E2 levels are low but, not when they are high (Herbison 
et al, 1990); i.e. their inhibitory action is eliminated on
pro-oestrus. It appears that GABA neurones here are 
inhibitory interneurones between the NA and LHRH neurones 
that lose their sensitvity to NA on pro-oestrus, thus freeing 
the LHRH neurones from tonic restraint. This mechanism may be 
involved in NA stimulation of the surge.
GABA also reduces NA turnover in the MPO concomitant with its 
inhibition of LH release (Adler and Crowley, 1986). This 
suggests that, quite apart from its role as a relay for the 
NA signal, GABA is a presynaptic inhibitor of NA activity in 
this area. Indeed, it has recently been proposed that it is a 
reduction in GABAergic tone which synchronizies the activity 
of LHRH neurones to stimulate the LH surge (Jarry et al, 
1991). This is supported by subsequent work which 
demonstrated that decreased GABA activity in the MPO and MBH 
precedes the surge (Seltzer and Donoso, 1992).
GABA is also inhibitory to LHRH release in the zona incerta 
(ZI) by a different mechanism. Here, its effects can be 
attributed to its inhibition of the stimulatory input to the 
LHRH system from the incertohypothalamic DA tract (Wilson et 
al, 1990). However, GABA produces a stimulatory effect on 
LHRH secretion in the ARN/ME. This is believed to be a result 
of its negative influence on the activity of the inhibitory 
tuberoinfundibular DA system (Nikolarakis et al, 1988).
Finally, the inhibtion of the LH surge elicited by 
stimulation of the medial raphe nucleus appears to be 
mediated by GABA (Morello et al, 1989).
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In general, the wide-ranging actions of GABA on LHRH 
secretion result from direct inhibition of LHRH neurones in 
the MPO or from inhibition of both stimulatory and inhibitory 
inputs to the LHRH neurones.
Summary
It is clear that the secretion of LH, including the 
preovulatory LH surge, is regulated by a complex neural 
network involving several classes of neurotransmitters. These 
modulate the secretion of LH by altering the activity of LHRH 
neurones within the hypothalamus.
The neurotransmitters which appear to be of paramount 
importance in this neural circuitry are NA, DA, 5HT, EOPs,
NPY and GABA; there is a complex interplay between these 
neurones with the effects of some being mediated by others, 
and this is represented in Figure 9.
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Figure 9. Schematic representation of the organization of 
the neural circuitry regulating the secretion of LHRH from 
the ME. Short arrows represent interneurone pathways and 
continuous lines depict direct neural connections. From: 
Ramirez et al, 1984.
AIMS
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As outlined in the Introduction, there is a wealth of 
information published on opiate modulation of the central 
control of the preovulatory LH surge. Much of this work has 
concentrated on the effects of the n-agonist, morphine, and
the general opiate antagonist, naloxone. Relatively little 
attention has been paid to the possible actions mediated by 
other receptor subtypes.
This investigation was designed to determine the possible 
involvement of k -  and a-receptors in the central opiate
effects on the surge, and to compare these to the responses 
produced by the ^-agonist, morphine.
Furthermore, it was decided to investigate the mediation of 
opiate effects on the LH surge by the biogenic amines, NA, DA 
and 5HT. To achieve this objective, the effects of the 
opiates on biogenic amine neurotransmission were measured in 
the hypothalamic areas which contain LHRH neurones (SCH, MPO, 
ME and ARN) on the early and late afternoon of pro-oestrus.
Studies of amine turnover in discrete hypothalamic nuclei 
have involved the measurement of amine depletion after 
administration of a synthesis inhibitor (Ranee et al, 1982). 
These inhibitors themselves alter LH secretion (Kalra and 
McCann, 1974), and so could alter the response which could be 
evoked by administration of further pharmacological agents.
The measurement of neurotransmitters and their metabolites, 
as used here, eliminates the need for pharmacological
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manipulations to determine the activity in the nerves under 
investigation. The concentration of metabolite reflects 
neuronal activity (Lookingland et al, 1987) and the ratio of 
the metabolite to its respective transmitter provides a 
qualitative index of the turnover rate of the latter 
(Commissoing, 1985).
MATERIALS AND METHODS
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Animals
An in-house colony of female Sprague-Dawley rats was 
established from stock purchased from Tuck and Sons, 
Battlesbridge, Essex. The animals were housed in a light- and 
temperature-controlled environment; lights on 06.00h-20.00h, 
temperature 21+1°C. Food and water were supplied ad libitum.
Vaginal lavages were performed on the rats between 09.0Oh- 
10 .30h each morning. The morphology of the cells sloughed 
from the vagina were used to identify the stage of the 
oestrous cycle of each rat (Mandl, 1951).
Those rats (200-330g) that had exhibited at least two 
consecutive four-day oestrous cycles were selected for 
experimentation on the morning of pro-oestrus. The records 
kept for animals that satisfied this criterion but, were not 
used for experimentation, showed that there was approximately 
a 97% probability that oestrus follow on the next day, i.e. 
the preovulatory LH surge occurred in 97% of the animals used 
in the experiments.
Drugs
The properties of the drugs are summarized in Table 3.
Naloxone is a specific opiate antagonist which has greatest 
affinity for the ^-receptor, but also possesses substantial 
affinity for both 6- and x-receptors.
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Morphine is a highly specific ^-agonist and displays very
little activity at other opioid receptor types. However, it 
has a low efficacy for ji-receptors, and so can act as an
antagonist in tissues with low receptor densities (Kenakin 
and Beek, 1980). In this study a long-acting preparation of 
morphine, Duromorph, was used which exhibits potent analgesic 
effects for up to 24 hours after administration (Johnston,
1990).
Druq Receptor Properties
Naloxone Opiate antaqonist
Duromorph ji-agonist
Tifluadom K-agonist
N-allylnormetazocine a-agonis t /fi-antagonis t
Table 3 s Drugs used in the study and their receptor 
properties.
Tifluadom is a specific K-agonist, being over xlOO more 
potent at the K - r e c e p t o r  than at any other opioid receptor 
(Burkhard, 1984).
N-allylnormetazocine (SKF 10047), as a racemic mixture, 
exhibits several pharmacological actions. The (+)-enantiomer 
binds at two sites in the rat brain; a high affinity cr-opioid
receptor and a low affinity phencyclidine (PCP)-receptor
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(Largent et al, 1986) which has also been designated a non­
opioid o-receptor. (-)-N-allylnormetazocine binds to y,-
receptors, where it acts as an antagonist (Compton et al,
1987), in addition to PCP-receptors.
I am grateful to the following establishments for the gifts 
of the drugs used in the study: Laboratories for Applied 
Biology Ltd. (London, U.K.) for the gift of Duromorph, Kalie- 
Chemie (Hannover, F.R.G.) for Tifluadom and the National 
Institute on Drug Abuse (U.S.A.) for N-allylnormetazocine 
(SKF 10,047). Naloxone was purchased from Sigma Chemicals 
Corporation (Poole, Dorset, U.K.).
Decapitation Procedure
\\
\
Trunk blood was collected immediately upon decapitation, 
centrifuged (3000rpm, 5mins, 4°C) and the separated plasma 
| stored at -80°C until LH determination. The brains were
rapidly removed, frozen on dry ice and stored at -80°C to 
prevent post mortem degradation of the brain aminergic 
neurotransmitters.
Brain Microdissection
The SCH, MPO, ME and ARN were isolated by a modification of 
the Palkovits Technique (Paxinos and Watson, 1986):
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Interaural 8.2 mm Bregma —0.8 mm
Figure 10. Coronal section (number 5) through the rat brain 
showing the location of the hypothalamic areas to be 
isolated. From: Paxinos and Watson, 1986.
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On removal of the brain from storage, the frontal lobes and 
hindbrain were separated by coronal cuts. The dorsal cut 
surface was placed on the mounting stage of a freezing 
microtome (-80°C) and the tissue held firmly in place by 
encasement of the base in Cryo-Gel. 50 pm coronal brain
slices were cut until the fused portion of the corpus 
callosum could be seen. Subsequently, 500 pm sections were
taken, numbered 0-12 and stored on microscope slides resting 
upon dry ice. The remainder of the brain was discarded.
When all thirteen sections had been cut, section numbers 4-11 
which contained the areas of interest were, in turn, 
transferred to a cold plate (-20°C) under a binocular 
microscope (xl6 magnification). The areas were punched from 
the sections using modified hypodermic needles of 0.66mm 
internal diameter. A different needle was used for each area 
and the needles were rinsed in alcohol between samples. The 
ME was isolated by punches of half the needle cross-sectional 
area.
As the hypothalamic areas were isolated by multiple punches 
it was possible for a fraction of each area to be lost. 
Therefore a record of the success of the punches was kept.
Chromatography
The specific hypothalamic areas were collected separately in 
microtubes (2ml) kept cold on dry ice. The isolated tissue 
was stored at -80°C until assayed. At a later date, 50pl of
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0.1M hydrochloric acid containing 2.5ng of 3,4- 
dihydroxybenzylamine (DHBA) was added to each sample which 
was then centrifuged (3000rpm, 5 mins., 4°C) in a Denley 
BR401 Refrigerated Centrifuge to ensure all the tissue was at 
the bottom of the tube. The sample was sonicated for 10 
seconds to disperse the tissue through the liquid and then 
re-centrifuged (as above). 20fil aliquots of supernatant were
drawn off and injected on to a high performance liquid 
chromatography (HPLC) system and the content of NA, DHPG, 
MHPG, ADR, DA, DOPAC, HVA, 5HT and 5HIAA were simultaneously 
measured by electrochemical detection (ECD); the full 
chemical names are given in the 'List of Abbreviations' and 
their chemical properties are summarized in Table 4. The 
internal standard to analyte peak area method (described 
below) was used to quantify the content of the monoamines in 
each of the areas. The minimum detectable quantity of each of 
the biogenic amines was 0.05-0.10ng/20jil of supernatant,
dependent on the noise level of the system.
The response of the system was checked by running mixtures of 
the amines in known concentrations from 0.2-2.0ng/20nl. The
system demonstrated a linear response to all of the amines 
measured over these concentrations. A standard mixture 
containing known concentrations (lng/20jil) of the amines
under investigation was run on the HPLC column each morning. 
The amines in the samples were identified by the coincidence 
of their retention times on the column with the known amines 
in the standard mixture. The ratio of the amine peak areas to 
the internal standard peak area in the standard mixture
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8826 1.8 HG 2 19:36 89/12/88
Attenuation 156 Offset 3278 Ranse 247838
- 3.48 NA
3.88 ADR
HIAA
17.13
8826 1.8 N8 2 19:36 89/12/88 OUT OF RANGE!
Method 6ASLC3AB
Method Text BASLC3AB
Sample
Weisht 1.88 Volume 1.08
Report Intall
Retention Relative Peak Response Peak Peak Peak
Time Time Area Factor Cone Name Code
3.40 8.73 1441063 1.493 0.60 NA
3.80 8.81 1495842 1.252 0.52 ADR
4.68 1 . 00 3582568 1.808 1.00 IS I. S.
6.45 1.38 2398724 8.978 0.65 DA X
9. 62 2. 85 19039 1 . 000 0.01 X
18.55 2.25 9661 1.000 0.08
11.25 2.48 1129788 1.362 0.43 SHI AA
13.37 2.85 2888 1 . 000 0.00
17. 13 3.66 1383864 1.400 0.54 5HT
11454549 3.76
Figure 11. HPLC trace of the standard solution containing 
lng/20fil of each of the identified compounds.
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indicates the percentage recovery at the detector of the 
amines per unit of internal standard. This ratio is known as 
the response factor. Addition of the same amount of internal 
standard to the samples thus allows an integrating computer 
to calculate the content of the amines in the samples by 
taking the ratio of the peak areas with the internal standard 
and incorporating the response factor. The mean amine content 
of each sample was scaled up by a factor of 50/20 to give the 
total amine content in each hypothalamic region.
Amine Description
DHBA Internal Standard
NA Transmitter
DHPG NA metabolite
MHPG NA metabolite
ADR Transmitter
DA Transmitter
DOPAC DA metabolite
HVA DA metabolite
5HT Transmitter
5HIAA 5HT metabolite
Table 4. Designation of the amines measured by the HPLC 
system described in the text. The full chemical names of the 
amines are given in the 'List of Abbreviations'.
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Once the samples had been run on the column in duplicate, the 
remaining protein pellet was stored at -80°C until the 
protein assay was carried out.
The HPLC equipment used was: a Gilson Model 302 pump fitted 
with a Gilson 5.SC pump head, a Gilson Model 802 manometric 
module, a Rheodyne 7125 injection valve, a Beckman 
Ultrasphere IP 4.6mm x 4.5cm guard column, a Beckman 
Ultrasphere 4.6mm x 15cm column; both columns were packed 
with 5mm ODS Hypersil (octadodecylsilane) ,a BAS MF-1000 
working electrode, a BAS MF-2020 auxiliary electrode , a BAS 
RE-1 Ag/AgCl reference electrode coupled to a BAS LC-3A 
amperometric detector set at a potential of +0.70V. The 
system was connected to a Trivector Trio Chromatography 
Computing Integrator. The flow rate was set at 0.6ml/min. The 
mobile phase was 6.74g/l citric acid, 4.81g/l sodium citrate, 
47mg/l EDTA, 100mg/l heptanesulphonic acid, 1.15ml/l glacial 
acetic acid, 3ml/l tetrahydrofuran (THF), 5.0-7.5% (V/V) 
methanol. The pH was adjusted to 4.9 with 10M NaOH. Methanol 
and THF were added as necessary in the routine running of the 
system.
Protein Estimation
A standard curve of protein content against absorbance at 
595nm after reaction with Coomassie Blue G250 (Pierce, Life 
Science Laboratories Ltd., Luton, U.K.) was first prepared. 
Known weights of bovine serum albumin (BSA) (0-40mg) were
IU£6S 
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aouaqrosqu
Absorbance = 0.28565 + 0.0061368[BSA] 
IT2 = 0.963
0.7 n
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Figure 12. Standard curve of absorbance at 595nm after 
reaction with Coomassie Blue G250 versus concentration of 
Bovine Serum Albumin (BSA).
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first dissolved in 100p,l of 0.1m sodium hydroxide (NaOH) and 
incubated overnight at 4°C. The following morning the BSA was 
diluted to 1ml with distilled water. Next, 1ml of Coomassie 
Blue G250 was added and the absorbance at 595nm read 
immediately on an LKB Biochrom Ultrospec 4050 
spectrophotometer using 200^ ,1 of 0.1M NaOH plus 1800pl of
distilled water as the blank solution. The absorbance of each 
tube was read in duplicate and the mean used for the 
calculation (see Figure 12).
The protein pellet remaining after HPLC was dispersed in 
210^1 0.1M NaOH by sonication and incubated overnight at 4°C. 
The next morning, two lOOp.1 samples were transferred to 
separate tubes and each treated as described above for the 
standard curve. The protein concentration in each tube was 
calculated by substitution of the absorbance into the 
regression equation of the standard curve. The protein 
content of the duplicate tubes was summed to give the total 
protein content of the original sample.
If the sample tissue content lay below two standard 
deviations of the mean and no tissue had been lost in the 
micropunch procedure itself, then the protein was deemed to 
have been lost in the course of as say/storage/transfer of the 
samples and was replaced by the mean protein content of the 
area for the calculation of the amine concentrations.
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Amine Concentration Calculation
The total amine content of the individual amines in each 
sample was divided by the total protein content of the 
sample, or the mean protein content for the particular area, 
to give the concentration of the amines in the original 
tissue in ng amine/^g protein.
Femoral Artery Cannulation
Surgical anaesthesia (complete cessation of the hind limb 
flexor withdrawal reflex) was induced as described in 
Experiment 4 and a cannula (0.63mm outside diameter) was 
inserted into the femoral artery.
Blood samples (200^1) were withdrawn through the cannula at 
30 minute intervals throughout the afternoon and early 
evening of pro-oestrus. The animals were killed by an 
overdose of ether when the experiment was completed.
The blood samples were immediately centrifuged (3000rpm, 
5mins., 4°C) and IOOjaI plasma separated and stored at -80°C
until LH determination. The red blood cells were 
reconstituted with lOOjil of warmed, heparinized saline (10
units/ml) and reinjected through the cannula. Animals were 
kept warm throughout the procedure either by radiant heat or 
by the use of a thermostat-controlled, heated dissection 
table.
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LH Radioimmunoassay
Reagents s
(i) Modified physiological saline (MPS) buffer? 8.8g NaCl 
(0.15M) and lOOmg Thiomersal were mixed well in 1 litre of 
distilled water on a stirrer, and the pH was adjusted to 7.0 
using 1M sodium hydroxide (NaOH). 20ml was discarded and 
7.8ml 0.5M NaH2P04 was added. Once made up, the solution was 
stored at room temperature.
(ii) 1% egg white (EW); this was prepared by dissolving lg of 
egg albumin in 100ml MPS and filtering through acetone-washed 
glass wool. The pH was adjusted to 7.0 using 1M NaOH when 
necessary. This solution was stored at 4°C and made up fresh 
each week as required.
(iii) Serum diluent (SD); a Is400 dilution of normal rabbit 
serum (NRS) was prepared? a 0.25ml volume of NRS was 
dissolved in MPS containing 0.05M EDTA. The was pH adjusted 
to 7.0 with 1M NaOH and the volume was made up to 100ml with 
MPS. The solution was stored at 4°C.
(iv) NIH-RP-3-rLH Standard? a standard of 5mg/ml in PBS was 
prepared by reconstitution in 1ml of distilled water. This 
solution was aliquoted into 25^ ,1 volumes, frozen and stored 
at -20°C. A standard curve was made up by adding 756p,l EW/MPS 
to the 25?il aliquot. In ice, eight eppendorfs were set out in 
two rows, and 200^1 of EW/MPS aliquoted into each. 200^ ,1 was
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removed from the standard tube and serially double diluted 
down. This gave eight points on the standard curve.
(v) NIH-rLH-S-10 Antibody; a 1:20 solution was provided. Of 
this, a 10ml aliquot was withdrawn and added to 990ml of SD 
(xlOO dilution) to give a dilution of 1:2000. This was 
aliquoted into 200^1 volumes and stored at -20°C. When 
required, a 200^ ,1 aliquot of the 1:200 dilution was added to 
5.8ml of SD (x30 dilution) to give a concentration of 
1:60000, which was subsequently diluted by three to give the 
recommended final working concentration of 1:180000.
Protocol:-
The standards, non-specific binding (NSB), zero and totals 
were included at the beginning of each assay and repeated at 
the end. On the second day, the label 125I-LH was made up in 
EW/MPS to give counts of 15000-20000/50ml. On the third day, 
precipitating serum (PPS) was prepared; 1ml donkey-anti 
rabbit immunoglobulin G (IgG) was made up in 23 ml EW/MPS. On 
the final day, 500ml EW was added to all of the tubes with 
the exception of the totals (n=5) prior to centrifugation. 
After one hour of spinning, the tubes were drained and 
counted; the totals were neither spun nor drained. The tubes 
were kept at 4°C for the duration of the assay.
The sensitivity of the assay was 0.4ng per sample and the 
intra- and interassay coefficients of variation were 10.5% 
and 8.7% respectively.
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Statistics
Scheffe's One-way Analysis of Variance and Covariance was 
performed on the data. When the 'F'-test was significant, it 
was followed by the repeated measure, multiple comparison t- 
test between means.
All statistical tests were carried out on the Glasgow 
University Mainframe (Glasgow VME) using the P1V programme of 
the statistical software package BMDP (Copyright: Regents of 
University of California, Los Angeles) and converted for use 
on I CL VME by the Program Library Unit, University of 
Edinburgh.
EXPERIMENT
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This investigation was planned to examine the effects of 
the four opiate drugs administered during the critical 
period, at various doses, on the plasma LH concentration 
immediately prior to the LH surge, and during the plateau 
phase of LH secretion.
The method was selected such that it would further allow an 
investigation of any relationship between neurotransmitter 
concentrations in the SCH, MPO, ME and ARN at the end of 
the critical period with surge levels of LH later in the 
day.
Materials and Methods
Experimental animals were injected intraperitoneally (IP) 
at 12.30h with either Duromorph, tifluadom, N- 
allylnormetazocine or naloxone dissolved in a 0.05ml/15g 
volume of physiological saline. The doses used were 
1,3,10,30 and 50 mg/kg except for Duromorph for which the 
highest doses were 40 and 60 mg/kg respectively. Control 
animals were injected with vehicle alone. The rats were 
subsequently divided into two groups; the first being 
decapitated at 14.30h and the second at 18.00h. The number 
of animals in each group is shown in Tables 5(a) and 5(b).
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Results
(1) 14.30h Decapitations
These results are summarised in Tables 5(a) and 6-9.
(a) Luteinizing Hormone
For control animals the plasma LH concentration at 14.30h 
was 2.1+0.3 ng/ml.
None of the four drugs significantly altered plasma LH 
levels at any of the doses used.
(b) Noradrenaline
The control values found for NA in the SCH, MPO, ME and ARN 
were 40.1+7.2, 47.6+8.9, 22.4+4.1 and 30.1+3.3 ng amine/pg
protein respectively (results expressed + SEM).
(i) Naloxone
No dose of naloxone significantly affected the NA 
concentrations in the SCH. The 1 mg/kg dose of naloxone 
significantly elevated NA levels in the MPO (p<0.001) and 
ARN (p<0.01)but, no other dose had any significant effect 
in these two areas. The 1, 3 (p<0.001) and 30 (p<0.01) 
mg/kg doses of naloxone significantly raised NA
concentrations in the ME, but the other two doses caused no 
significant alterations.
(ii) Duromorph
The 1 mg/kg dose of Duromorph significantly elevated 
(p<0.01) NA concentrations in the SCH; the other doses used 
were ineffective. The 1 and 10 mg/kg doses also caused 
significant increases (p<0.05) in the NA concentrations in 
the MPO. The 1, 3 (p<0.001) and 40 (p<0.05) mg/kg doses 
significantly elevated NA concentrations within the ME. The 
1 (p<0.05) and 3 (p<0.001) mg/kg doses resulted in 
significant increases in NA concentrations in the ARN.
(iii) Tifluadom
Tifluadom had no significant effect on NA concentrations in 
the SCH at any of the doses used, but the 10 mg/kg dose 
significantly elevated NA concentration in the MPO 
(p<0.01). The 1, 3 (p<0.001), 10 (p<0.05) and 30 (p<0.01) 
mg/kg doses all caused significant increases in NA 
concentrations in the ME. The 1 (p<0.01), 10 (p<0.001) and 
30 (p<0.01) mg/kg doses significantly raised NA 
concentration in the ARN.
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(iv) N-allylnormetazocine
None of the doses of N-allylnormetazocine used had a 
significant effect on NA concentrations in the SCH, nor in 
the MPO. The 1 (p<0.01) and 3 (p<0.001) mg/kg doses of N- 
allylnormetazocine significantly increased NA 
concentrations in the ME. The 3 (p<0.01) and 30 (p<0.05) 
mg/kg doses of N-allylnormetazocine significantly raised 
the NA concentrations of the ARN.
(c) Dopamine
The concentrations of DA in the SCH, MPO, ME and ARN of 
control animals were 2.4+0.5, 3.5+0.6, 21.4+6.0 and 5.8+1.8 
ng amine/pig protein respectively (values given + SEM).
(i) Naloxone
The 1 (p<0.05), 3 (p<0.01) and 30 (p<0.05) mg/kg doses of 
naloxone caused significant elevations of DA concentrations 
in the SCH. The 1 and 3 mg/kg doses of naloxone 
significantly increased DA concentrations in the MPO 
(p<0.001 and p<0.01 respectively), and in the ME (both 
p<0.05). However, no dose of naloxone significantly altered 
DA concentrations in the ARN.
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(ii) Duromorph
The 1 and 10 mg/kg doses of Duromorph significantly 
increased the DA concentrations of the SCH (both p<0.001) 
and the MPO (p<0.01 and p<0.001 respectively). No dose of 
Duromorph had a significant effect on the DA concentrations 
of the ME or of the ARN.
(iii) Tifluadom
None of the doses of Tif luadom used significantly altered 
the DA concentrations in the SCH or in the ME.
Nevertheless, the 1 (p<0.05) and 10 (p<0.001) mg/kg doses 
of Tifluadom significantly raised DA concentrations in the 
MPO. The latter dose also significantly increased (p<0.01) 
the DA concentrations in the ARN.
(iv) N-allylnormetazocine
The 1 (p<0.05) and 30 (p<0.001) mg/kg doses of N- 
allylnormetazocine significantly elevated DA concentrations 
in the SCH. In addition, the 3 (p<0.05) and 10 (p<0.01) 
mg/kg doses of N-allylnormetazocine significantly raised DA 
concentrations in the MPO. However, this opiate had no 
significant effect on DA concentrations either in the ME or 
in the ARN at any of the doses studied.
(d) 5-Hydroxyindoleacetic Acid
The values for 5HIAA concentrations in the SCH, MPO, ME and 
ARN of controls were 8.3+2.0, 8.7+1.3, 5.1+0.8 and 11.3+3.4 
ng amine/jig protein respectively (results expressed + SEM).
(i) Naloxone
The 1 (p<0.01), 10 and 30 (both p<0.05) mg/kg doses of 
naloxone significantly elevated 5HIAA concentrations in the 
SCH compared to those in the controls. Furthermore, the 1,
3 and 10 mg/kg doses of naloxone significantly increased 
5HIAA concentrations in the MPO and the ME (all p<0.05).
The 30 mg/kg dose of naloxone also significantly raised 
5HIAA levels in the ME (p<0.01). However, naloxone had no 
significant effect on 5HIAA levels in the ARN at any dose 
administered•
(ii) Duromorph
The 1 (p<0.01), 40 and 60 (both p<0.05) mg/kg doses of 
Duromorph significantly elevated 5HIAA concentrations in 
the SCH compared to those in controls. The 1 (p<0.001), 3 
(p<0.01), 10 (p<0.05) and 60 (p<0.01) mg/kg doses of 
Duromorph caused significant increases in the 5HIAA 
concentrations of the MPO. The 3 mg/kg dose of Duromorph 
significantly elevated 5HIAA concentrations in the ME and 
ARN, as did the 60mg/kg dose in the ARN (all p<0.05).
(iii) Tifluadom
The 1 (p<0.01), 3 (p<0.001), 10 and 30 (both p<0.05) mg/kg 
doses of Tifluadom significantly increased 5HIAA 
concentrations in the SCH at 14.3Oh compared to controls. 
The 1 (p<0.001), 3 (p<0.01) and 10 (p<0.001) mg/kg doses of 
Tifluadom significantly increased the 5HIAA concentrations 
in the MPO. Only the 3 mg/kg dose of Tifluadom 
significantly affected (p<0.01) the 5HIAA concentrations in 
the ME, causing an increase. The 1 (p<0.05) and 10 (p<0.01) 
mg/kg doses of Tifluadom caused significant elevations in 
the 5HIAA concentration of the ARN.
(iv) N-allylnormetazocine
None of the doses of N-allylnormetazocine administered had 
significant effects upon 5HIAA concentrations in the SCH, 
MPO, ME or ARN.
(e) Serotonin
The 5HT concentrations in the SCH, MPO, ME and ARN of 
control animals were 23.1+3.3, 23.0+2.4, 13.1+2.2 and 
23.1+3.6 ng amine/\iq protein respectively (results 
expressed + SEM).
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(i) Naloxone
The 1 (p<0.01) and 10 (p<0.05) mg/kg doses of naloxone 
significantly raised the 5HT concentrations of the SCH 
compared to controls. However, no dose of naloxone 
significantly altered the 5HT concentrations of the MPO.
The 1 (p<0.001) and 3 (p<0.01) doses of naloxone 
significantly elevated 5HT concentrations in the ME, while 
only the 1 mg/kg dose did so in the ARN (p<0.01).
(ii) Duromorph
The 1 mg/kg dose of Duromorph caused a significant rise in 
the 5HT concentrations of the SCH, MPO (both p<0.001), ME 
and ARN (both p<0.01) compared to controls. In addition, 
the 40 (p<0.05) mg/kg dose of Duromorph also significantly 
raised 5HT concentrations in the ME.
(iii) Tifluadom
The 1 mg/kg dose of Tifluadom significantly elevated 5HT 
concentrations in the SCH (p<0.01), MPO (p<0.001), ME 
(p<0.05) and ARN (p<0.01) compared to the levels in the 
controls. The 10 mg/kg dose of Tifluadom also significantly 
increased 5HT concentrations in the SCH (p<0.01), MPO 
(p<0.05) and the ARN (p<0.01), and the 30mg/kg dose 
significantly raised the 5HT concentrations in the SCH and 
ME (both p<0.01).
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(iv) N-allylnormetazocine
No dose of N-allylnormetazocine significantly altered 5HT 
concentrations in any of the four regions studied with 
respect to control animals.
(v) Ratio Of 5HIAA/5HT
The controls values for the ratio of 5HIAA/5HT in the SCH, 
MPO, ME and ARN were 0.368+0.069, 0.472+0.109, 0.461+0.065 
and 0.478+0.106 respectively (results expressed + SEM).
(i) Naloxone
Naloxone had no significant effect on the ratio of 
5HIAA/5HT in any of the four areas examined.
(ii) Duromorph
Only the 10 mg/kg dose of Duromorph significantly increased 
the ratio of 5HIAA/5HT in the SCH compared to that seen in 
controls. No significant effects of Duromorph were evident 
in the MPO, ME or ARN.
(iii) Tifluadom
None of the doses of Tifluadom had significant effects on 
the ratio of 5HIAA/5HT in the SCH or the MPO. Nevertheless, 
the 50mg/kg dose of Tifluadom significantly elevated the
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ratio of 5HIAA/5HT in the ME (p<0.05) and the ARN (p<0.001) 
compared to those of controls.
(iv) N-allylnormetazocine
No dose of N-allylnormetazocine used significantly affected 
the ratio of 5HIAA/5HT in any of the four areas studied.
(2) 18.00h Decapitations
These results are summarized in Tables 5(b) and 10-13.
(a) Luteinizing Hormone
The plasma LH concentration at 18.0Oh in control animals 
was 9.5+2.2 ng/ml.
(i) Naloxone
The 10 mg/kg dose of naloxone significantly elevated 
(p<0.05) plasma LH concentrations at 18.00h compared to 
those seen in controls.
(ii) Duromorph
Both the 40 and 60 mg/kg doses of Duromorph significantly 
reduced (p<0.05) plasma LH levels in comparison to control 
values.
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(iii) Tifluadom
The 3 (p<0.01), 10, 30 and 50 mg/kg (p<0.05) doses of 
Tifluadom significantly reduced plasma LH concentrations 
from those seen in the controls.
(iv) N-allylnormetazocine
N-allylnormetazocine had no significant effect on plasma LH 
levels at any of the doses used.
(b) Noradrenaline
The NA concentrations in the SCH, MPO, ME and ARN of 
control animals at 18.00h were 22.1+5.5, 29.1+7.0, 28.7+4.4 
and 26.8+3.5 ng amine/ng protein respectively (results 
expressed +SEM).
(i) Naloxone
None of the doses of naloxone significantly affected NA 
levels in either the SCH, MPO or ARN. However, the 3 
(p<0.01), 10 and 50 (p<0.05) mg/kg doses of naloxone 
significantly increased NA concentrations in the ME 
compared to controls.
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(ii) Duromorph
Duromorph did not significantly affect NA concentrations in 
the SCH, MPO, ME or ARN at any of the doses administered.
(iii) Tifluadom
No dose of Tifluadom significantly altered NA 
concentrations in the SCH, MPO, ME or ARN compared to the 
values recorded in the controls.
(iv) N-allylnormetazocine
N-allylnormetazocine had no significant effect on NA 
concentrations in the SCH, MPO or in the ME. However, the 
30 mg/kg dose of N-allylnormetazocine significantly 
elevated (p<0.05) NA concentrations in the ARN at 18.00h.
(c) Dopamine
The control values for the DA concentrations in the SCH, 
MPO, ME and ARN were 2.6+0.7, 3.8+0.4, 36.3+8.0 and 4.4+1.3 
ng amine/jig protein respectively (values expressed + SEM).
(i) Naloxone
No dose of naloxone significantly altered DA concentrations 
in any of the four areas studied compared to values 
observed in control animals.
(ii) Duromorph
No dose of Duromorph significantly altered DA 
concentrations in the SCH, ME and ARN compared to control 
values. However, the 3 mg/kg dose of Duromorph did 
significantly increase (p<0.001) DA concentrations in the 
MPO.
(iii) Tifluadom
Only the 50 mg/kg dose of Tifluadom significantly increased 
(p<0.001) DA concentrations in the SCH at 18.0Oh compared 
to controls. In the other three areas studied, no dose of 
Tifluadom significantly altered DA concentrations.
(iv) N-allylnormetazocine
The 50 mg/kg dose of N-allylnormetazocine also 
significantly elevated (p<0.05) DA concentrations in the 
SCH compared to controls. DA concentrations in the MPO, ME 
and ARN were not significantly affected by any of the doses 
of N-allylnormetazocine administered.
(d) 5-Hydroxyindoleacetic Acid
Control values for 5HIAA in the SCH, MPO, ME and ARN were 
8.7+2.6, 10.4+2.7, 5.9+1.3 and 7.7+1.2 ng amine/fig protein
respectively (results expressed + SEM).
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(i) Naloxone
Naloxone had no significant effects on 5HIAA concentrations 
in the SCH, MPO and ME compared to values recorded in 
controls. However, in the ARN, the 1 and 10 mg/kg doses of 
naloxone significantly elevated (both p<0.01) 5HIAA levels 
above those observed in the controls.
(ii) Duromorph
No dose of Duromorph significantly altered 5HIAA 
concentration in any of the four regions studied.
(iii) Tifluadom
Tifluadom had no significant effects on 5HIAA 
concentrations in any of the four areas studied.
(iv) N-allylnormetazocine
The 50 mg/kg dose of N-allylnormetazocine significantly 
increased 5HIAA concentrations in the SCH, while the 3 and 
30 mg/kg doses significantly increased 5HIAA concentrations 
in the ME (all p<0.05). No dose of N-allylnormetazocine had 
a significant effect on 5HIAA concentrations in the MPO and 
the ARN.
(e) Serotonin
The 5HT levels for controls at 18.00h were 18.9+3.1, 
21.2+4.3, 14.8+2.0 and 19.6+3.0 ng amine/pg protein for the 
SCH, MPO, ME and ARN respectively (values given + SEM).
(i) Naloxone, (ii) Duromorph and (iii) Tifluadom
Neither naloxone, Duromorph nor Tifluadom had significant 
effects on 5HT concentrations in any of the four areas 
studied at any of the doses administered.
(iv) N-allylnormetazocine
The 3 and 30 mg/kg doses of N-allylnormetazocine 
significantly increased (p<0.01) 5HT concentrations in the 
SCH. However, N-allylnormetazocine did not significantly 
alter 5HT concentrations in the MPO, ME or ARN at any of 
the doses used.
(f) Ratio of 5HIAA/5HT
The results for the ratio of 5HIAA/5HT in control animals 
in the SCH, MPO, ME and ARN were 0.447+0.081, 0.717+0.227, 
0.453+0.087 and 0.425+0.049 respectively (values expressed 
+ SEM).
(i) Naloxone, (ii) Duromorph and (iii) Tifluadom
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None of these drugs had any significant effect on the ratio 
of 5HIAA/5HT in any of the four areas studied regardless of 
the dose administered.
(iv) N-allylnormetazocine
In the group of animals receiving 50 mg/kg N- 
allylnormetazocine, the 5HIAA/5HT ratio in the SCH 
(p<0.001) and ARN (p<0.05) was significantly greater than 
that seen in the controls. The 30mg/kg dose also 
significantly increased the ratio of 5HIAA/5HT in the ARN 
compared to that of controls (p<0.001). However, N- 
allylnormetazocine had no significant effects on the ratio 
of 5HIAA/5HT in the MPO, nor in the ME.
Discussion - Luteinizing Hormone
The ability of the lOmg/kg dose of naloxone to increase the 
LH surge amplitude may reflect an enhanced response of 
pituitary gonadotrophs to the LHRH signal on the afternoon 
of pro-oestrus as a result of the administration of the 
antagonist. Similarly, the reduced LH surge magnitude 
evident after the injection of the higher doses of 
Duromorph and Tifluadom could be explained by inhibition of 
pituitary responsiveness to LHRH caused by the j i -  and k -
agonists. However, the hypothalamus contains only a low 
density of opioid receptors (Khachaturian et al, 1985) and 
opioids have been shown to have no direct effect on 
secretion of LH from the anterior pituitary (for review,
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see Bicknell, 1985). Thus, it is probable that the effects 
of the opiates in this experiment do not result from 
alterations of the pituitary responsiveness to LHRH, but 
rather from effects on the secretion of LHRH itself. This 
hypothesis is dealt with in more detail in the General 
Discussion under the section entitled 'Site of Action of 
Opiates'.
The higher doses of naloxone administered increased the 
amplitude of the preovulatory LH surge. This indicates 
that, although reduced, EOP tone is not totally eliminated 
during the critical period; the increased amplitude 
resulting from antagonism of EOP secretion at this time.
i
f
Paradoxically, the lowest dose of the antagonist depressed 
the surge release of LH (although not significantly), 
suggesting the existence of a population of opiate 
receptors which have a positive influence on the LHRH 
surge-generating system. These stimulatory receptors would 
appear to be more sensitive to naloxone since their actions 
predominate at the lowest dose. Their effects are over­
ridden by activation of the inhibitory receptors as the 
higher doses of naloxone result in increased LH release. It 
is possible that the EOP neurones involved in the surge- 
generating system possess autoreceptors that, when 
activated, limit the outflow of EOP. Hence, naloxone 
antagonism at these receptors would increase the release of 
EOPs and thus inhibit LH secretion. However, it may be that
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two separate opioid systems exist, one stimulatory and the 
second inhibitory to the surge.
The stimulation of the LH surge that resulted from 
administration of the lowest dose of Duromorph implies that 
the stimulatory (auto)receptors postulated above may be of 
the ^-opioid type.
The highest two doses of Duromorph completely abolished the 
LH surge, providing confirmation of ^-opiate suppression in
this situation. However, as stated in the Introduction, 
morphine has a low efficacy for the ^-receptors and so can
act as an antagonist in regions where receptors are sparse, 
as they are in these areas (see Table 2). The low doses of 
Duromorph may be displacing more potent EOPs from post- 
synaptic receptors and removing their inhibition. At the 
higher doses, sufficient Duromorph could be present to 
maximally activate the post-synaptic receptors and produce 
its inhibitory action.
Tifluadom, administered at 12.30h, generally reduced plasma 
LH levels at both 14.30h and 18.00h which suggests that k -  
as well as ^-opioid receptors participate in opiate
suppression of the LH surge, contrary to the findings of 
Pfeiffer et al (1987). However, K-receptors do not appear
to be involved in the stimulatory EOP mechanism suggested 
above as all doses of Tifluadom reduced the LH surge 
amplitude.
i
|
Previously, work from this laboratory had been unable to 
demonstrate a-opiate inhibition of LH release at 14.30h on 
pro-oestrus after administration of the a-agonist, N- 
allylnormetazocine, at 12.30h (Gopalan et al, 1989). In the 
former experiments drugs were injected under light ether- 
induced anaesthesia which was itself found to lower LH 
levels (although not significantly). The ether-induced 
decrease may have masked any further reduction that could 
have been caused by the a-agonist. In the present
experiments, all doses of N-allylnormatazocine, injected at 
12.3Oh, reduced plasma LH concentration at 14.3Oh compared 
to controls. However, the reductions were not significant, 
leaving the involvement of a-receptors unclear.
The results, both within and between groups decapitated at 
18.0Oh, exhibited a wide variance. This is likely to have 
resulted from the use of N-allylnormetazocine as a racemic 
mixture; as pointed out earlier, the (+)enantiomer is a a- 
agonist while the second is a ji-antagonist. Furthermore, 
the (+)enantiomer may also act at non-opioid a-receptors.
It is possible that, similar to naloxone, the ^-antagonist
properties are responsible for the stimulatory effects of 
N-allylnormetazocine. Thus the a-agonist properties would
appear to cause inhibition of the preovulatory LH surge 
since two of the doses used reduced the surge levels of LH 
(again non-significantly). However, the possibility that 
the stimulatory actions of this drug are mediated by its 
actions at non-opioid a-receptors cannot be discounted.
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Aminergic Activity at 14.30h
Of the monoamines measured, 5HIAA was the only metabolite 
which appeared within the detectable limits of the HPLC-ECD 
system. When raised concentrations of 5HT were found, 
increased levels of 5HIAA were almost always observed. This 
indicates that, at times when 5HT content is elevated, the 
release of this monoamine may also be increased. Since the 
enzyme monoamine oxidase (MAO) is involved in the 
catabolism of all three monoamines measured it is probable 
that a similar relationship may exist between 
concentrations of the catecholamines and their secretion. 
This premise is reviewed in more detail in the General 
Discussion, under the section entitled, 'Catecholamine 
Concentrations and Neuronal Activity'.
i
I
I
The only dose of naloxone which significantly altered the 
magnitude of the preovulatory LH surge (lOmg/kg) had no
i
effect on the concentrations of NA or DA in any of the four 
areas studied. Thus, it appears that the catecholamines may 
be of little importance in the mediation of naloxone- 
enhancement of the LH surge amplitude.
The lOmg/kg dose of naloxone did, however, increase 5HIAA 
concentrations in the SCH, MPO and ME. Taken on their own, 
the results suggest that the naloxone-induced increase in 
the LH surge may be mediated by antagonism at presynaptic 
opioid receptors on 5HT neurones which are known to make 
connections with LHRH neurones in this area (Kiss and
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Halasz, 1985), and believed to stimulate LHRH release (King 
et al, 1986).
However, several other doses of naloxone also increased 
5HIAA concentrations in these three regions but, without 
the same effects on LH. These doses also generally 
increased DA concentrations in the MPO and ME. DA is 
thought to be stimulatory to LHRH secretion by an action in 
the MPO (Kawakami et al, 1975) and to inhibit LHRH release 
at the level of the ME (Fuxe et al, 1977). This latter 
action may account for the failure of the increased 5HT 
(and DA) activity in the MPO, produced by the lower doses, 
to enhance the LH surge. This hypothesis is further 
supported by the finding that levels of DA in the ME 
similar to those of controls are associated with elevated 
LH concentrations during the surge. DA projections to the 
external layer of the ME secrete this amine into the 
hypophyseal portal blood system as PRL inhibiting factor 
(PIF) (Ben-Jonathan, 1985). Naloxone suppresses PRL 
secretion by increasing the outflow of DA from the ME 
(Pfeifer et al, 1987). The possibility that the increased 
DA concentration in the ME found in the present study is a 
reflection of naloxone's actions on the regulation of PRL 
secretion cannot be discounted.
The lowest dose of naloxone markedly elevated NA 
concentrations in the MPO, ME and ARN, but reduced LH surge 
levels (although not significantly). Only in the ME did any 
other dose of naloxone alter NA concentrations. Elevated NA
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levels were associated with both high and low circulating 
LH concentrations during the surge and this was dependent 
on dose administered. Hypothalamic NA is generally believed 
to be stimulatory to LHRH neurones when circulating gonadal 
steroid concentrations are high, such as during pro­
oestrus. However, inhibitory actions have also been 
reported at this time (Dotti and Taleisnik, 1984). If the 
increased NA concentrations found in the work presented 
here are mediating the effects of naloxone, then it would 
appear that NA is exerting an inhibitory influence on LHRH 
secretion. The failure of the higher dose of naloxone, 
which increased NA concentrations in the ME, to reduce the 
surge amplitude may be attributable to the absence of 
concurrent DA inhibition in the ME. Thus, it may be the 
cumulative effects of NA and DA that mediate the negative 
influence of naloxone on the surge.
Consequently, the results are consistent with the 
hypothesis that naloxone enhancement of the LH surge is 
primarily mediated by 5HT in the MPO. This effect of 5HT 
may be reinforced by a similar stimulatory action of DA in 
the MPO. There is also evidence that naloxone activates an 
inhibitory action of DA in the ME which could negate the 
above stimulation. Furthermore, naloxone's reduction of the 
surge may also involve the stimulation of an inhibitory NA 
input to the LHRH neurones.
Similarly to naloxone, the lower doses of Duromorph 
generally elevated biogenic amine concentrations in the
four areas examined. As previously indicated, this can be 
attributed to Duromorph's ability to act as an antagonist 
in areas sparsely populated with ^-receptors. However,
unlike naloxone, the lower doses of Duromorph elevated the 
LH surge amplitude. This was associated with increased 5HT 
activity in all four areas studied and elevated DA levels 
in the MPO, but with no alteration of DA activity in the 
ME. Hence, the apparent stimulation of the LH surge caused 
by the lower doses of Duromorph may result from its n-
antagonist activity increasing the stimulatory biogenic 
amine activity but, only in the absence of the inhibitory 
influence exerted through DA in the ME.
The highest two doses of Duromorph completely abolished the 
LH surge, but in association with elevated 5HT activity in 
the MPO and ME. From the above, such activity would be 
expected to cause increased rather than reduced secretion 
of LH. However, this was in combination with both elevated 
NA concentrations in the ME and unaltered DA concentrations 
in the MPO. It could be that the stimulatory action of 5HT 
is not sufficient to over-ride the inhibitory influence of 
NA without the support of DA stimulation in the MPO. This 
suggestion implies that a combination of the stimulatory 
inputs from 5HT and DA neurones may be required to produce 
LHRH hypersecretion.
The effects of the higher doses of Duromorph are likely to 
result from its agonist properties, since increasing its 
concentration by an order of magnitude will greatly
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increase its receptor occupancy rate. It is difficult to 
reconcile the similar inceases of NA concentrations in the 
ME resulting from both the low and high doses of Duromorph. 
Such increases could be explained if the agonist effects on 
NA were not direct, but were mediated by inhibitory 
interneurones (possibly GABA) that possessed a relatively 
dense population of receptors. The antagonist activity of 
Duromorph would then not be evident in this system, and 
elevation of NA concentrations would occur regardless of 
dose. Thus, the paradoxical stimulation of the surge by 
Duromorph may be mediated by a ^-antagonist-induced
increase of stimulatory 5HT activity in the MPO and ME 
which may be enhanced by DA activity in the MPO. 
Furthermore, \i-inhibition of the surge may be mediated by
an inhibitory action of NA in the ME.
The K-agonist, Tifluadom, was very successful in reducing 
the LH surge amplitude at all but the lowest dose. The 
action of Tifluadom on LH concentrations was clearly 
mirrored by its ability to elevate NA levels, most commonly 
in the ME. This result is consistent with the previous 
findings that increased NA activity in the ME after opiate 
administration is associated with a decreased surge 
amplitude. It would appear that the inhibitory NA pathway 
has the greatest influence on the LHRH neurones, since the 
increased 5HT and DA activity in the MPO failed to enhance 
LH release in the face of this NA inhibition. Thus, the 
opioid receptor population which activates the inhibitory
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NA p a t h w a y  a p p e a r s  t o  be c o m p o s e d  of a h e t e r o g e n o u s  g r o u p  
of ji- a n d  K - r e c e p t o r s .
The putative a-agonist had least effect on biogenic amine 
concentrations in the areas studied, and had no significant 
effects on LH concentrations during the surge. This 
provides qualitative support for the hypothesis that opioid 
effects on the LH surge are mediated by aminergic neurones 
within the hypothalamus. However, the lower doses of N- 
allylnormetazocine did increase NA concentrations in the 
ME, and this was associated with a decreased LH surge 
magnitude for one of the doses. This indicates that the 
opioid receptor population which activates the inhibitory 
NA pathway might include a-receptors. However, given the
high degree of activity this drug possesses for several 
receptor types, it is possible that N-allylnormetazocine 
has both positive and negative influences on the surge; 
these actions negating each other. The results, taken on 
their own, do not provide stong support for the putative 
role of opioid a-receptors in mediating EOP effects on the
preovulatory LH surge.
In conclusion, it appears the opioid antagonist enhancement 
of the LH surge involves stimulatory actions of 5HT and DA 
in the MPO while the agonist inhibition involves the and 
K-opioid activation of an inhibitory NA pathway projecting 
to the ME.
Aminergic Activity at 18.00h
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The results indicate that aminergic activity within the 
SCH, MPO, ME and ARN decreases on the late afternoon of 
pro-oestrus, since the concentrations of the amines are 
mostly lower than at 14.30h. This was expected, since it is 
generally accepted that alterations to the activity of 
aminergic neurones projecting to the LHRH neurones during 
the critical period play a major role in the generation of 
the preovulatory LH surge. Similar changes in unmanipulated 
aminergic activity have been previously reported (Ranee and 
Barraclough, 1982).
Administration of the drugs at 12.30h was relatively 
ineffective at altering biogenic amine concentrations at 
18.00h. This is in marked contrast to their effects on LH 
concentrations at this time, and on the amines earlier on 
the afternoon of pro-oestrus. It is possible that by this 
time the drugs may have been metabolised to inactive forms. 
However, Duromorph has potent analgesic actions up to 24 
hours after administration, and can be detected in the 
circulation throughout this period (Johnston, 1990). Of all 
the drugs, Duromorph had least effect on neurotransmitter 
concentrations at 18.00h. It appears that the lack of 
effect of Duromorph, and by inference of the other opiates, 
cannot be attributed to breakdown over the course of the 
experiment. An alternative explanation is that the neural 
circuitry on which these drugs exert their actions is less 
succeptible to pharmacological manipulation at 18.0Oh. Such 
a possibilty lends support to the hypothesis that the
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neural activity in the early afternoon is responsible for 
the generation of the surge, rather than the activity at 
the time of the surge.
The antagonist, naloxone, increased only NA concentrations 
in the ME, and 5HIAA concentrations in the ARN. These 
effects are similar to, but less extensive, than those 
recorded at 14.30h, and may represent the 'tail-end' of its 
actions on these systems. Duromorph and Tifluadom produced 
virtually no alterations of the amine concentrations. This 
may reflect an increase in EOP activity which masks the 
effects of these drugs. Such an increase would be expected 
at 18.00h as the tonic EOP suppression of LH would be 
reinstituted to curtail LH secretion on completion of the 
surge. Unlike its effects earlier in the day, N- 
allylnormetazocine increased DA activity in the SCH, 5HT 
activity in the SCH, ME and ARN, and NA activity in the 
ARN. The non-opioid properties of N-allylnormetazocine may 
account for such actions. As the EOP tone increases, it 
would mask the possible opioid actions of N- 
allylnormetazocine while leaving the non-opioid actions 
unaffected.
In summary, the relationship between the effects of the 
drugs on neurotransmitter concentrations at 18.0Oh and on 
LH secretion is unclear. However, it is evident that, in 
saline-treated animals; spontaneous aminergic activity is 
decreased at a time when the release of LH would be 
returning to the basal secretion pattern.
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TREATMENT PLASMA LH CONCENTRATION
Dose Saline Naloxo ne Duromo rph Tifluadom SKF 10047
Zero 2.1+0.3 (12)
1 mg/kg 1.1+0.2 <5) 1.0+0.1 (5) 1.3+0.2 (5) 0.7+0.1 (5)
3 mg/kg 1. 1±0.1 (5) 1.9+0.6 (10) 1.2+0.2 (10) 1.0+0.1 (10)
10 mg/kg 1.6+0.1 (11) 0.8+0.1 (5) 1.1+0.1 (5) 0.9+0.1 (5)
30 mg/kg* 2.9+0.7 (5) 1.6+0.3 (10) 1.3+0.1 (5) 1.2+0.1 (10)
50 mg/kg* 3.5+1.6 (5) 1.7+0.3 (5) 1.1+0.2 (5) 1.4+0.1 (5)
Table 5(a). Plasma LH concentrations (ng/ml + SEM) at 
14.30h on pro-oestrus after administration of drugs at 
12.30h on the same day. The number of animals in each group 
is given in parentheses.
TREATMENT PLASMA LH CONCENTRATION
Dose Saline Naloxone Duromorph Tifluadom SKF 10047
Zero 9.5+2.2 (14)
1 mg/kg 5.0+1.7 (5) 15.8+4.5 (5) 7.0+4.1 (5) 10.5+3.7 (5)
3 mg/kg 5.9+2.5 (5) 5.2+1.9 (5) 1.8+0.2b(10) 5.3+2.3 (9)
10 mg/kg 23.l+7.5a(9) 5.6+4.0 (5) 2.0+0.6a (6) 14.5+7.9 (5)
30 mg/kg* 19.3+4.0 (5) 2.2+0.9a(10) 1.8+0.2a (5) 19.8+13.3(5)
50 mg/kg* 19.6+5.1 (5) 1.2+0.la (4) 3.1+1.0a (5) 4.7+2.0 (4)
Table 5(b). Plasma LH concentrations (ng/ml + SEM) at 
18.00h on pro-oestrus after administration of drugs at 
12.30h on the same day; as p<0.05, bs p<0.01 compared to 
controls using Scheffe's Analysis of Variance and 
Covariance. The number of animals in each group is given in 
parentheses.
* The doses of Duromorph used were 40 and 60 mg/kg 
rather than 30 and 50 mg/kg respectively.
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|TREATMENT BIOGENIC AMINE CONCENTRATION IN THE SCH RATIO OF
NA DA |5HIAA | 5HT 5HIAA/5HT
| Saline 40.1+7.2 2.4+0.5 8.3+2.0 23.1+3.3 0.368+0.069
Naloxone
lmg/kg 47.1+9.6 6.6+2.0 a 23.5+4.7 b 44.4+5.2 b 0.560+0.141
3mg/kg 37.3+6.7 7.3+1.7 b 16.6+4.9 37.1+5.7 0.393+0.082
lOmg/kg 47.7+9.4 3.0+0.4 18.2+5.6 a 39.4+8.1 a 0.452+0.064
30mg/kg 38.3+1.1 5.8+2.0 a 19.6+2.4 a 29.6+2.0 0.681+0.111
50mg/kg 46.3+9.0 4.3+0.8 11.9+2.1 15.4+3.4 0.716+0.100
Duromorph
lmg/kg 70.9+16.4b 10.0+2.5 c 20.5+4.6 b 61.3+14.lc 0.351+0.076
3mg/kg 43.9+4.7 4.8+1.1 10.7+2.0 29.5+3.4 0.410+0.064
lOmg/kg 28.8+5.9 10.5+2.8 c 17.2+6.9 25.5+12.7 1.200+0.580b
40mg/kg 36.1+7.1 3•8+0•6 16.7+2.7 a 27.6+6.7 0.730+0.093
60mg/kg 26.2+5.8 2.6+0.7 20.1+7.4 a 23.0+4.7 0.674+0.233
Tifluadom
lmg/kg 48.6+11.0 8.0+1.4 23.1+4.2 b 64.5+20.0b 0.544+0.160
3mg/kg 52.4+12.1 4.7+1.4 27.2+6.5 c 42.1+8.1 0.720+0.209
lOmg/kg 53.8+8.2 6.6+2.0 21.7+3.3 a 64.8+13.lb 0.388+0.114
30mg/kg 42.8+6.9 3.7+1.0 21.9+3.0 a 62.2+10.2b 0.367+0.037
50mg/kg 40.5+13.9 8.1+3.1 14.4+4.0 22.7+5.8 0.633+0.074
SKF 10047
lmg/kg 42.8+9.2 7.1+2.6 a 20.3+5.0 46.3+10.4 0.569+0.178
3mg/kg 37.4+4.4 4.4+0.9 16.4+2.0 39.9+8.4 0.484+0.131
lOmg/kg 36.1+6.9 5.9+1.5 16.0+2.4 30.1+14.4 1.140+0.148
30mg/kg 40.5+8.2 10.3+4.4 c 19.2+5.5 46.2+12.0 0.436+0.069
50mg/kg 26.6+6.3 4.7+0.5 13.4+4.6 23.8+4.2 0.514+0.096
Table 6. Biogenic amine concentrations (ng/jxg protein + 
SEM) and the ratio of 5HIAA/5HT in the SCH at 14.30h on 
pro-oestrus after administration of drugs at 12.30h on the 
same day; a: p<0.05; b: p<0.01; c: p<0.001 compared to 
controls using Scheffe's Analysis of Variance and 
Covariance.
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TREATMENT BIOGENIC AMINE CONCENTRATION IN THE MPO RATIO OF
NA DA |5HIAA |5HT 5HIAA/5HT
Saline 47.6+8.9 3.5+0.6 8.7+1.3 23.0+2.4 0.472±0.109 |
Naloxone
1 mg/kg 1 0 8 . 8 + 3 4 . 8  b 10.6+2.1 c 21.8+6.9 a 40.8+15.2 0.590+0.074
3mg/kg 74.4+8.6 9.1+2.2 b 21.2+3.7 a 35•3+6.2 0.574+0.029
10 mg/kg 43.1+7.8 4.6+1.5 19.9+4.0 a 23.8+5.3 0.866+0.293
30 mg/kg 36.0+8.0 8.2+0.2 17.1±3.6 51.9+10.6 0.311+0.150
50 mg/kg 28.2+12.6 3.4+1.3 13.9+4.6 25.4+6.6 0.561+0.192
Duromorph
1 mg/kg 82.5+16.2a 6.8+1.9 a 22.0+0.8 c 56.1+12.6c 0.459+0.077
3 mg/kg 76.9+10.5 4.4+1.1 19.3+3.3 b 39.1+5.3 0.536+0.136
10 mg/kg 91.8+29.9a 11.0+2.4 c 18.8+7.7 a 36.3+14.3 0.767+0.173
40 mg/kg 42.4+9.1 5•3+0.8 13.7+1.9 24.1+6.0 0.790+0.179
60 mg/kg 39.5+13.4 4.5+0.9 21.0+4.0 b 37.4+10.3 0.720+0.189
Tifluadom
1 mg/kg 74.5+4.8 9.1+3.4 a 38.8+15.4c 70.8+25.7c 0.594+0.119
3 mg/kg 53.9+4.8 5.3+0.5 27.4+3.2 b 29.7+4.4 0.999+0.223
10 mg/kg 95.7+22.0b 11.6+2.9 c 34.8+7.9 c 51.2+7.8 a 0.745+0.192
30 mg/kg 51.4+10.1 5.7+0.6 20.0+3.3 33.4+6.4 0.622+0.052
50 mg/kg 53.9+25.7 5.4+1.2 19.4+3.9 28.2+5.6 0.800+0.248
SKF 10047
1 mg/kg 56.1+1.2 4.6+0.8 19.6+2.4 28.9+10.3 1.230+0.456
3 mg/kg 69.7+11.3 7.3+1.4 a 26.5+6.9 20.8+2.4 1.077+0.267
10 mg/kg 61.2+14.7 9.6+2.8 b 22.6+9.3 26.5+6•2 0.874+0.228
30 mg/kg 42.7+5.7 6.7+0.5 13.5+2.0 26.3+2.4 0.534+0.090
50 mg/kg 37.9+9.9 5.9+1.3 15.6+2.9 28.1+4.1 0.604+0.121
Table 7. Biogenic amine concentrations (ng/fig protein + 
SEM) and the ratio of 5HIAA/5HT in the MPO at 14.30h on 
pro-oestrus after administration of drugs at 12.30h on the 
same day; as p<0.05; bs p<0.01; cs p<0.001 compared to 
controls using Scheffe's Analysis of Variance and 
Covariance.
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1 TREATMENT BIOGENIC AMINE CONCENTRATION IN THE ME RATIO OF
NA DA |5HIAA 5HT 5HIAA/5HT
Saline 22.4+4.1 21.4+6.0 5.1+0.8 13.1+2.2 0.461+0.065 |
Naloxone
1 mg/kg 1 0 1 .4 + 2 1 .0  c 57.1+19.3a 13.6+2.8 a 66.6+15.6c 0.227+0.057
3 mg/kg 72.6+7.1 c 61.1+16.7a 12.7+5.2 a 34.6+10.4b 0.220+0.093
10 mg/kg 46.2+9.8 22•5+6.5 11.9+1.8 a 20.5+1.9 0.688+0.067
30 mg/kg 66.6+16.8b 42.3+18.3 14.9+4.2 b 28.2+5.3 0.583+0.200
50 mg/kg 12.0+3.2 3.0+1.0 6.7+2.8 11.0+4.8 0.625+0.134
Duromorph
1 mg/kg 80.2+14.3c 46.6+16.9 10.2+1.1 42.7+4.1 b 0.248+0.032
3 mg/kg 69.1+8.9 c 71.7+21.5 15.1+2.6 a 29.9+5.1 0.534+0.088
10 mg/kg 46.0+15.6 71.0+39.5 12.6+4.8 33.3+15.0 0.622+0.313
40 mg/kg 45.9+9.1 a 58.8+14.4 11.3+2.1 27.8+6.8 a 0.572+0.146
60 mg/kg 35.8+11.3 26.5+11.3 7.3+1.0 14.2+3.9 0.559+0.082
Tifluadom
1 mg/kg 86.7+13.3c 47.1+25.2 10.5+2.4 33.6+4.3 a 0.308+0.039
3 mg/kg 64.8+11.8c 57.5+20.0 15.0+2.7 b 20.3+5.0 0.737+0.142
10 mg/kg 63.1+7.9 a 30.6+10.7 11.7+2.2 30.8+7.0 0.474+0.152
30 mg/kg 70.7+19.9b 60.7+29.2 11.8+2.6 40.2+13.9b 0.373+0.073
50 mg/kg 30.9+10.3 37.1+16.5 9.2+2.4 8.7+2.1 1.028+0.391a
SKF 10047
1 mg/kg 71.9+14.4b 35.1+24.1 14.0+3.6 40.0+10.3 0.365+0.043
3 mg/kg 80.9+15.2c 60.1+18.5 12.5+2.3 44.6+12.8 0.436+0.114
10 mg/kg 38.0+15.0 41.3+10.2 15.4+3.8 37.3+7.6 0.464+0.186
30 mg/kg 29.8+7.8 30.4+21.3 20.5+12.7 32.3+14.6 0.570+0.121
50 mg/kg 35.2+14.3 7.8+1.4 24.1+18.0 28.1+13.1 0.755+0.368
Table 8. Biogenic amine concentrations (ng/jig protein + 
SEM) and the ratio of 5HIAA/5HT in the ME at 14.30h on pro­
oestrus after administration of drugs at 12.30h on the same 
day; as p<0.05; bs p<0.01; c: p<0.001 compared to controls 
using Scheffe's Analysis of Variance and Covariance.
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|TREATMENT BIOGENIC AMINE CONCENTRATION IN THE ARN RATIO OF
NA | D A 5HIAA | 5HT 5HIAA/5HT
Saline 30.1+3.3 5.8+1.8 11.3+3.4 23.1+3.6 0.478+0.106
N a l o x o n e
1 mg/kg 1 0 0 .9 + 3 5 .7  c 11.1+3.3 22.1+4.2 52.5+15.3b 0.538+0.180
3 mg/kg 43.8+7.8 8.8+1.5 19.0+6.9 26.9+8.8 0.968+0.473
10 mg/kg 50.6+15.7 5.2+1.5 12.9+2.3 20.6+3.2 0.698+0.107
30 mg/kg 48.0+10.5 5.5+1•8 16.1+4.1 38.8+5.9 0.422+0.113
50 mg/kg 23.8+4.5 5.7+1.5 15.2+1.6 18.3+4.4 1.026+0.410
Duromorph
1 mg/kg 65.7+13.2a 5.6+1.2 19.3+4.3 54.3+20.7b 0.492+0.169
3 mg/kg 93.3+8.89c 11.3+1.1 23.6+4.3 a 30.1+6.3 0.960+0.273
10 mg/kg 50.1+7.4 6.0+1.6 14.2+4.8 27.9+14.8 0.753+0.274
40 mg/kg 55.6+17.7 4.4+1.4 13.0+2.2 18.6+4.8 0.868+0.130
60 mg/kg 52.5+12.3 8.6+2.0 21.9+3.6 a 38.2+7.6 0.628+0.096
Tifluadom
1 mg/kg 81.9+15.7b 14.7+4.0 27.3+7.0 a 82.9+26.7b 0.409+0.149
3 mg/kg 56.5+8.6 8.9+2.9 15.2+1.7 23.1+4.0 0.747+0.125
10 mg/kg 126+41.4 c 20.8+8.9 b 36.2+15.3b 87.5+49.2b 0.494+0.053
30 mg/kg 87.8+17.2b 7.1+1.8 19.8+4.4 48.1+13.5 0.447+0.090
50 mg/kg 30.6+8.0 6.7+4.1 16.4+3.1 11.8+0.8 1.362+0.190c
SKF10047
1 mg/kg 57.0+8.6 6.1+1.0 15.8+1.4 38.8+6.8 0.455+0.072
3 mg/kg 78.6+17.6b 10.7+2.2 23.5+7.9 25.2+8.1 0.652+0.122
10 mg/kg 44.6+21.3 6.6+1.9 7.9+1.4 20.4+6.4 0.478+0.139
30 mg/kg 67.3+13.2a 7.5+1.3 17.7+0.9 44.2+7.1 0.441+0.078
50 mg/kg 32.9+8.8 7.6+3.8 13.8+5.1 24.7+6.9 0.581+0.130
Table 9. Biogenic amine concentrations (ng/jig protein + 
SEM) and the ratio of 5HIAA/5HT in the ARN at 14.30h on 
pro-oestrus after administration of drugs at 12.30h on the 
same day; as p<0.05; bs p<0.01; cs p<0.001 compared to 
controls using Scheffe's Analysis of Variance and 
Covariance.
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|TREATMENT BIOGENIC AMINE CONCENTRATION IN THE SCH RATIO OF
NA | DA |5HIAA 5HT 5HIAA/5HT
Saline 22.1+5.5 2.6+0.7 8.7+2.6 18.9+3.1 0.447+0.081
Naloxone
1 mg/kg 27.2+5.9 3.1+1.3 13.3+3.9 16.7+5.0 0.873+0.624
3mg/kg 32.7+4.6 4.4+1.2 10.2+1.6 19.1+6.6 0.923+0.412
10 mg/kg 51.5+13.0 5.4+0.9 19.0+4.3 33.2+8.0 0.653+0.123
30 mg/kg 26.5+7.7 4.1+0.0 10.8+6.1 17.2+4.8 0.592+0.198
50 mg/kg 26.1+7.3 4.4+1.8 11.8+2.9 17.3+3.5 0.741+0.196
Duromorph
1 mg/kg 29.6+4.4 5.0+2.0 12.3+4.8 37.9+13.6 0.322+0.187
3 mg/kg 26.9+4.6 3.0+0.9 10.4+1.4 18.6+4.0 0.594+0.086
10 mg/kg 18.7+9.5 2.5+0.2 8.9+1.5 9.1+2.2 0.811+0.172
40 mg/kg 24.4+4.7 2.3+0.4 9.7+2.4 19.3+5.0 0.603+0.103
60 mg/kg 23.7+9.7 3.4+1.9 16.8+10.1 21.5+8.7 0.738+0.213
Tifluadom
1 mg/kg 20.6+7.3 1.9+0.7 5.9+0.1 12.6+3.1 0.573+0.154
3 mg/kg 23.3+2.5 3.9+0.7 8.4+1.2 20.4+3.5 0.473+0.073
10 mg/kg 14.7+3.2 4.7+2.5 18.7+8.2 17.6+3.0 1.084+0.401
30 mg/kg 32.1+6.8 3.7+1.4 14.4+0.9 30.1+11.8 0.603+0.168
50 mg/kg 13.8+5.2 10.0+3.2 c 15.8+6.1 15.3+3.5 0.963+0.151
SKF10047
1 mg/kg 52.0+12.0 4.5+0.9 13.5+4.1 23.5+8.3 0.623+0.156
3 mg/kg 40.5+10.7 5.6+1.8 16.2+2.1 35.1+5.2 b 0.524+0.089
10 mg/kg 44.2+10.8 4.1+0.8 16.8+7.0 28.9+3.3 0.608+0.289
30 mg/kg 45.5+6.2 2.7+0.9 18.4+1.4 40.0+2.2 b 0.466+0.057
50 mg/kg 37.0+5.4 15.4+10.6a 27.4+5.9 c 21.8+5.1 1.610+0.680c
Table 10. Biogenic amine concentrations (ng/jig protein + 
SEM) and the ratio of 5HIAA/5HT in the SCH at 18.0Oh on 
pro-oestrus after administration of drugs at 12.30h on the 
same day; as p<0.05; bs p<0.01; c: p<0.001 compared to 
controls using Scheffe's Analysis of Variance and 
Covariance.
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TREATMENT BIOGENIC AMINE CONCENTRATION IN THE MPO RATIO OF
NA DA |5HIAA 5HT 5HIAA/5HT
Saline 29.1+7.0 3.8+0.4 10.4+2.7 21.2+4.3 0.717+0.227
Naloxone
1 mg/kg 71.3+13.9 6.0+1.7 8.1+2.6 22.2+1.9 0.380+0.145
3 mg/kg 53.6+12.6 5.2+1.7 14.0+2.6 20.4+7.9 0.738+0.365
10 mg/kg 46.2+9.6 6.1+1.5 15.7+2.7 30.2+4.5 0.552+0.081
30 mg/kg 30.1+9.0 2.1+1.5 5.8+2.3 14.0+5.0 0.425+0.052
50 mg/kg 43.0+16.0 4.8+1.6 10.1+3.7 22.1+7.0 0.434+0.025
Duromorph
1 mg/kg 50.8+5.2 13.3+4.8 c 25.8+6.1 33.7+12.0 0.717+0.042
3 mg/kg 30.4+4.5 4.7+0.9 11.0+3.5 15.9+3.5 1.066+0.532
10 mg/kg 26.9+3.6 6.0+2.1 17.5+4.2 22.3+4.4 0.785+0.151
40 mg/kg 38.6+6.4 4.3+1.5 17.1+5.1 15.1+3.4 1.572+0.576
60 mg/kg 47.6+3.9 4.0+0.9 18.5+6.5 22.4+5.8 0.868+0.273
Tifluadom
1 mg/kg 42.5+6.8 2.7+0.5 8.4+1.1 18.9+6.1 0.612+0.239
3 mg/kg 29.1+3.5 3.4+0.8 9.7+1.2 18.2+2.6 0.608+0.083
10 mg/kg 22.5+0.4 2.4+0.3 10.0+0.5 18.6+5.1 0.633+0.186
30 mg/kg 52.3+12.3 3.8+0.4 10.4+2.5 23.0+2.8 0.508+0.244
50 mg/kg 40.0+15.9 4.0+1.5 10.4+4.0 26.1+6.9 0.521+0.133
SKF10047
1 mg/kg 40.5+11.9 2.4+0.6 8.8+3.1 13.6+3.9 0.811+0.262
3 mg/kg 53.1+5.7 6.6+1.8 25.6+9.8 36.9+8.8 0.728+0.172
10 mg/kg 27.8+3.5 2.3+1.2 12.7+4.8 21.3+2.7 0.579+0.179
30 mg/kg 28.3+0.3 3.8+2.1 10.6+2.8 15.4+3.2 0.812+0.262
50 mg/kg 32.4+10.2 7.9+0.0 18.9+11.2 11.8+3.3 0.530+0.131
Table 11. Biogenic amine concentrations (ng/jig protein + 
SEM) and the ratio of 5HIAA/5HT in the MPO at 18.0Oh on 
pro-oestrus after administration of drugs at 12.30h on the 
same day; a: p<0.05; b: p<0.01; c: p<0.001 compared to 
controls using Scheffe's Analysis of Variance and 
Covariance.
j
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|TREATMENT BIOGENIC AMINE CONCENTRATION IN THE ME RATIO OF
NA DA 5HIAA | 5HT 5HIAA/5HT
Saline 28.7+4.4 36.3+8.0 5.9+1.3 14.8+2.0 0.453+0.087
Naloxone
1 mg/kg 35.7+5.8 27.7+8.1 12.2+3.3 19.3+2.9 0.749+0.084
3 mg/kg 66.3+11.9b 20.2+6.4 16.0+4.2 26.4+8.2 0.767+0.285
10 mg/kg 58.4+13.3a 50.3+17.1 14.6+5.0 18.2+3.9 0.604+0.119
30 mg/kg 29.6+10.4 6.6+2.4 5.3+1.9 10.4+4.1 0.658+0.200
50 mg/kg 55.3+12.9a 10.1+3.6 11.1+5.3 23.4+11.4 0.481+0.034
Duromorph
1 mg/kg 29.8+3.4 32.9+15.1 9.2+2.9 17.5+5.1 0.587+0.165
3 mg/kg 40.2+7.8 22.7+13.4 10.8+2.7 18.0+4.0 0.733+0.206
10 mg/kg 30.3+9.2 23.5+15.4 8•3+2.5 19.1+2.8 0.458+0.136
40 mg/kg 27.8+3.9 24.5+4.8 9.5+1.8 17.7+5.0 0.569+0.234
60 mg/kg 40.6+16.3 30.2+12.9 6.6+2.9 13.9+6.2 0.811+0.402
Tifluadom
1 mg/kg 27.0+5.7 14.2+4.3 11.8+3.2 10.2+4.8 1.000+0.000
3 mg/kg 37.0+8.1 25.5+6.3 6.4+1.0 14.9+4.1 0.600+0.128
10 mg/kg 26.4+5.9 44.2+16.3 10.7+2.6 15.4+2.3 0.732+0.192
30 mg/kg 35.2+7.0 53.4+23.3 15.2+10.6 12.6+3.4 1.050+0.551
50 mg/kg 34.4+8.8 19.5+8.4 12.6+1.9 11.8+2.6 1.267+0.434
SKF10047
1 mg/kg 35.5+11.3 15.1+4.4 7.5+2.5 32.6+13.1 0.393+0.220
3 mg/kg 40.6+10.6 33.9+10.2 14.3+3.0 a 21.3+3.6 0.787+0.202
10 mg/kg 32.0+8.9 14.4+8.6 5.6+0.7 15.7+7.2 0.580+0.251
30 mg/kg 72.3+21.4 22.4+5.9 15.2+4.2 a 25.1+3.8 0.595+0.125
50 mg/kg 37.2+17.7 15.3+12.1 13.1+0.2 23.0+18.1 1.510+1.200
Table 12. Biogenic amine concentrations (ng/^g protein + 
SEM) and the ratio of 5HIAA/5HT in the ME at 18.00h on pro­
oestrus after administration of drugs at 12.30h on the same 
day; as p<0.05; bs p<0.01; c: p<0.001 compared to controls 
using Scheffe’s Analysis of Variance and Covariance.
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|TREATMENT BIOGENIC AMINE CONCENTRATION IN THE ARN RATIO OF
NA DA |5HIAA 5HT 5HIAA/5HT
Saline 26.8+3.5 4.4+1.3 7.7+1.2 19.6+3.0 0.425+0.049
Naloxone
1 mg/kg 31.7+6.0 4.6+1.5 17.0+3.6 b 21.7+4.4 0.973+0.313
3 mg/kg 43.6+10.1 7.3+2.2 11.4+2.0 21.2+5.6 0.616+0.193
10 mg/kg 34.5+7.5 7.4+2 .4 15.4+3.6 b 13.0+2.2 1.170+0.334
30 mg/kg 42.8+6.5 2.9+0.4 10.9+1.2 36.2+16.7 0.666+0.243
50 mg/kg 30.8+5.2 4.0+1.2 8.2+1.1 17.5+3.6 0.561+0.171
Duromorph
1 mg/kg 41.8+5.1 7.5+1.8 10.3+1.5 21.9+6.1 0.465+0.129
3 mg/kg 24.6+5.9 3.0+0.9 6.9+1.8 16.0+5.8 0.437+0.141
10 mg/kg 34.7+6.0 4.1+1.8 11.5+1.3 14.5+4.6 0.626+0.084
40 mg/kg 23.8+4.5 4.4+1.4 7.7+2.4 7.9+1.4 0.501+0.059
60 mg/kg 26.4+6.8 2.2+0.2 8.2+2.7 13.0+2.2 0.595+0.126
Tifluadom
1 mg/kg 27.4+2.0 4.3+0.9 8.4+2.8 21.8+5.7 0.507+0.238
3 mg/kg 25.1+4.5 4.1+1.0 8.7+1.0 18.8+2.6 0.491+0.050
10 mg/kg 28.9+4.6 7.0+2.1 11.3+1.8 17.8+4.7 0.770+0.161
30 mg/kg 25.3+10.9 5.1+2.1 6.3+1.2 10.6+2.2 0.574+0.074
50 mg/kg 22.7+6.5 4.5+0.2 8.4+0.7 No Result No Result
SKF10047
1 mg/kg 38.6+8.3 4.6+1.4 11.0+1.2 19.1+5.8 0.934+0.371
3 mg/kg 35.6+3.1 6.1+1.3 10.4+2.4 19.3+4.6 0.781+0.168
10 mg/kg 30.8+4.7 5.3+1.8 8.9+2.8 9.8+1.2 0.948+0.301
30 mg/kg 45.6+10.2a 1.9+0.5 15.7+7.8 24.7+18.4 1.776+0.981c
50 mg/kg 18.7+5.5 6.6+3 * 2 10.2+2.7 8.6+1.7 1.290+0.450a
Table 13. Biogenic amine concentrations (ng/mg protein + 
SEM) and the ratio of 5HIAA/5HT in the ARN at 18.00h on 
pro-oestrus after administration of drugs at 12.30h on the 
same day; as p<0.05; bs p<0.01; c: p<0.001 compared to 
controls using Scheffe's Analysis of Variance and 
Covariance.
92
o
oN
(0
+>
<u
e
p
o
a
o i
VO o
I
&
eo
•d
a
3ft
<H
pQ)
-P
<d
to
3Pi
-P
to
a)
01
o
Pi
Q*
a
o
oro
■P<d
sHto
+1
toc
o•H
■P<d
Pi
■PC
a)
uc
ou
inPI
<d
e(0
fd
rH
OO
•
o
vQ*
U
o
V04
in
o
•
o
V04
cd
<d
T3
a)
m
<Dxs-p
co
&
o
ro
•
<N
(MSBfd l«/6u) 
U0T)«1)U»3U03 JI
(d
>w'
ro
0
P
3
•H
b
o-p
T30
P<d&Ou
sa
li
ne
-t
re
at
ed
 
an
im
al
s 
us
in
g 
Sc
he
ff
e'
s 
An
al
ys
is
 
of
 
Va
ri
an
ce
 
an
d 
Co
va
ri
an
ce
o
G
93
oto
e
o
•o
(0
3
rH
O  S m
n
-H
EH
ooo o
1— 1 
o
1 "I
o
— 1— » 
o
1
©
CO CM rl
u
<1>
•P
<d
03
3M
-Pm
<1)01
Ou
cu
g
o
xi
o
o
•
00
•pcti
s
+i
0)
G
O
•H
-P<d
u
+>
G
<D
O
G
O
U
«PI
<d
e(0
<di—I
P<
o
o
•
o
Vcu
o
o
Vcu
m
o
•
o
V
04
(d
<d
•a
Q)
0)
CD
xs-p
G
O
.c
o
ro
•
<N
ou
•P
a
o
o
(•Ktid |«/6u) 
U0I)U)U»9U03
CO
o
u
3
*3
Co
nt
ro
l 
Na
lo
xo
ne
 
Du
ro
mo
rp
h 
Ti
fl
ua
do
m 
N
-
a
l
l
y
l
n
o
r
m
e
t
a
z
o
c
i
n
e
io
n 
10
0 
n 
10
0 
b 
io
o 
n 
lo
o 
n
94
oo
00
o o
s*
o S'
co
pu£>
CO
<D01
0 u
01
a
o
x:
o
ro
+>
<d
ffi
CJ
co
a)X3
+>
C•H
W
+1
CO
c
O•H
+>
<dn
-Pa
a)uc
o
u
a>c•H
rH
<tfC
0)M
T3
<dM
O
53
r-H
o
o •
• a)
o u
V c
a <d
•H•• M
o (d
>o
rH o
O
• TJ
o oV <d04
0)•• oXi a
<d•k •H
IT) H
O <d• >O
V04 o
•• CO
<d •H
CO• >1
H
cd <d•a a
0)
§ CO
CO 0)
CD
£3 <1)
+> X3Oa Wo O*
£3 c
o •H
ro CO
• O
CM
H CO
rH
*P <rt
cd •5
CO Gcr» <d
(ui»%oxd 6n/6u)
U O t ) S X ) U > 3 U » 3  m |
Cd
a>u
poi
95
a
A
Q*
U
O
6O
Vi
3
Q
o
VO
°s
S' o a
n « •0 . Q
(ui»«id 6n/6u) 
u«i^ «2)u»3uo3 uh
01
0U*P01
<3>01
Ou
04
a
o
£1O
ro
-P
cd
oPM
£
d)xs
-p
c•H
s
+1
to
C3
O•H
-PcdVI
-Paa)oc
ou
a)c*H
rH
cdaa)vi
TJcd
VI
o£
A
a)M0oi
o
o•
o
Va
u
ov04
LDO
•
O
V04
id
a)G
•rH
iH
cd
01
o-p
•a
<d
VIcd
fu
-t
re
at
ed
 
an
im
al
s 
us
in
g 
Sc
he
ff
e’
s 
An
al
ys
is
 
of
 
Va
ri
an
ce
 
an
d 
Co
va
ri
an
ce
.
52
96
6n/6u) 
U O t ) U ) U 9 3 U « 3  u h
97
0)
a
•H
U
o
N
to
-P
Oeu
o
g
rH
> 1
o 8
rH
rH
o(0 ° ’» U) O O o
&
o
•o
id l. 
3 
»H 
«H
_ ©> o ^ co*
S'o 8
0)
p
-P
CO
CD01
Ou
Q*
a
o
.G
oro
O
A
Q*
U
0
e
ou
3
Q
_  tn 
’'s 
© 8
«s w
G
O
•H
-P
<d
M
-P
G
(D
U
G
O
U
(1)
G
•H
pH
<d
G
0)
M
V
(tf
M
O
S
O
14
-P
G
0
U
6n/6u) 
U O I ) U ) U 9 3 U « 3  u h
0 
U 
301 
•H
(0
10
98
(ui»oxd 6n/6u)
UOT)ttliU»U<>3 |ff
99
(dm <n
a
a
o
X
o
•H
(0
SB
om
_ 0> 
o a
o
o
«O CO
(uphold 6n/6u) 
uoi)U)u>3Uog uc
U0
-P
td
co
3U
-Pco001
oM
Q*
C
O
XO
ro
■P0
OPM
£
0
XI■p
c
■H
coC
o•H
+>0Pi
■PC
0oc
ou
0e
•H
aoQ
a>»✓
in
0H3O*•H
O
o
•
o
Va.
o
Vcu
in
o•
o
Va
td
<dT3
—  0 
£W W 
+ 1
ra
0.C
-P
CO
X
o
co•
CM
0 
•P
T30
Pi
td01
WO
O
sa
li
ne
-t
re
at
ed
 
an
im
al
s 
us
in
g 
Sc
he
ff
e'
s 
An
al
ys
is
 
of
 
Va
ri
an
ce
 
an
d 
Co
va
ri
an
ce
.
100
(u»%«id 6n/6u) 
uo;%«2)u»3u«3 |}f
101
6n/6u) 
U0i%«x)u»uo3 uf
102
c
o
X3
o
CO
-pid
EC
o
co
o
■P
c
•H
swCO
+1
in
o•
o
v04
<d
m
O
co•H
CO
rH
<d
a
CO
(uphold 6n/6u) 
U O T }« X lU > 9 U » 3  U tflllS
CO
a 
o•H
■P<du-pc 
a) u a  
o 
o 
•a •H 
O •H
-P
<D 
Oid
a)
rH
o•o
c  *H 
0  M
T3>i
«1 
m
co
VO
0)ppOi-H
CM
103
«
G
XJ
Qi
U
O
6
O
U
G
Q
1— 1 
o
~T— 1
o
1— '
o
— r~ 
o
«0 m ro
o
CM
I
O
o<0
_ cn
''n
21 P 0
<D
G
0
X
o
•H
cd
a
Om
« 01 s*
o 0
"SOo
I 1 I ' I ' I ' I ' I '
o o o o o o °
U  fl 4  PI fN rH
o u
H 1— '— r5 O 000 *o
o
T~
M
«o a
(uphold f>n/6u) 
u o p « n u » u « 3  tftfZB S
G
0
JG
o
ro
•
-P
cd
oP4
s
<1)
JG
+>
C
*H
Spa
w
+1
to
G
O
•H
+>
<d
u
+>
G
0
O
G
O
O
•a
•H
s
O
•H
-P
a)
u
<d
Q)
rH
o
•o
c
•H
X
0 
u 
•0
EC
1
in
io
©
s01
•H
b
••
.Q MH
0•v
in CO
o •H• CO
o >1
V rH
a idr;
••
cd
CO
• »
CD
id m
•0 m
0
0) x:
o
id w
co
CP
0 c
JG •H
-P CO
G
G
O CO
rH
x: (rt
o g
ro •H• G
CM id
«—1
T3
■P 0
id -P
id
CO 0
cr> u
-p
Pt 1
•0 0
G
m •H
0 rH
0
G CO
O
•H O
-P ■P
id
Pi •a
-p 0
CO Pi
•H id •
G a 0-rH S o
o G•Q u <d
(d ■HrH U
u o cd
0 o >
■p • oo u
id VQ* *0
CO c
G •• cd
u u
-p 0
CO • K u
CD iH co O cd1 • •Ho o U
u V 0a. a >
104
0
a
o
u
t  rr o O <n
u
IB o  a
( u t » u d  6n/£u) 
u o T i « n u » u o j  U U IH S
C
o
XI
o
ro
■P<0
0
XS
•P
c•H
2Wco
+1
m
a
o•H
■P
0M
-P
a
Q)oc
o
o
•a
•H
O
u•H
■P(1)
O0
a)rH
o
T3G•H
>iK
0 u •o >1 «1
in
vo
©u
p
&
••
.Q m
O• *»
m 03o •H« 03o
V r—1
a <de
••
0
e
0
0 4-1•a 4H0
XIa U
0 CO
m
O'
0 g
.c •H
-p 0
P
c
o 0iH
x: 0
o g
ro *H• GCN O
i—1
•o+> 0
0 -P
003 0
O' Pi
P -P
u l•o 0a
•H
o i—10c 0o
•H 0
-P -p
0
Pi •o
-P 003 Pi
■H 0 •
G 9* 0-rH & o
g 0 g
T3 u 0
*d •H
rH PI
Pi O 0
0 O >
-P • oo u
<d V
a •o03 g
P •• 0
M u+> 003 •v u0 rH Go o 0
1 • •Ho o Pi
u V 0a. a >
j
I
105
o
g
o
o
N
G
-P
0
6u
o
c
o(d °in O O
« O'O U
0> o 0
«s
a)
a
o
K
O
•H
td
2
« O'o VfO*
0> o 6
0
U
s >-JJ o  O u>
u
40 o a
(uphold 6n/6u) 
uopu^u»»uo() tftflllS
G
O
x:
o
ro
0)
G
O
•H
+>
td
P
-P
G
(1)
U
G
O
U
•d
•H
s
-P(1)
O
g
a)iH
0
•d
G
•H
X
0
P
•d>1
a
1
in
10
0)
p
•H
tu
••
M-l
o
in CO
o •H
• CO
o >i
V i—1Q* td
•#
td
CO• —
<D<d M-l
•d <H
0)
0) X3
6 otd w
CO
O'
a) G
X5 •H
-p CO
G
a
0 CO1—1
X5 <rt
O g
ro •H• G
CN Gi—1
•d
-P a)td x>
G
(0 <D
d> P
G +>
P 1
•d <D
G
•H
O rH
G
G CO
O
•H o
+> +>td
V-l •d
•P a)
CO p
•H G •
G g. a)
e uJes o G
*d o G
G •Hi—1 P
P o G
<1) o >
-P • O
M-l o CJ
G V04 ■d
CO G
G •• G
P o
*P <D
0) O
(1) H G
0 O Gl • •H
o o P
p V G04 04 >
106
( u i 6 n / 6 u )  
uoi)«j^ u*au«3 CHS
107
u
<D 
■P H-l 
cd
to
P
u
-p
m
a>
0
1
o
u
Q*
co
43
o
CO
■p<0
o
o
•
o
Va*
u
o
v04
in
o
jc5
04
u
o
B
o
u
p
Q
^ i n 1.
t 1— i— 1— i— 1— r
o  o  o  c
_ tn
*****
2* © 8
O
a
o
x
o
rH
(d
2
oin
_ 0* 
8-
tn 
o  8
fO « «
oa
0)43
•P
(3
•H
S  
W  
CO 
+ 1
01
<3
O
-H
-P
<d
u
•p(3
a)o(3
Oo
a
•H
C
O
-P
O
u
a>
co
o
v
04
<d
*d
•a
0)
CO
0)43
■P
C
O
43
O
CO•
CN
0
U
r— *— r
5  o  oO S  00
(ui»^ojd 6n/6u) 
uoi)«Jc^ u»uo3 m e
0
U
PCn
•H
Cu
108
o
o
N
<0
•p
0)
6
o
c
rH
>1
•H
A
Q*
U
O
S
O
U
P
Q
o a
f0 2
~\— ■— r T— '— I— r
oCM
S*
s*o a
m 2* 9 h Q
0
C
0
X
o
rH
0
£
t— 1—r
oin
o a
n jy
9ua
u0
-PMH
<d
CO
PM
■P
(0
0
0
1
o
u
Q*
g
o
a
o
ro
■P
<d
0Xi
-P
g
*H
s
w
CO
+1
(0
c
o
■H
•P
<d
o
+>
g
0
o
c
o
u
G
•H
G
O
-P
OPi
0
CO
o
o•
o
V04
o
o
V04
in
o
•
o
V
a
<d
<d
0
w
0
x:
-p
G
O
Xi
o
ro
•
CM
0
U
t— ■— r
(u»)«xd 6n/6u)
uoi^ BX)U93u«3 m e
U'w '
0U
Pon
109
6
O
•o
<d
3
H
«H
-H
i— '— r
o>
2* g a
r> 41 a 
o . o
n
0
+>
<d
CO
3M
-P
co
001
ouai
g
o
xi
o
ro
co
co•H
+>rd
u
+>
G
0
O
G
OO
G•H
G
O
•Po
u
0
w
o
o•
O
v
a
u
o
V
a
m
o•
o  
V ai
0
u
G
<d
•H
M
(d
>oCJ
•a
G
<d
0
o
G
<d
•H
U
cd
>
O
CO
•H
CO
>1
<d
id S
> i
<d
•a
0
co
o
jG
+>
G
O
Xi
o
ro•
CN
o
p
■Jf i— 1—r
5  o  cO «n cy  rH
V
«O Q
Ed &n/6u) 
►owoa iB S
0U
3
O'
110
XX
(Uu
6 A
o
u
p
Q
i— 1— 1— 1— 1— 1— r
O V
(N <-
_ O'
s«*' ' n
8* o 
->— 1— r
IS <0 «  o• • • ♦
rH O  O  O
ou
* r- 
O 5
u
u
Q)
-P
<d
to
Ou
-pto
<D
01
OM
Q*
G
O
.Coro
-Pfd
«uco
d)
A
-p
G
•H
2w
CO
+1
s e
2 _ 0* in
8 ^
O'
0  8  <!
rS w  M
« gUfe w«*>« m
n
Q 'Wn O
o•H
+>cd
Pd
(0
00
a>p
p
o*
o
o
•
o
VQ4
u
o
Vcu
mo
•
o
V
a
<d
>s(d
•o
0)
to
a£■p
g
o
X3 o  co • 
CN
d)
o
G
<d
•HU
<d
>o
o
•a
G<d
0)
o
G
(d
•HU
<d
>
m
O
co
0) 
>1 
1—H
<d
s
to
(1)
0)
.G
o
CO
O'
G
•H(0
P
CO 
1—I 
<d
G<d
•oa)
4J<d
0 u 
+>
1
a)
G •H 
1—I
cdto
O
-p
•oa)p
<d
&ou
Ill
0)
a
3 *H QjUS/(fUIBS E fi
*h *9 ob <d o
112
1— * -r i1— r
C4 oo
rH o o
6
O
•o
<d
3
•H
~i— 1— r
CO ■«*
© o
_  «3T» o ^
S'o 8
”2(0
O
a
o
x
o
rH
(0
55
1 1 1-
«r
o
0» 
o 8
-20a
00
U
d)-P
<d
(0
3 M -P CO 
<1>01
oVl
04
a
o
43o
ro
•P
<d
a)
43
+>
PS•H
§
+1
EhW
•n\
3M
sin
m
O
O•H
-P
<d
PS
o
o
•
o
V04
U
o
V
04
• w
in
o•
o
V
04
<D
UC
id
•H
U
id
S
u
•O<3
id
a>
u
o
id•H
M
id
>
m
0
m
•H
to
>i
id
id
•a
0)
Q)43
+>
C
O
43oro
•
CN
oVi
-P
fl
0
O
« a•H H 
0
o a
as/»viBS
00
0)
Vi
3tn
113
xi
Q*
U
O
B
O
u
3
Q
I— '— r
o <o
CN «H
T— '— I— '— |-
(N CO «• • •▼ H O ©
_  *7»Ojj
S'© B
o
o
0
Pi
•P
a
o
u
c
o•H
■P
0
M
+J
CO
•H
C
•H
B
730
Pi0}
-P
0
co
M
■Pto
001
O
Pi
cu
a
o
xo
CO
00
0u
CBS/HHI1S
730
■p
0 0 
Pi 
-p1 0 
a
•H
rH0
0
O
-P
730
Pi
0
&O
U
oo•
o
V
a
u
o
v
a
a
ino
•
o
Va*
<d
0
73
0
0
0xs
-p
co
X3o
co
•
CNI
■P
<d
0
O'3
u
73
m
O
0
Uc
•H
&
&U
•ac
0
0
o00
•H
Pi0
>
o
0 
•H 0 
>i 
r—I 
0
0
0
0
jC
Ow
tr>
0•H0
3
0
rH
0
i 1--1--1--1--1---
o o o*o ^ Cl
'— I— 1— I— 1— I— r
o © ©
VO T* CN
u
(uiv^ oxd 6n/6u)
U01^ «X)U19U«3 uh
114
o-p
Pi0 T3+> 0
<w Pi
115
B
O
•o
0
3iH
"i— 1— i— •— i— 1—r
o o o c
01
s*
o 0
0
p
•P i— i— r-
5 ° oO °  oo
u
(ui*%oxd 6n/6u)
UOt)«X)U»3U»3 nn
P0
-P
0
0
3
P
■P0
001
o
Pi
CU
G
O
xio
o•
00
-p0
0Xi
■p
G
•H
S
WW
+1
0
G
O
•H
+>0
Pi
■P
G0
O
G
O
O
0
G
•H
iH
0
G
0
Pi
730
Pi
O
53
X
0\
*H
0
Pi
§.-H
b
0
-P
TJ0P0
g
o
u
oo
•
o
VQi
•
u 0
OG«H 0
O •H• P
O 0
V >
04 O
V••
XJ 73
G
0ino 0• Vo G
V 0
a •H
P
•• 0
0 >
• 4-1
>1 O
0
•o 0
-H
0 0£ >i0 rH
0 0t-t
0 3
X!
•P 0
G 0O 4H
4-1
X 0o Xco O• W
CM
rH cr>
G
-P -H
0 0
3
0Cn 0
3 rHP 073 §
4-1 G
O 0
G 73O 0•H -P-P 0
0 0P p■P p>
0 1-H 0G G•H •Hg rH
X3 0
0 0
116
JS
cuu
o
£
o
u
3
Q
o»
o S
"S
o
u
43
a
o
u
(uix^oxd £n/6u) 
uoi)«j)u»auo3 mi
U
043
«W
0
0
3
Pi
+>
CQ
0
01
o
u
Qt
g
o
ao
o•
00
-p<d
0
.G
43
g■H
W
+1
CO
c
o■H
+>
0u
+>a
0o
goo
0
c
•H
«H
0
G
0U
73
0
u
o
s
u
o\
o
-p
730
&
£o
u
o
o•
o 
V ai
u
o
v
CU
in
o•
o
Va
0
0•a
0
CO
0JG43
a
O
.co
co•
CN
430
CQCT»
0
Pi
*0
«w
O
go•H
430Pi
43
0
•H
G
0
O
G0•H
Pi0
>
O
73
a0
0
uG0
•H
Pi0
>
0
CO
•H
0
>i
iH0
Co
nt
ro
l 
Na
lo
xo
ne
 
Du
ro
mo
rp
h 
Ti
fl
ua
do
m 
N
-
a
l
l
y
l
n
o
r
m
e
t
a
z
o
c
i
n
e 117
om
#»>N _ 0>
o S'
u0)-p
G
CO
OP
■P
CO
<D01
OU
CU
G
O
.Go
o•
00
o-p
T30)
&Ou
o
o•
o 
V ai
o
o
va
ino
_ o» S*''v
S’o B
m V  ^« o o
_ 0»o u ro*
tn 
o B
CO
G
O•H
■PcdP
-P
Ga)o
g
oo
<d
G•H
r—I
<d
G
a)p
T3G
P
OS
o
V04
G
W
+1 —  Q)
G
•a
CO
0)
.G
■P
G
O
Aon
•
CM
(ui>^ oid 6n/6u)
uoi)«x)u»9uog dh
O
u
•H
fit* sa
li
ne
-t
re
at
ed
 
an
im
al
s 
us
in
g 
Sc
he
ff
e’
s 
An
al
ys
is
 
of
 
Va
ri
an
ce
 
an
d 
Co
va
ri
an
ce
.
118
ja
Oiu
o
6
o
u
3
Q
ooo
CM
O
CO
_ tn
S *  
0» o 8
<o • «
0)
G
o
K
O
H
(0
z
ooo
CM
O
CO
om
_ 0>
0* 
o 8
" 8oo
O
a r2 o0 co
o
u
a)
-pm
<o
01
3
M
+>01
<D
0
1
O
Pi
a
G
o
Ao
o•
oo
+>
<0
ffl
o
w
(D
.g
+>
G
•H
(ui»)«xd 6n/6u)
U01)«Z)U»3U03 (J{
01
G
O
■H
-P
<d
Pi
■P
G
0)
O
G
O
V
<D
G
•H
a
o
Q
(0
0
CN
©
U
301
O
-P
•a
a>Pi
<d&o
u
o
o
•
o
V
CU
u
o
V
CU
mo•
o
v
cu
<0
*0
73
—  CD 
W 
+1
01
0) X3 
+>
G
0
x:o
CO
eg
<d
u
G
(0
•H
Pi<0
>
O
O
T3
G
<0
a)
u
G<0
•H
Pi<0
>
M-l
0
01
01
i—I 
<0
m
<1>
m
a)
X3
u
o>
G
•H01
G
01 I—I 
*0
G10
T3a)
■p<0
a)
Pi
+>
i
0
G
•Hi—I 
(001
119
(uis^oxd 6n/6u) 
uoi)ftX)u>3Uft3 g(
120
(ut»%«id 6n/6u) 
UOT)ftI)U>3U<>3 dc
121
u
<D
-pm
<d
CQ
Pu
+>
CQ0)01
ou
cu
e
o
jpo
o
•
00
0
-P
•O0)u(0&o
u
o
o
•
o
V
Cu
O
O
V
CU
in o
•
o
V
cu
>1G <0•H T3
—  q>
CQ
0)Xl
+>
C 
O 
A oro•
CM
-P<d
CQt7»
(ux>i«xd 6n/6u)
U O T lB X )U 13U O ^  ty f
O <N 
0)PP
cn
*H
122
o
o
N
0
4*
0
B14
0 
3»H
>t
rH
iH
0
1
55
XJ
Oiuo
B
ou
3
Q
_ 0» s *
o* o fl
"8oa
0
a
o
M
0•H
fd
55
- f r " * « wO u<o*
2* o fl
"80a
0
U
43
3
0
U
(uis^ oxd 6n/6u)
U01)«X)U»3U«3 UHIBS
I
OM04
3
O
43
o
o
•
00
+3
0
53oCO
04343
3•H
awCO 
+ 1
CQ(3
O•H+3
cdu+3
(30
u
3Ou
•0•H0
*C
o•H
4>0000rH
o*0(3•H
>iX0M
T3
>im1
in
0
CN
0
U
rH
oo•
o
VCU
••
o •
0rH 0o 3• 0o •H
V U
04 0
>• • O
o o
• •*
m (3o 0•
o 0V 004 3
0•• •H
M
0• >
>i0 44
T3 0
0 0e •H
0 00 >irH
0 043 343
3 0o -
043 44O 44
ro 0• 43Csl UH CO
43 O'
0 3•H
0 0
O' 33
U 0
*0 rH
m 2
o •H
3a 0o•rH •043 00 43O 043 00 u•H 43
(3 1•H 0g 3
■0 •H
0 rH
0U 0
04-> O4-1 43
0
•00 03 14U 043 Q«0 g0 0o o
123
i
ou
cu
g
o
43oo
•
00
-p(d
S.
0
43
+>
(3
•H
aww
+1
o
o•
o
Vcu
u
o
V
Cu
in
o
&
id
>i
<d
•o
0
0
c
o
X
o
rH
<0
a
O u
o fi
"5oa
0
u
-P
a
o
o
0
O CQ
(ui»%oid 6n/6u) 
uoim%u»u«3 tftJIBS
0a
o
•H
-P
0u
+>
c
0
o
ao
o
*0*H
U
O
•H
-P0
O
0
0
rH
o*0
G
*H
0Pi•0
>i«
1
in
<N
0
U
0
0
xs
+>
G
O
43o
CO
CM
-P0
0Cn
B•0
o
G
O
•H
-P
0
Pi
-P0
•H
G
•00
Pi
0
■P
0
0
-P00o
124
<o
A
ft
U
O
eo
3
Q
X-1— T" 
o m
°X
S'o B
"8OQ
CO
3M
■P01
001
Ou
ft
c
o
£1
o
o
•
00
-pfl
0X5
-p
G•H
sw
+1
0
GO
•H
+><d
+>
G
0
O
G
OCJ
TJ
•HO
<
O
•H
■P0O0
0
rH
o•oc
•H
>i
0M
TJ>i
EC1
to
•00Pi0
i*0u
o
o
•
o
Vft
u
o
Vft
ino•
o
Vft
>»
•o
0
co
0JG•p
G
O
.Go
co•
CN
(ut»%«xd 6n/6u) 
uoiiti)u>auo3 UUIBS
CN
0
Pi301
•H
ft
0C
•H
rH
00
0
■P
-t
re
at
ed
 
an
im
al
s 
us
in
g 
Sc
he
ff
e'
s 
An
al
ys
is
 
of
 
Va
ri
an
ce
 
an
d 
Co
va
ri
an
ce
.
125
co *n
i
o
Pi
ft
c
o
X
o
o
•
00
o
o
•
o
V
ft
u
o
V
ft
0o
G<0•H
Pito
>o
•*» 'O
in g
O (0
o
V
ft
(0
> 1
<0
•o
0
A
ftu
o
e
o
Pi
3
Q
i— 1— i— '— i— •— r
_ m
S'o fl
n ®aoQ
6n/6u)
uot^u^u»3ui»3 trams
0
G
0
+>
<0
Pi
-P
G
0
U
G
O
L)
TJ
•H
U
O
•H
-P
0
O
«0
0
rH
o
•o
G
•H
X
0 
Pi 
•O
ffl
1
m
<N
0
U
•HIP
0
0
X
+>
G
0
Xi
o
CO
<N
-P
0
0CT>
3
Pi
•O
O
G
O
•H
■P
0
Pi
-P
0
•rH
G
tT5
0
P
0
-P
0
0
3
Pi
-P
0
0
O
126
0
C
u
0
■P
fd
CQ
PU
-P
CQ
001
ou
a
c
o
JZ
o
o
•
co
0+>
T3(1)M
cd
£Oo
o
o
•
o 
V ai
u
o
vQ*
A
0*P
0
e
o
14
0
Q.
I— '— I—r
_ D>O M
& o 6
a»
a
o
M
0H
cd
53
om
8-
©if
<•>« «oo
-pcd
s:
uw
0>.*3
■P
(3•H
XwW 
+ 1
CQc
o•H
-P
(d
Pi
•P
C3
0U
C3
Oo
c•H
C3
0
-Pou
0w
m
o
•
o
Va
•o
0
CQ
0
Xi
-P
a
o
&o
ro
•
CN
0u
ft ° O in
u
o
CN
0
a-H
«© a
fen/£u)
in<t
0
CN
CN
au
po>*H
&< sa
li
ne
-t
re
at
ed
 
an
im
al
s 
us
in
g 
Sc
he
ff
e'
s 
An
al
ys
is
 
of
 
Va
ri
an
ce
 
an
d 
Co
va
ri
an
ce
.
127
(uphold 6n/6u) 
U « T ^ B X ) U » 3 U 0 3  M S
sa
li
ne
-t
re
at
ed
 
an
im
al
s 
us
in
g 
Sc
he
ff
e'
s 
An
al
ys
is
 
of
 
Va
ri
an
ce
 
an
d 
Co
va
ri
an
ce
.
128
©
fl
•H
U
o
N
(0
4J
0)
B
U
o
G
(0
I
2
t— 1— r
_ o»ou
0» 
o  S
X I
ft
o
6
O
kl
Q
T— •-T~
o o
T--1— I--r
O O
o»
"'s B» 
o 6
«s
ou
-p
a
o
u
«
O  CQ
(ui»)«jd 6n/6u)
uoi%u)u»3uo3 m e
U0
■P
4-1
<d
to
PM
P(0
0
0
1
o
u
ft
G
o
Ao
o
•
00
P
rd
0
.fl
P
fl
•H
S
w
+1
CQ
G
0•H
P
<d
u
P
fl
0
u
g
o
o
fl
•H
fl
o
p
o
u
0
w
ClCl
0u
fl
o**H
fc.
o
p
T3
0U
<d
§•o
o
o
o
•
o
V
ft
o
o
V
ft
• V
ino
•
oV
ft
>1
<d43
0
0
0
X!
p
fl
o
X3o
ro
•
CM
0
u
fl
<d•H
U
<d
>o
u
T3
fl0
0
U
fl
<d
U
<d
>
4-1
o
<0
•H0
rH
<d
0
0
4H
4H
0x:
o
OT
cr>
fl
•Hm
P
to
rH
<d
c
<d
T3
0P0
0
iHPI
0
fl•H
rH
(d0
129
(u|n«^d 6n/6u) 
u o p c x ) u w u «3 m e
130
XBS/VUIBS
131
132
0
c
•H
133
US/UUIBS
EXPERIMENT
135
This experiment was designed to investigate the ability of 
the opiate-agonists, Duromorph, Tifluadom and N- 
allylnormetazocine, to reverse the naloxone-induced 
hypersecretion of LH during the surge (demonstrated in 
Experiment 1).
The drug doses selected for investigation were the minima 
which significantly altered the magnitude of the 
preovulatory LH surge in Experiment 1. This was with the 
exception of N-allylnormetazocine, since no dose of this 
drug significantly affected the surge. For N- 
allylnormetazocine, the minimum dose which produced a non­
significant reduction of the surge amplitude was used.
Furthermore, the effects of these treatments on the 
biogenic amine concentrations in the SCH, MPO, ME and ARN 
were to be investigated concomitant with their effects on 
the LH surge and its naloxone-enhancement. It was hoped 
that the central effects could be related to any effects on 
LH concentrations found.
Materials and Methods
Duromorph (40mg/kg), Tifluadom or N-allylnormetazocine 
(3mg/kg) were co-administered with the antagonist naloxone 
(lOmg/kg) IP. in a 0.05ml/15g volume of physiological 
saline at 12.30h. Three groups of controls (from Experiment 
1) were used for each treatment; the first administered 
0.05ml/15g physiological saline (IP), the second
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administered lOmg/kg Naloxone alone and the third 
administered the respective opiate agonist without co­
administration of Naloxone. The rats were subsequently 
decapitated at 14.30h or 18.00h.
In this experiment the control values for saline-, 
naloxone-, Duromorph-, Tifluadom- and N-allylnormetazocine- 
treated groups are those from the animals in Experiment 1. 
The number of animals in each group is shown in Table 14.
Results
(1) 14.30h Results
These results are summarised in Tables 14-18 and Figures 
24-29.
(a) Luteinizing Hormone
The animals treated with 3mg/kg N-allylnormetazocine 
concomitant with lOmg/kg Naloxone exhibited significantly 
raised levels of plasma LH compared to animals treated with 
either saline, naloxone or N-allylnormetazocine (all 
p<0.01). However, no other treatment had a significant 
effect on plasma LH concentrations.
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(b) Noradrenaline
(i) Duromorph + Naloxone
NA concentrations in the SCH, MPO, ME and ARN of animals 
co-administered 40mg/kg Duromorph with lOmg/kg naloxone 
were not significantly different from those of saline-, 
naloxone- and Duromorph-treated animals.
(ii) Tifluadom + Naloxone
Animals treated with 3mg/kg Tifluadom plus lOmg/kg naloxone 
had NA concentrations in the SCH and ARN which did not 
differ significantly form saline-, Tifluadom- and naloxone- 
treated groups. However, in the MPO, these animals 
exhibited significantly lowered NA concentrations compared 
to saline- (p<0.05) and Tifluadom-treated (p<0.05) animals. 
NA concentrations in the ME of this group were 
significantly reduced (p<0.01) compared to the Tifluadom- 
treated group.
(iii) N-Allylnormetazocine + Naloxone
The NA concentrations in the SCH of this group were not 
significantly different from saline-, Naloxone- nor N- 
allylnormetazocine-treated groups. But, in the MPO, ME and 
ARN the NA concentrations of this group were significantly 
lower than the N-allylnormetazocine-treated group (p<0.001, 
0.001 and 0.01 respectively).
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(c) Dopamine
(i) Duromorph + Naloxone, and
(iii) N-Allylnormetazocine + Naloxone
Neither of the above two groups exhibited DA concentrations 
that were significantly different from those of their 
respective control groups.
(ii) Tifluadom + Naloxone
There were no significant differences between DA 
concentrations in the SCH, MPO and ME of this group and the 
saline-, naloxone- and Tifluadom-treated groups. DA 
concentrations in the ARN of this group were significantly 
j elevated compared to both saline- and naloxone-treated
groups (both p<0.01).
(d) 5-Hydroxyindoleacetic Acid
(i) Duromorph + Naloxone
In the SCH, this group exhibited significantly lower 5HIAA 
concentrations than both the naloxone- and the Duromorph- 
treated groups (both p<0.05). There were no significant 
differences between the 5HIAA levels of this group and any 
of the three control groups in either the MPO or the ARN. 
The 5HIAA concentrations in the ME were significantly
i
i
|
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elevated above that of the saline- (p<0.001), naloxone- and 
Duromorph-treated (both p<0.01) groups.
(ii) Tifluadom + Naloxone
5HIAA concentrations in both the SCH and MPO of this group 
were significantly reduced in comparison to the Tifluadom- 
treated group only (p<0.01 and 0.05 respectively).
Furthermore, the ME of this group showed significantly 
higher 5HIAA levels than in the saline-treated animals 
(p<0.01) but, there were no significant differences from 
any of the control groups in the ARN.
(iii) N-allylnormetazocine + Naloxone
There were no significant differences between this group 
and any of the control groups in the SCH, ME and ARN. In 
the MPO, the 5HIAA concentrations were significantly lower 
in these animals than in the N-allylnormetazocine-treated 
group (p<0.01).
(e) Serotonin
There were no significant differences between the 5HT 
levels in any of the four brain areas of the groups co­
administered naloxone and their respective controls. The 
only exception was that the 5HT concentrations in the ME of 
the Duromorph + Naloxone- and the N-allylnormetazocine + 
Naloxone-treated groups were significantly elevated above
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those of animals administered saline (p<0.01 and p<0.05 
respectively).
(f) 5HIAA/5HT
There were no significant differences in the ratio of 
5HIAA/5HT in any of the four areas examined under any of 
the treatment regimes.
18.00h Results
These results are summarised in Tables 14 and 19-22, and in 
Figures 24 and 30-34.
(a) Luteinizing Hormone
The plasma LH levels of all three groups administered an 
agonist along with naloxone were significantly lower than 
that of the naloxone-treated group (p<0.001), but not 
significantly different from the saline-, and their 
respective agonist-treated groups.
(b) Noradrenaline
(i) Duromorph + Naloxone and
(ii) Tifluadom + Naloxone
The only differences produced by the above treatments were 
that in the SCH and MPO they both significantly lowered NA
concentrations below those of the naloxone-treated group 
(p<0.01 and p<0.05 respectively).
(iii) N-allylnormetazocine + Naloxone
No significant differences were found in the SCH, ME and 
the ARN. In the MPO, the NA concentrations of this group 
were significantly reduced compared to N- 
allylnormetazocine-treated animals (p<0.05).
(c) Dopamine
No significant differences occurred in the DA 
concentrations of the four areas studied after any of the 
treatments administered.
(d) 5-Hydroxyindoleacetic Acid
(i) Duromorph + Naloxone, and
(ii) Tifluadom + Naloxone
No significant effects were found in the MPO, ME and ARN 
with either of these combined treatments. However, both 
significantly reduced 5HIAA concentrations in the SCH 
compared to the naloxone-treated group (both p<0.001).
(iii) N-allylnormetazocine + Naloxone
No significant differences resulted from this treatment.
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(e) Serotonin
(i) Duromorph + Naloxone
No significant effects resulted form this treatment in the 
SCH, MPO nor the ARN. However, in the ME the combined 
treatment produced significantly raised 5HT concentrations 
compared to saline-, naloxone- and Duromorph-treated groups 
(all p<0.001).
(ii) Tifluadom + Naloxone
No significant effects were found.
(iii) N-allylnormetazocine + Naloxone
In the SCH, administration of the combined treatment 
resulted in a significant reduction of the 5HT levels 
compared to the naloxone- and N-allylnormetazocine-treated 
groups (both p<0.05), but no significant effects were 
evident in the MPO, ME nor ARN.
(f) 5HIAA/5HT
(i) Duromorph + Naloxone
No significant effects in the SCH or ME resulted from this 
treatment. However, the ratio of 5HIAA/5HT was
significantly reduced in the MPO by the combined treatment 
compared to the Duromorph-treated group (p<0.01), and in 
the ARN compared to the naloxone-treated group (p<0.05).
(ii) Tifluadom + Naloxone and
(iii) N-allylnormetazocine + Naloxone
In the SCH, MPO and ME, no significant effects of these 
treatments were found. In the ARN, both of the above 
treatments produced a significantly lower ratio of 
5HIAA/5HT than did naloxone administration (p<0.01 and 
p<0.001 respectively).
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Discussion 
Luteinizing Hormone
Of all the treatments administered, only the combination of 
N-allylnormetazocine and naloxone altered plasma LH 
concentrations at 14.30h, causing an increase compared to 
the saline-, naloxone- and N-allylnormetazocine-treated 
groups. The marked elevation found may be due to the \i-
antagonist properties of (-)N-allylnormetazocine which, in 
combination with the opiate antagonist properties of 
naloxone, may have reduced the EOP tone sufficiently to 
advance the surge on pro-oestrus. Such an event can result 
from administration of naloxone alone (Allen and Kalra, 
1985). Thus, the elevated LH levels at 14.30h may represent 
the rising phase of an ’early' surge.
Duromorph, Tifluadom and N-allylnormetazocine all 
successfully reduced the naloxone-induced elevation of LH 
concentrations at 18.00h. This clearly indicates that ji-, 
k -  and a-receptors are all involved in naloxone enhancement 
of the LH surge amplitude. Furthermore, reduction of 
naloxone-enhanced LH secretion by N-allylnormetazocine 
supports the existence of opioid a-receptors within this
neural network, since antagonism by naloxone is itself a 
test for opioid activity. The suppression of the LH surge 
which resulted from administration of the and K-agonists
was prevented by naloxone. The results indicate that the 
effects of Duromorph and Tifluadom on LH secretion on the
afternoon of pro-oestrus are mediated by specific actions 
at their respective opioid receptors.
Aminergic Activity at 14.30h
As reported in Experiment 1, the lOmg/kg dose of naloxone 
did not alter NA nor DA concentrations in any of the four 
areas studied, but did increase 5HT activity in the SCH and 
MPO during the critical period, and increase the magnitude 
of the preovulatory LH surge. Such a finding was taken to 
indicate that naloxone enhancement of the surge amplitude 
was mediated by indoleamine, and not by CA neurones. 
However, it is possible that small, non-significant 
alterations of CA activity may be sufficient to mediate 
changes in LHRH secretion which can alter the LH surge 
amplitude.
Duromorph's ability to negate the effects of naloxone on 
the surge was not reflected in any alteration of CA 
activity, which provides further evidence that the 
mechanism of naloxone-enhanced LH secretion does not 
involve hypothalamic CA's. However, when administered 
concomitantly, Duromorph and naloxone increased 5HIAA 
concentrations in the ME above those of the agonist-treated 
group, suggesting that the naloxone enhancement of the LH 
surge involves the antagonism of ^-receptors to increase
the stimulatory activity of 5HT in the ME.
As reported in Experiment 1, Duromorph increased NA 
concentrations in the ME and reduced the magnitude of the 
LH surge. Co-administration of naloxone prevented both of 
these actions of Duromorph. If NA is fulfilling an 
inhibitory role in the regulation of LHRH secretion, it 
would appear that the n-inhibition of the surge is mediated
by an inhibitory action of NA.
The K-agonist increased 5HIAA concentrations in the SCH,
MPO and ME, and the effect was generally antagonized by 
naloxone. Such an action on the activity of 5HT is 
inconsistent with the k-inhibition of the surge and the
antagonism of this inhibition by naloxone. However, 
naloxone also significantly decreased NA concentrations in 
the MPO and ME that had been caused to rise by the 
administration of Tifluadom. In light of the above, the 
actions of Tifluadom on circulating LH levels may be 
explained by mediation of its effects through an inhibitory 
NA pathway. It appears that this inhibitory action of NA is 
of greater influence on the LHRH neurones than the actions 
of 5HT since NA inhibition combined with 5HT stimulation 
results in a decreased surge.
Naloxone also increased DA concentrations in the ARN that 
resulted from the administration of Tifluadom. The ARN is 
the site of tuberoinfundibular DA perikarya. The rise in DA 
concentrations may reflect increased synthesis in the cell 
body which is often associated with increased release from 
the nerve terminal. The inference is that naloxone
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increases the DA released from the ME and thus could 
decrease the PRL secretion induced by K-agonist
administration.
Naloxone decreased the NA concentrations in the MPO, ME and 
ARN, and the 5HIAA levels in the MPO, that resulted from 
the administration of the a-agonist, N-allylnormetazocine.
This finding clearly demonstrates the opioid nature of the 
receptors on which N-allylnormetazocine exerts its 
influence on NA and 5HT neurones in these areas. Thus, it 
appears that there may also be opioid a-receptors which
can, when activated, reduce the amplitude of the 
preovulatory LH surge.
To conclude, this experiment provides further evidence that 
naloxone enhancement of the LH surge is mediated by 
activation of a stimulatory input from 5HT neurones 
projecting to LHRH neurones. Furthermore, this effect of 
naloxone may be exerted primarily through p,-receptors.
The results also demonstrate that opioid suppression of the 
LH surge involves a heterogeneous population of p , - ,  k -  and 
a-receptors, and that the suppression may be mediated by an 
inhibitory action of NA in the MPO and ME.
Aminergic Activity at 18.00h
Naloxone increased NA concentrations in the SCH and MPO, 
5HIAA and 5HT concentrations in the SCH, and the ratio of
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5HIAA/5HT in the ARN. The co-administration of each of the 
agonists returned all of these values to the same levels as 
in the saline-treated animals, which suggests that the 
actions of naloxone may still be mediated by a mixed 
population of receptors, involving all three subtypes.
While the 40mg/kg dose of Duromorph and the 3mg/kg dose of 
Tifluadom did not affect the amine concentrations compared 
to saline-treated control animals, they did cause several 
changes when co-administered with naloxone, in comparison 
to the levels that resulted from administration of naloxone 
alone. These are outlined in the paragraph above.
N-allylnormetazocine increased NA and 5HT concentrations in 
the SCH and MPO, and the ratio of 5HIAA/5HT in the ARN. The 
effects on NA in the SCH, 5HT in the MPO, and the ratio of 
5HIAA/5HT in the ARN were not antagonized by naloxone, 
lending support to the conclusion that, as EOP tone 
increases, the non-opioid actions of N-allylnormetazocine 
are revealed. The other actions were antagonized by 
naloxone. Again this would point to naloxone antagonism of 
opiate suppression of LH release, if these transmitters 
retain the same action on LHRH neurones as they possess 
earlier on pro-oestrus.
The results suggest that the inhibition of the LHRH surge- 
generating system produced by these opiates may continue 
throughout the afternoon of pro-oestrus. If this is the 
case, it is probable that the LH surge in these animals is
149
completely abolished, rather than delayed until later on 
the day of pro-oestrus.
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|TREATMENT PLASMA LH CONCENTRATION
14.30h 18 . OOh
Saline 2.1+0.3 (12) 9.5+2.2 (14)
Naloxone 1.6+0.1 (11) 23.1+7.5 c (9)
Duromorph 1.6+0.3 (10) 2.2+0.9 af (8)
+ Naloxone 4.3+2.3 (10) 5.2+1.3 f (5)
Tifluadom 1.2+0.2 (10) 1.8+0.2 af (10)
+ Naloxone 3.4+1.2 (10) 4.1+1.6 f (10)
SKF10047 1.0+0.1 (10) 5.3+2.3 f (9)
+ Naloxone 5.8+1.5 beh (8) 8.2+1.8 f (9)
Table 14. Plasma LH concentrations (p,g/ml+SEM) at 14.3Oh
and 18.0Oh on pro-oestrus after administration of drugs at 
12.30h on the same day; as p<0.05; bs p<0.01; cs p<0.001 
compared to saline-treated animals, ds p<0.05; es p<0.01; 
f: p<0.001 compared to naloxone-treated animals and gs 
p<0.01; hs p<0.01; i: p<0.001 compared to appropriate 
opiate agonist-treated animals; using Scheffe's Analysis of 
Variance and Covariance. The number of animals in each 
group is shown in parentheses.
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TREATMENT BIOGENIC AMINE CONCENTRATION IN THE SCH RATIO OF
NA | DA |5HIAA | 5HT 5HIAA/5HT
Saline 40.1+7.2 2.4+0.5 8.3+2.0 23.1+3.3 0.368+0.069
Naloxone 47.7+9.4 3.0+0.4 18.2+5.6 a 39.4+8.1 0.452+0.064
Duromorph 36.1+7.1 3.8+0.6 16.7+2.7 a 27.6+6.7 0.730+0.093
+Naloxone 19.9+3.4 2.8+0.8 7.9+1.2 dg 14.4+1.6 0.590+0.088
Tifluadom 52.4+12.1 4.7+1.4 27.2+6.5 c 42.1+8.1 0.720+0.209
+Naloxone 33.2+10.3 6.5+2.3 11.3+1.8 h 31.8+11.7 0.540+0.169
SKF 10047 37.4+4.4 4.4+0.9 16.4+2.0 39.9+8.4 0.484+0.131
+Naloxone 18.4+6.1 3.4+1.2 16.4+5.1 31.4+12.2 0.553+0.054
Table 15. Biogenic amine concentrations (ng/p,g protein + 
SEM) and the ratio of 5HIAA/5HT in the SCH at 14.30h on 
pro-oestrus after administration of drugs at 12.30h on the 
same day. a: p<0.05; bs p<0.01, c: p<0.001 compared to 
saline-treated animals, d: p<0.05; e: p<0.01; f: p<0.001 
compared to naloxone-treated animals and gs p<0.05; h: 
p<0.01; i: p<0.001 compared to appropriate opiate agonist- 
treated animals; using Scheffe's Analysis of Variance and 
Covariance.
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TREATMENT BIOGENIC AMINE CONCENTRATION IN THE MPO RATIO OF
NA DA |5HIAA I 5HT 5HIAA/5HT
Saline 47.6+8.9 3.5+0.6 8.7+1.3 23.0+2.4 0.472+0.109
Naloxone 43.1+7.8 4.6+1.5 19.9+4.0 a 23.8+5.3 0.866+0.293
D u r o m o r p h 42.4+9.1 5.3+0.8 13.7+1.9 24.1+6.0 0.790+0.179
+ N a l o x o n e 30.4+3.8 3.6+0.4 11.4+1.9 17.7+1.5 0.731+0.199
Tifluadom 53.9+4.8 5•3+0.5 27.4+3.2 c 29.7+4.4 0.999+0.223
+Naloxone 26.0+3.8ag 5.9+1.3 15.4+2.1 9 28.5+4.8 0.688+0.150
SKF 10047 6 9 . 7 + 1 1 . 3 a d 7 . 3+1.4 26.5+6.9 c 20.8+2.4 1.077+0.267
+Naloxone 25.2+6.0 i 3.4+1.6 4.6+1.0 h 29.0 0.193
Table 16. Biogenic amine concentrations (ng/jig protein + 
SEM) and the ratio of 5HIAA/5HT in the MPO at 14.30h on 
pro-oestrus after administration of drugs at 12.30h on the 
same day. a: p<0.05; b: p<0.01, c: p<0.001 compared to 
saline-treated animals, ds p<0.05; es p<0.01; fs p<0.001 
collared to naloxone-treated animals and gs p<0.05; h: 
p<0.01; is p<0.001 compared to appropriate opiate agonist- 
treated animals; using Scheffe's Analysis of Variance and 
Covariance.
153
TREATMENT BIOGENIC AMINE CONCENTRATION IN THE ME RATIO OF 
5HIAA/5HTNA DA | 5HIAA 5 HT
Saline 22.4+4.1 21.4+6.0 5.1+0.8 13.1+2.2 0.461+0.065
Naloxone 46.2+9.8 22.5+6.5 11.9+1.8 20.5+1.9 0.688+0.067
Duromorph 45.9+9.1 58.8+14.4 11.3+2.1 27.8+6.8 a 0.572+0.146
+Naloxone 42.7+7.8 48.9+14.7 23.7+6. 5 c e h 41.4+7.5 b 0.706+0.174
Tifluadom 64.8+11.8b 57.5+20.0 15.0+2.7 a 20.3+5.0 a 0.737+0.142
+Naloxone 27.5+8.0 h 53.2+13.4 19.5+6.1 b 19.9+7.4 1.060+0.322
SKF 10047 8 0 . 9 + 1 5 . 2  Cd 60.1+18.5 12.5+2.3 4 4 . 6 + 1 2 . 8  bd 0.436+0.114
+Naloxone 21.2+5.5 i 40.8+16.3 10.0+1.9 35.3+8.0 a 0.308+0.067
Table 17. Biogenic amine concentrations (ng/jig protein + 
SEM) and the ratio of 5HIAA/5HT in the ME at 14.30h on pro­
oestrus after administration of drugs at 12.30h on the same 
day, as p<0.05; bs p<0.01, cs p<0.001 compared to saline- 
treated animals, ds p<0.05; es p<0.01; fs p<0.001 compared 
to naloxone-treated animals and gs p<0.05; hs p<0.01; is 
p<0.001 compared to appropriate opiate agonist-treated 
animals; using Scheffe's Analysis of Variance and 
Covariance.
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TREATMENT BIOGENIC AMINE CONCENTRATION IN THE ARN RATIO OF
NA DA |5HIAA 5HT 5HIAA/5HT
Saline 30.1+3.3 5.8+1.8 11.3+3.4 23.1+3.6 0.478+0.106
Naloxone 50.6+15.7 5.2+1.5 \ 12.9+2.3 [20.6+3.2 10.698+0.I07
Duromorph 55.6+17.7 4.4+1.4 13.0+2.2 18.6+4.8 0.868+0.130
+Naloxone 28.8+5.2 5.6+1.1 9.3+2.1 22.3+4.4 0.512+0.111
Tifluadom 56.5+8.6 8.9+2.9 15.2±1.7 23.1+4.0 0.747+0.125
+Naloxone 30.7+6.1 15.1+2.7be 14.6+1.6 24.5+5.1 0.670+0.081
SKF 10047 78.6+17.6b 10.7+2.2 23.5+7.9 25.2+8.1 0.652+0.122
+Naloxone 18.4+5.6 h 9.6+4.3 17.7+4.5 22.2+6.3 1.230+0.514
Table 18. Biogenic amine concentrations (ng/(ig protein + 
SEM) and the ratio of 5HIAA/5HT in the ARN at 14.30h on 
pro-oestrus after administration of drugs at 12.30h on the 
same day. as p<0.05; bs p<0.01, cs p<0.001 compared to 
saline-treated animals, ds p<0.05; e: p<0.01; fs p<0.001 
compared to naloxone-treated animals and gs p<0.05; hs 
p<0.01; i: p<0.001 compared to appropriate opiate agonist- 
treated animals; using Scheffe's Analysis of Variance and 
Covariance.
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TREATMENT BIOGENIC AMINE CONCENTRATION IN THE SCH RATIO OF
NA DA 5HIAA 5HT 5HIAA/5HT
Saline 22.1+5.5 2.6+0.7 8.7+2.6 18.9+3.1 0.447+0.081
|Naloxone 51.5+13.Ob 5.4+0.9 19.0+4.3 b 33.2+8.0 a 0.653+0.123
Duromorph 24.4+4.7 e 2.3+0.4 9.7+2.4 e 19.3+5.0 d 0.603+0.103
+Naloxone 21.5+2.8 e 3.8+1.2 11.7+1.9 f 27.8+4.3 0.457+0.088
Tifluadom 23.3+2.5 e 3.9+0.7 8.4+1.2 e 20.4+3.5 d 0.473+0.073
+Naloxone 22.7+3.2 e 3.7+0.5 6.6+0.7 f 21.4+1.8 0.311+0.023
SKF 10047 40.5+10.7a 5.6+1.8 16.2+2.1 a 35.1+5.2 b 0.524+0.089
+Naloxone 33.0+4.6 4.1+1.0 10.4+1.2 20.4+2.3dg 0.521+0.078
Table 19. Biogenic amine concentrations (ng/^g protein + 
SEM) and the ratio of 5HIAA/5HT in the SCH at 18.00h on 
pro-oestrus after administration of drugs at 12.30h on the 
same day. as p<0.05; bs p<0.01, cs p<0.001 compared to 
saline-treated animals, d: p<0.05; es p<0.01; fs p<0.001 
compared to naloxone-treated animals and g: p<0.05; h: 
p<0.01; i: p<0.001 compared to appropriate opiate agonist- 
treated animals; using Scheffe's Analysis of Variance and 
Covariance.
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TREATMENT BIOGENIC AMINE CONCENTRATION IN THE MPO RATIO OF 
5HIAA/5HTNA j DA 5HIAA 5HT
Saline 29.1+7.0 3.8+0.9 10.4+2.7 21.2+4.3 | 0.717+0,227
Naloxone 46.2+9.6 a 6.1+1.5 15.7+2.7 30.2+4.5 | 0.552+0,081
Duromorph 38.6+6.4 4.3+1.5 17.1+5.1 15.1+3.4 d 1.572+0.576 ae
+Naloxone 23.1+3.4 d 3.7+0.5 11.7+2.1 23.4+4.6 0.524+0,068h
Tifluadom 29.1+3.5 a 3.4+0.8 9.7+1.2 18.2+2.6 0.608+0.083
+Naloxone 26.1+2.9 d 5.4+1.2 8.4+1.1 24.4+2.4 0.350+0.045
SKF 10047 53.1+5.7 b 6.6+1.8 25.6+9.8 36.9+8.8 a 0.728+0.172
+Naloxone 35.2+6.3 g 3.7+0.8 14.1+2.1 30.8+4.9 0.475+0.036
Table 20. Biogenic amine concentrations (ng/pg protein + 
SEM) and the ratio of 5HIAA/5HT in the MPO at 18.00h on 
pro-oestrus after administration of drugs at 12.30h on the 
same day. as p<0.05; bs p<0.01, cs p<0.001 compared to 
saline-treated animals, d: p<0.05; es p<0.01; fs p<0.001 
compared to naloxone-treated animals and gs p<0.05; h: 
p<0.01; is p<0.001 compared to appropriate opiate agonist- 
treated animals; using Scheffe's Analysis of Variance and 
Covariance.
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TREATMENT BIOGENIC AMINE CONCENTRATION IN THE ME RATIO OF
NA | DA |5HIAA I 5HT 5HIAA/5HT
Saline 28.7+4 .4 I 36.3±8.0 |5.9±1.3 14.8+2.0 0.453+0.087
Naloxone 58.4+13.3 50.3+17.1 |14.6+5.0 |l8.2±3.9 | 0.604+0.119
Duromorph 27.8+3.9 24.5+4.8 9.5+1.8 17.7+5.0 0.569+0.234
+Naloxone 35.3+6.9 50.1+21.1 15.3+3.1 42.9+8. 3c£i 0.368+0.043
Tifluadom 37.0+8.1 25.5+6.3 6.4+1.0 14.9+4.1 0.600+0.128
+Naloxone 26.5+5.6 56.0+19.3 16.4+9.0 20.5+3.6 1.005+0.723
SKF 10047 40.6+10.6 33.9+10.2 14.3+3.0 21.3+3.6 0.787+0.202
+Naloxone 29.5+5.4 39.9+11.9 17.1+5.2 18.0+3.2 1.034+0.354
Table 21. Biogenic amine concentrations (ng/p,g protein + 
SEM) and the ratio of 5HIAA/5HT in the ME at 18.00h on pro­
oestrus after administration of drugs at 12.30h on the same 
day. as p<0.05; bs p<0.01, cs p<0.001 compared to saline- 
treated animals, ds p<0.05; es p<0.01; fs p<0.001 compared 
to naloxone-treated animals and gs p<0.05; hs p<0.01; is 
p<0.001 compared to appropriate opiate agonist-treated 
animals; using Scheffe's Analysis of Variance and 
Covariance.
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TREATMENT BIOGENIC AMINE CONCENTRATION IN THE ARN RATIO OF
NA DA |5HIAA 5HT 5HIAA/5HT
Saline 26.8+3.5 4.4+1.3 7.7+1.2 19.6+3.0 0.425+0.049
Naloxone 34.5+7.5 7.4+2.4 15.4+3.6 13.0+2.2 1.170+0.334c
Duromorph 23.8+4.5 4.4+1.4 7.7+2.4 7.9+1.4 0.501+0.059e
+Naloxone 26.0+6.2 6.6+1.7 10.4+1.5 18.1+3.1 0.541+0.091d
Tifluadom 25.1+4.5 4.1+1.0 8.7+1.0 18,. 8+2; 6 0.491+0.050e
+Naloxone 31.4+5.0 6.7+1.6 9.6+1.9 20.5+2.9 0.490+0.095e
SKF 10047 35.6+3.1 6.1+1.3 10.4+2.4 19.3+4.6 0.781+0.168a
+Naloxone 23.7+2.7 4.1+0.8 8.3+2.3 13.3+1.8 0.467+0.084f
Table 22. Biogenic amine concentrations (ng/jig protein + 
SEM) and the ratio of 5HIAA/5HT in the ARN at 18.00h on 
pro-oestrus after administration of drugs at 12.30h on the 
same day. as p<0.05; b: p<0.01/ cs p<0.001 compared to 
saline-treated animals, ds p<0.05; es p<0.01; f: p<0.001 
compared to naloxone-treated animals and g: p<0.05; hs 
p<0.01; i: p<0.001 compared to appropriate opiate agonist- 
treated animals; using Scheffe's Analysis of Variance and 
Covariance.
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This experiment was undertaken as a simple method (with low 
morbidity and no mortality) to determine whether the LH surge 
was delayed by opiate agonist treatment to the day following 
natural pro-oestrus.
Materials and Methods
Rats were administered drugs (IP) in a 0.05ml/15g volume of 
physiological saline at 12.30h without anaesthesia and 
returned to daily vaginal smearing for at least sixteen days. 
The doses used were 3mg/kg for Tifluadom and N- 
allylnormetazocine, 40mg/kg for Duromorph and lOmg/kg for 
Naloxone. Control animals were injected with 0.05ml/15g 
physiological saline alone.
Results
These results are summarized in Table 23.
All animals in the this experiment were found to be in 
oestrus on the day following drug administration at 12.3Oh on 
pro-oestrus, regardless of which treatment was applied.
Ninety per cent, of the rats treated with saline, naloxone 
and Tifluadom continued with regular four-day oestrous cycles 
for at least sixteen days following treatment. The 
corresponding figures for Duromorph and N-allylnormetazocine 
were 80% and 100% respectively.
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Discussion
Regardless of treatment, all animals sloughed cornified 
vaginal epithelial cells on the day following treatment as is 
typical during oestrus. This was as expected as cornification 
results from high E2 levels on pro-oestrus; E2 being elevated 
prior to the drug administration.
No cornified cells were evident in any of the lavages 
performed on the second day after treatment and there was no 
temporal shift in the oestrous cycles of these rats. This 
indicates that E2 had returned to its normal low level on the 
day following treatment. Thus, in those animals that had 
suppressed LH levels on the afternoon of pro-oestrus, the 
preovulatory LH surge was not delayed by 24 hours as has been 
reported for other pharmacological manipulations (Everett and 
Sawyer, 1950).
Therefore, treatments that suppressed LH release on the 
afternoon of pro-oestrus could have, (i) delayed the surge 
until later on the day of pro-oestrus, as has inhibition of 
catecholamine synthesis (Coen and Coombs, 1983), or (ii) 
completely abolished the preovulatory LH surge.
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TREATMENT
% ANIMALS IN 
OESTRUS ON 
FOLLOWING DAY
% OESTRUS 
CYCLES 
UNDISTURBED
n
SALINE 100 90 10
NALOXONE
(lOmq/kq)
100 90 10
DUROMORPH
(40mg/kq)
100 80 5
TIFLUADOM
(3mq/kq)
100 90 10
SKF 10047
(3mq/kq)
100 100 10
Table 23. Percentage of animals in oestrus on the day 
following drug administration at 12.3Oh on pro-oestrus and 
percentage with at least four regular four day cycles 
following drug administration at 12.3Oh on pro-oestrus 
(n=number of animals in each group).
EXPERIMENT
The aims of these experiments were twofold: (i) to establish 
LH profiles on the afternoon and early evening of pro-oestrus 
for the various drug regimes, and (ii) to confirm that 14.30h 
is indeed towards the end of the critical period for 
initiation of the LH surge in these animals.
Materials and Methods
Drugs were injected (IP) in a 0.05ml/15g volume of 
physiological saline at 12.30h. The doses used were as in 
Experiment 3. The control animals were given saline alone. In 
both Experiments 4(a) and 4(b) only one group was used, these 
being the saline-treated controls; the number of animals in 
these two groups were 12 and 10 respectively.
(a) Xylazine + Urethane Anaesthesia at ll.OOh
Initial attempts were made to anaesthetize the rats with 
0.7g/kg urethane (IP) in combination with 5mg/kg xylazine 
(SC) as this had been reported to leave the LH surge intact 
(de Greef et al, 1987). However, these doses were found to be 
insufficient to induce surgical anaesthesia. Further urethane 
was injected until cessation of the hindlimb flexor 
withdrawal reflex was achieved. Blood samples were withdrawn 
from the rats between 14.30h to 20.00h at 30 minute 
intervals.
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(b) Urethane Anaesthesia at 14.30h.
Animals were injected (IP) with a saturated solution of 
urethane in physiological saline (0.3g/100mg body weight in a 
volume of 0.450ml/100mg body weight) at 14.30h. Blood samples 
were withdrawn from 15.00h to 20.00h at 30 minute intervals.
(c) Urethane anaesthesia at 16.00h.
Animals were anaesthetized with urethane (as in Experiment 4 
(b) above) at 16.00h and blood samples were taken at periods 
of 30 minutes from 16.3Oh until 20.00h. The number of animals 
in each group are shown in Table 25.
Results
(a) Xylazine + Urethane Anaesthesia at ll.OOh.
The plasma LH concentrations at 14.30h to 20.00h (inclusive) 
at 30 minute intervals were 0.96+0.29, 1.04+0.36, 1.52+0.59, 
1.73+1.06, 1.35+0.57, 1.23+0.67, 1.17+0.30, 1.02+0.62, 
1.06+0.58, 1.11+0.46, 1.10+0.52 and 1.20+0.21 respectively; 
none of these values were significantly different from the 
control group in Experiment 1, decapitated at 14.3Oh.
(b) Urethane Anaesthesia at 14.30h.
These results are summarized in Table 24.
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Time
PLASMA LH CONCENTRATIONS (ng/ml)
Animal Identification Numbers
442 458 459 462 463 464 465 468 469 472
15.OOh NR NR LOW LOW LOW 2.27 NR NR NR NR
15•3 0h NR NR LOW LOW LOW 2.15 LOW NR NR NR
16.OOh LOW NR LOW LOW LOW 4.86 LOW LOW LOW LOW
16•30h LOW NR LOW LOW LOW 9.34 LOW 1.16 LOW LOW
17.OOh LOW LOW LOW LOW LOW NR LOW LOW LOW LOW
17.30h LOW NR LOW LOW LOW NR 5.13 LOW LOW LOW
18.OOh LOW NR LOW LOW LOW NR NR 1.29 LOW LOW
18•30h LOW NR LOW LOW LOW NR NR LOW LOW LOW
19.OOh LOW NR LOW LOW LOW NR NR LOW 1.72 LOW
19•30h LOW NR LOW LOW LOW NR NR NR NR LOW
20.OOh 0.71 NR LOW LOW LOW NR NR NR NR LOW
|
Table 24. Plasma LH concentrations (ng/ml) of individual 
animals throughout the afternoon of pro-oestrus after 
injection of saline at 12.30h followed by urethane 
anaesthesia at 14.30h on the same day? LOW: concentration 
below the limit of detection (0.4ng/ml); NR: no result.
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Time p]Lasma LH Concentration (ng/ml)
Saline Naloxone Duromorph Tifluadom SKF10047
16.30h LOW 17.4+3.4 LOW LOW LOW
17.OOh LOW 17.5+2.8 LOW LOW LOW
17.30h LOW 20.0+2.4 LOW LOW LOW
18.OOh LOW 12.9+3.5 LOW LOW LOW
18•30h LOW 6.5+1.3 LOW LOW LOW
19.OOh LOW 3.2+0.4 LOW LOW LOW
19•30h LOW 1.8+0.2 LOW LOW LOW
20.OOh LOW 1.2+0.2 LOW LOW LOW
n 6 3 3 5 3
Table 25. Plasma LH concentrations (+SEM) throughout the 
afternoon of pro-oestrous in rats treated with opiate drugs 
at 12.30h and subsequently anaesthetized with saturated 
urethane at 16.OOh on the same day. LOW=below the level of 
detection. n=number of animals in each group.
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Of the 10 animals used, only two exhibited plasma LH 
concentrations on the afternoon of pro-oestrus that were 
elevated above baseline values.
(c) Urethane anaesthesia at 16.OOh
These results are summarized in Table 25.
All animals, except those treated with naloxone, exhibited 
plasma LH concentrations on the afternoon of pro-oestrus that 
were below the level of detection of the assay. The group 
treated with naloxone showed maximal LH concentrations at 
17.3Oh (20.0+2.4) which thereafter fell to minimum values by 
the time of the final sampling point at 20.OOh (1.2+0.2).
Discussion
Xylazine + Urethane Anaesthesia at 11.OOh
The failure of the combined xylazine and urethane anaesthesia 
to induce surgical anaesthesia in the doses previously 
reported may be a result of the use of different strains of 
rats; the de Greef group having used a hybrid strain, bred at 
their own institution, which exhibit 5-day oestrous cycles.
It is possible that the hybrid strain may be more susceptible 
to anaesthesia, or their neural circuitry involved in the LH
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surge more resistant to pharmacological suppression, than the 
Sprague-Dawley rats used in this project.
The top-up doses of urethane necessary to induce surgical 
anaesthesia in the animals in the current experiment were 
only slightly less than that which would induce the 
equivalent level of anaesthesia without the concurrent 
administration of xylazine. It is probable that the dose of 
urethane used completely abolished the preovulatory LH surge 
in these animals.
Urethane Anaesthesia at 14.30h
Eighty per cent, of the rats used in this experiment had 
their LH surge completely abolished by urethane 
administration. Urethane is known to inhibit the surge 
release of LH by suppression of the neural stimulus for the 
secretion of LH. This suggests that 14.30h is still within 
the critical period for the initiation of the preovulatory LH 
surge in early pro-oestrus. The remaining twenty per cent, of 
the animals in this experiment displayed plasma LH levels on 
the afternoon of pro-oestrus that were similar to those of 
unanaesthetized saline-injected animals, decapitated at 
18.OOh. It would appear that, in these animals, the critical 
period was over by 14.30h on the afternoon of pro-oestrus.
The results indicate that 14.3Oh is indeed toward the latter 
stages of the critical period in these animals. It follows 
that the neurotransmitter concentrations at this time, in the
181
areas involved in control of preovulatory secretion of LH, 
are a fair reflection of the central activity which 
stimulates the surge.
Urethane Anaesthesia at 16.OOh
The failure of rats treated with saline to exhibit 
preovulatory surges after administration of urethane at 
16.OOh indicates that, in these rats, the critical period may 
extend to as late as this hour. No information can be gained 
from this experiment concerning the effects of the opiate 
agonists on the preovulatory LH surge, since the anaesthetic 
itself blocked the anticipated rise. However, it is clear 
from the results that naloxone not only increases the 
magnitude of the surge (as indicated by earlier experiments), 
but also temporally advances the critical period and the 
onset of the LH surge itself. This is evident from that fact 
that the plateau phase of the surge occurs from 16.3Oh (or 
earlier) until 17.30h, a period when LH levels would be 
anticipated to be rising in untreated animals, indeed, the 
very occurrence of a surge in the naloxone-treated animals 
indicates that the critical period is advanced prior to the 
time of the urethane administration which abolished the surge 
in saline-treated animals.
I
i
GENERAL DISCUSSION
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Site of Action of Opiates
The mode of administration of the drugs (IP) does not 
preclude effects on the LH concentrations mediated by actions 
outside the hypothalamus. The alterations of LH levels could 
result from actions of the drugs on:-
(i) the plasma half-life of LH,
(ii) the responsiveness of pituitary gonadotrophs to LHRH,
(iii) the axon terminals/perikarya within the hypothalamus,
(iv) the perikarya of neurones outwith the hypothalamus.
The half-life of glycoproteins, such as LH, depend upon the 
renal clearance and metabolic inactivation of the hormone. LH 
is a relatively small glycoprotein with an approximate 
molecular weight of 30000. This is small enough to cross the 
glomerular filtration barrier. However, the amount of protein 
lost in the urine each day is in the milligram range, and is 
predominantly albumin. Protein filtered in the glomerulus is 
reabsorbed by pinocytosis in the proximal tubule. Since 
virtually no protein is normally lost in the urine, it would 
be impossible for increases in LH concentrations to result 
from decreased renal clearance, but reduced levels could 
result from inhibition of reabsorption. For the drugs used 
here to have such an effect, it would require the cells of 
the proximal convoluted tubule to express opioid receptors. 
K-binding sites have been described in the rat kidney using
radioligand binding in kidney sections (Quirion et al, 1983). 
However, a recent autoradiographic study has demonstrated
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that the rat kidney does not possess binding sites for p,-, k- 
or 6-opioids (Dissanayake et al, 1991). The absence of k -
binding sites in the rat kidney is consistent with functional 
studies which have shown that the diuretic effects of k -
agonists are completely abolished by adrenal demedullation 
(Ashton et al, 1989). Thus, it appears that the effects of 
the opiate drugs used in the current investigation on plasma 
LH concentrations are unlikely to be a result of changes in 
renal clearance of the hormone.
Polypeptides are rapidly denatured in the circulation by 
serum proteases. This results in very short half lives of 
polypeptide hormones, such as LH, of only a few minutes. A 
change in the rate of breakdown of LH in the plasma itself 
could result from a change in activities and/or 
concentrations of proteases in the circulation. An alteration 
of protease activity would require binding of the drugs to 
the enzymes in such a manner as to alter their conformation 
or to block their active sites. It is unlikely that one, or 
all, of the drugs should have such an affinity for proteases 
that they could significantly alter the concentrations of LH 
in the plasma. To change the actual concentration of these 
proteases would involve an increase/decrease of synthesis and 
release of protein. Such events occur over a relatively long 
time course and so are unlikely to produce the acute effects 
found over the few hours of these experiments. Thus, it is 
proposed that the effects of these drugs reflect changes in 
the secretion, and not the catabolism, of LH.
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As outlined above, the secretion of LH could be modified by 
an alteration of the signal to the pituitary gonadotrophs 
(i.e. secretion of LHRH) or by changes of their 
responsiveness to this signal.
Pituitary gonadotrophs possess opioid receptors (Simantov and 
Snyder, 1977), and opiates and EOPs inhibit basal and LHRH- 
induced secretion of LH from cultured pituitary cells (Blank 
et al, 1986; Cacicedo and Sanchez-Franco, 1986). Thus, the 
possibility that opiates alter circulating LH concentrations 
at the level of the pituitary in vivo cannot be entirely 
discounted. However, it has also been proposed that opiates 
do not alter LH secretion by an action on the pituitary 
(Bicknell, 1985) but, by effects at the hypothalamus to alter 
LHRH secretion into the hypophyseal portal blood system 
(Ching, 1983). Furthermore, a highly significant correlation 
between the concentrations of LHRH in hypophyseal plasma and 
LH in the circulation is evident after systemic 
administration of catecholaminergic drugs (Sarkar and Fink, 
1981) indicating that these drugs exert their effects on LH 
via the hypothalamus. The pituitary is only sparsely 
populated with opioid receptors (Khachaturian et al, 1985) 
which suggests that the direct actions of opiates on the 
gonadotrophs may be of relatively minor importance compared 
to their effects within the CNS.
It is generally accepted that the actions of EOPs, and 
therefore opiates, in the CNS are invariably inhibitory 
(North, 1979). Reports of stimulation resulting from
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ionotophoretic application of EOPs are now considered to have 
resulted form inhibitory actions on local neurones projecting 
to the cells from which the responses were measured.
EOPs exert their inhibitory influence by hyperpolarizing the 
membrane of their target cells, ^-receptor activation
increases the calcium-sensitive potassium conductance 
(Williams et al, 1982) to decrease the action potential 
duration (North and Williams, 1983), while K-receptor
activation decreases the voltage-dependent calcium 
conductance by decreasing channel open time (Werz and 
Macdonald, 1984; Werz and Macdonald, 1985; Macdonald and 
Werz, 1986). Thus EOPs decrease spontaneous electrical 
activity and transmitter release from their target cells in 
the CNS.
The central effects of the opiates occur at hypothalamic and 
extrahypothalamic loci. Within the hypothalamus, implantation 
of naloxone into the MPO, ME and ARN stimulated LH release, 
while implants into other nuclei failed to do so (Kalra, 
1981). Furthermore, naloxone stimulates the outflow of LHRH 
from the MBH-POA of OVX, steroid-primed rats in vitro (Leadem 
et al, 1985). Thus, the effects of opiates appear to be 
confined to the preoptic-tuberal pathway which contains the 
LHRH neurones. Here, the opiates could be exerting their 
influence directly upon the LHRH neurones since they make 
functional connections in these areas (Leranth et al, 1986). 
Alternatively, or additionally, they may alter the activity
i
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of nerve terminals impinging upon the LHRH neurones, as has 
been described in detail in the Introduction.
Injection of opiates into regions outwith the hypothalamus 
can also alter LH secretion. Microinjection of morphine into 
the medial and dorsal raphe nuclei, the amygdala and the 
periaqueductal grey all suppressed LH release (Johnson et al, 
1982; Lakoski and Gebhart, 1982). These effects of opiates 
almost certainly represent actions on neurones which project, 
directly or indirectly, to the LHRH neurones in the preoptic- 
tuberal pathway. Again, these effects may be direct upon 
these neurones, or indirect via actions on nerve terminals 
located on them.
In summary, it appears that systemic administration of 
opiates could alter LH secretion by actions at both a CNS and 
pituitary level. The central actions could occur at 
hypothalamic and extrahypothalamic loci to alter, directly or 
indirectly, the secretion of LHRH from the ME. The action in 
the pituitary may alter the response of the gonadotrophs to 
the LHRH signal from the hypothalamus. This last effect may 
be of least physiological importance since it has yet to be 
demonstrated in vivo.
Catecholamine Concentrations and Neuronal Activity
The metabolites of both NA and DA were consistently below the 
level of detection of the system. It is therefore necessary
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to assess the nature of the information conveyed by the 
concentrations of the neurotransmitters alone.
In general, transmitters are synthesized in perikarya and 
transported via the axon to the nerve terminal where they are 
stored in vesicles but, in aminergic neurones some synthesis 
also occurs in the nerve terminal itself (see Figure 4). Upon 
release, they bind to their respective receptors and/or are 
metabolized or subject to re-uptake. Thus they can appear 
both intra- and extraneuronally. The perikarya of the NA and 
DA neurones lie outwith the four areas in which the 
measurements in the present study are made (with the 
exception of DA in the ARN). Released NA and DA are rapidly 
metabolized or taken up into their neurones. It follows that 
the majority of the NA and DA measured in this experiment is 
situated within the nerve terminals of their respective 
neurones.
An increase in concentration in the nerve terminal could 
result from increased synthesis, axonal transport and/or 
decreased release. Secretion of transmitter itself stimulates 
synthesis and axonal transport. Thus, only when release 
outstrips supply would concentrations of the transmitter 
fall. Intuitively, increased concentrations are likely to 
reflect decreased release. However, the information recorded 
regarding 5HT does not support this hypothesis. The 
concentration of the 5HT metabolite, 5HIAA, was within 
detectable limits in virtually every sample measured. The 
production of 5HIAA directly relates to the secretion of 5HT.
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In every instance where 5HT levels were significantly 
elevated, 5HIAA concentrations were also increased (in most 
cases significantly). It appears that when release is 
increased, so too is the replenishment process; to such a 
degree that elevated, rather than reduced, transmitter 
concentrations result. Increased transmitter concentrations 
may result from a direct stimulation of synthesis or by 
secretion-induced synthesis.
In conclusion, the evidence indicates that in the SCH, MPO,
ME and ARN, concentrations of NA and DA relate directly to 
the activity in the nerve terminals of these neurones (except 
DA in the ARN).
Opiate Effects on the LH Surge
Antagonism of EOP tone by administration of naloxone 
increases the basal release of LH in OVX rats (Sylvester et 
al, 1982). However, conflicting results have been obtained 
when the antagonist is administered to pro-oestrous or to 
OVX, steroid-primed rats, with both increases (Sylvester et 
al, 1980; Piva et al, 1985; Petragalia et al, 1986) and no 
effects (Gabriel et al, 1986) having been reported. The 
latter result indicates that EOP tone is completely abolished 
during the LH surge. The former results demonstrate that EOP 
tone may be reduced but not abolished at this time. In the 
experiments reported here, in conscious, unrestrained rats a 
marked elevation of LH surge magnitude was found after 
administration of the higher doses of naloxone, lending
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support to the hypothesis that EOP tone persists to some 
degree throughout the spontaneous LH surge.
The lower doses of naloxone failed to have a similar effect. 
This suggests that there may be a threshold below which 
antagonism of EOP tone will not succeed in augmenting the 
amplitude of the LH surge. Indeed, the LH levels that 
resulted from administration of the lower doses of naloxone 
were half those of controls. Furthermore, the lowest dose of 
Duromorph almost doubled the LH surge concentrations. These 
findings are similar to previously reported work where low 
doses of morphine increased LH surge levels (Pang et al, 
1977). Although none of the effects found here was 
significant, the results provide qualitative evidence for a 
stimulatory opioid input to the LH surge-generating system. 
Others have demonstrated such a stimulatory activity of 
opioids under certain experimental conditions (Piva et al, 
1986). As postulated earlier, an opioid autoreceptor could 
account for these actions, although the existence of such 
receptors have not been demonstrated on EOP neurones to date. 
Alternatively, a distinct stimulatory pathway may exist, and 
this possibility will be dealt with in more detail later in 
the Discussion.
The ability of morphine to suppress LH secretion has been 
demonstrated on many occasions, under various experimental 
conditions (see Kalra et al, 1989). Here, again, activation 
of jA-receptors has been demonstrated to have a profound
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inhibitory effect on the secretion of LH on the afternoon of 
pro-oestrus.
There are conflicting reports concerning the involvement of 
k - receptors in the suppression of LH secretion. Inhibition of
LH secretion has been demonstrated by administration of 
specific K-agonists (Leadem and Kalra, 1983; Marko and Romer, 
1983; Leadem and Yagenova, 1987). However, k - inhibition of LH 
secretion was questioned by the ability of a ^-antagonist to
reverse the suppression of LH release caused by the 
administration of a K-agonist (Pfeiffer et al, 1987). The
inference from this last experiment is that the inhibition of 
LH secretion by K-opioids results from the interaction of 
poorly-selective agonists with ji-receptors. In the present
study, a marked suppression of LH release was found after 
administration of very low doses of the highly selective k -
agonist, Tifluadom. The suppression was prevented by 
administration of the antagonist naloxone which binds to both 
and K-receptors. Although specific antagonists of the
receptor subtypes were not used, it is unlikely that an 
agonist, such as Tifluadom, which exhibits a selectivity of 
over two orders of magnitude greater for the K-receptor over 
the n-receptor, should exert its effects through the latter 
subtype. It is therefore proposed that the suppression of LH 
secretion, evident after administration of Tifluadom, results 
from a specific action at K-opioid receptors.
The disparity between the data obtained here and those of 
Pfeiffer et al (1987) may result from the different
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experimental models. The work showing an absence of K-action 
was carried out on OVX rats while K-suppression was found in 
intact rats on the afternoon of pro-oestrus. Since CNS ji- 
receptor populations have been shown to vary over the 
oestrous cycle, decreasing on the afternoon of pro-oestrus as 
a result of elevated circulating gonadal steroids (Limonta et 
al, 1989), it is not inconceivable that k - receptor numbers
might also fluctuate over the oestrous cycle. Thus, the 
differing results may reflect actions of gonadal steroids on 
opioid receptor numbers. It is also possible that the 
responsiveness of the cells on which the receptors are 
located varies over the oestrous cycle, as has been proposed 
for n-receptors during the preovulatory LH surge (Berglund et
al, 1988).
Very little work has been carried out to determine the 
possible involvement of a-receptors in the control of LH
secretion. Where this has been attempted, it has proved 
inconclusive (Gopalan et al, 1989). N-allylnormetazocine 
proved to have widely divergent effects on the LH surge, 
depending on the dose administered. None of the changes in LH 
concentrations were significant due to the large standard 
deviations found in all groups injected with N- 
allylnormetazocine. As pointed out earlier, this drug acts at 
a variety of receptors. Its effects on LH secretion are 
unlikely to be mediated by its action on PCP-receptors since 
these are relatively sparse in the hypothalamus and thought 
to be involved mainly in the behavioural actions of this drug 
(Largent et al, 1986). The ji-antagonist properties of N-
I
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allylnormetazocine would be expected to increase the release 
of LH as did naloxone. This was seen to result from some 
doses of N-allylnormetazocine. However, suppression of LH 
secretion was evident after administration of two of the 
doses of N-allylnormetazocine. Having eliminated PCP- and jx-
receptor mediated actions, the suppression may be ascribed to 
the o-agonist properties of the drug. This conclusion is
supported by the ability of naloxone to prevent the N- 
allylnormetazocine-induced suppression of LH levels. With the 
advent of the highly selective o-agonist, ditolylguanidine
(Weber et al, 1986), it should be possible to confirm such an 
action of o-opioid receptor activation.
In conclusion, all three of the opioid receptor subtypes 
appear to suppress LH release when activated by exogenous 
opiate agonists during the preovulatory surge. The evidence 
in favour of this hypothesis is strongest for ^-receptors, 
and weakest for a-receptors.
NA Mediation of Opiate Effects on LH
As described in the Introduction, NA is generally believed to 
be stimulatory to LHRH neurones in the presence of ovarian 
steroids but, inhibitory in their absence. Two mechanisms 
have been proposed to account for these actions of NA.
In the first scheme, both stimulatory and inhibitory NA 
inputs make direct connections to the LHRH neurones. The 
existence of such connections is supported by the ability of
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LC stimulation to inhibit the LH surge via p-receptors (Dotti
and Taleisnik, 1982 and 1984). EOPs inhibit the stimulatory 
NA input, but are themselves inhibited by E2. Thus, 
increasing E2 frees the stimulatory NA input from tonic EOP 
inhibition which over-rides the inhibitory actions of this 
catecholamine to elicit the preovulatory LH surge. This 
mechanism is summarized diagrammatically in Figure 35.
The second hypothesis involves the activation of inhibitory 
inter neurones (GABA) to mediate the inhibitory effects of NA 
on LHRH neurones. Again, a second stimulatory input is under 
tonic inhibition of EOPs and is relaxed under the influence 
of E2f resulting in the LH surge. The ability of p-adrenergic
agonists to stimulate LH release (Al-Hamood et al, 1985) 
supports the existence of such an interneurone pathway since 
p-activation is generally held to have an inhibitory action 
on its target cell. Thus, p-stimulation of LH release may 
result from the suppression of the activity of inhibitory 
interneurones projecting to the LHRH neurones, rather than 
direct stimulation of the LHRH cells themselves.
Regardless of which of the above paradigms is active, opiate 
suppression of LH release would be expected to involve a 
decrease of NA activity in the areas containing LHRH 
neurones. Morphine has been shown to decrease NA turnover in 
the MPO concomitant with its suppression of LH release in 
OVX, steroid-primed rats (Akabori and Barraclough, 1986).
This finding is consistent with the hypothesis that ji-
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Oestrogen switch
Without oestrogenWith oestrogen
NA
NA,
EOP,
GnRH
GnRH
Figure 35. The ’Oestrogen Switch'; a diagrammatic 
representation of the different balance of the direct 
excitatory and inhibitory NA inputs to the LHRH-release 
system, brought about by the presence or absence of 
oestrogen. EOPs suppress the stimulatory input to the LHRH 
cells. The EOP neurones concentrate, and are inhibited by, 
oestrogen. Thus, in the presence of high levels of oestrogen, 
the excitatory NA input is released from tonic EOP 
suppression, and stimulates the preovulatory LH surge. Fronts 
Grossman and Dyer, 1989.
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suppression of the LH surge is mediated by inhibition of a 
stimulatory NA input to LHRH neurones in the MPO.
Administration of Duromorph to pro-oestrous rats generally 
elevated NA activity in the areas studied. The elevation 
occurred most consistently in the ME, where the increased 
activity was reversed by naloxone, indicating that it 
resulted from a specific action at opioid receptors. If the 
action of Duromorph in the ME is responsible for the opiate's 
suppression of LH release, an inhibitory role for NA in the 
ME can be inferred. The involvement of an inhibitory action 
of NA is somewhat surprising because NA is generally believed 
to be stimulatory in the presence of E2 (Grossman and Dyer, 
1989). However, opioid receptor activation mimics the high 
EOP tone which exists in the absence of steroids, and the 
work of Dotti and Taleisnik (1982) demonstrates that an 
inhibitory NA input to the LHRH neurones can be activated on 
pro-oestrus. Thus, an inhibitory action of NA is not to be 
wholly unexpected. As opioid receptor activation has an 
inhibitory effect on the electrical activity of the cell on 
which it is situated (North, 1979), the stimulation of NA 
found here must involve the suppression of activity in an 
inhibitory, non-opioid interneurone.
The effects of the k -  and a-agonists on NA activity in the ME 
were almost identical to those of Duromorph at doses which 
decreased the amplitude of the preovulatory LH surge. 
Tifluadom and N-allylnormetazocine also produced this effect 
in the MPO. Thus the inhibitory NA pathway may project to
|
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LHRH neurones at the level of the MPO as well as the ME, and 
these neurones may also be activated by k - and a-opioid
agonists.
In summary, pi-, k - and a - inhibition of the preovulatory LH 
surge may involve the activation of an inhibitory NA input to 
the LHRH neurones of the preoptic-tuberal pathway. This may 
act in concert with the more widely accepted suppression of 
the stimulatory NA input to the MPO caused by opiates 
(Grossman and Dyer, 1989).
DA Mediation of Opiate Effects on LH
DA is not considered to play a primary role in the generation 
of the LH surge (see Ramirez et al, 1984). However, 
manipulations of the DA systems projecting to the preoptic- 
tuberal pathway can alter LH secretion. As detailed in the 
Introduction, the effects of DA on LH release are dependent 
on the system involved; the tuberoinfundibular system being 
inhibitory in the ME and the incertohypothalamic being 
stimulatory in the MPO. DA turnover in the ME is decreased on 
pro-oestrus (Ahren et al, 1971), implicating a reduction of 
its inhibitory influence in the elevated release of LHRH 
during the preovulatory LH surge. However, a stimulatory 
action of DA prior to the surge has also been elucidated, and 
this was mediated by receptors pharmacologically distinct 
from those which cause inhibition (Sarkar and Fink, 1981).
For the opiate agonist inhibition of the surge to be mediated 
by alterations of DA neurotransmission, one would expect an
increase in DA activity in the ME and/or a decrease in the 
MPO. The effects of the opiate agonists in these areas were 
inconsistent with their effects on the LH surge, confirming 
that this neurotransmitter may be of minor importance in the 
mediation of opiate inhibition of the surge.
The antagonist, naloxone, exhibited a more consistent pattern 
of effects on the DA activity, which indicated that 
naloxone's enhancement of the surge may be mediated, in part, 
by increasing the stimulatory action of DA in the MPO. 
However, the opiate agonists failed to alter the increased DA 
activity in the MPO which was caused by naloxone, but did 
prevent its stimulation of the LH surge. This suggests that 
DA mediation of the naloxone-induced increase in the LH surge 
amplitude may be of relatively little importance.
The results for DA are equivocal, and suggest that DA may be 
of little importance in the mediation of opiate modulation of
the preovulatory LH surge. The feedback effects of the
ovarian steroids on the two DA systems may thus be direct, or
be mediated by a neural system other than EOPs.
Given that many DA cells of the tuberoinfundibular tract 
concentrate P (Fox et al, 1990), it would appear that P may 
act directly upon neurones of this tract to decrease their 
activity on the afternoon of pro-oestrus (Ahren et al, 1971; 
Kerdelhue et al, 1989). If so, DA in the MPO may be involved 
in the P-enhancement of the surge, rather than possessing an 
obligatory role in its initiation.
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Concentration of ovarian steroids by the DA neurones of the 
incertohypothalamic tract has not been demonstrated. However, 
it has been noted that GABA and DA produce reciprocal effects 
on LHRH secretion in the MPO; the former being inhibitory and 
the latter stimulatory (Wilson et al, 1990). It is possible 
that GABA exerts its influence on LHRH neurones in this area 
by altering DA activity, in addition to its widely known 
effects on NA neurotransmission (Adler and Crowley, 1986; 
Herbison et al, 1990).
5HT Mediation of Opiate Effects on LH
The physiological role of 5HT in the regulation of LH 
secretion has not been definitively established. The reports 
of the effects of 5HT have ranged from stimulation to 
inhibition, and to no effect on LH release.
The inhibitory effects of 5HT may result from an action 
mediated by other neuronal systems, since blockade of the LH 
surge by stimulation of the medial raphe nucleus is dependent 
on GABA (Morrello and Taleisnik, 1989).
When isolated from pro-oestrous rats, the ME will release 
LHRH in response to 5HT (Vitale et al, 1985). This 
observation clearly establishes a facilitatory role for 5HT 
in the ME in the modulation of LH secretion on pro-oestrus. 
Further support is seen in the naturally occurring increase 
of 5HT activity in the ME on the afternoon of pro-oestrus
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(Kerdelhue et al, 1989). Increased 5HT synthesis in the MPO 
of OVX rats in response to ovarian steroids (King and Kang,
1988) points to a stimulatory role for 5HT in this area also. 
Thus, opiate agonist inhibition of the LH surge should 
involve decreased activity of 5HT in the MPO and ME, if 
opiate effects on LH are mediated by 5HT neurones.
The conclusion from the current experiments is that 5HT may 
not play a pivotal role in mediating the suppression of the 
LH surge caused by the opiate agonists. However, some 
evidence was provided which implicated a stimulatory action 
of 5HT in the MPO and ME in the mediation of the naloxone- 
induced enhancement of the LH surge, and that this 
stimulatory action appeared to be via ji-receptors; an
intriguing finding, since recent evidence has been provided 
which indicates that 5HT systems are involved in P- 
enhancement of the surge (King and Kang, 1988). Thus, 5HT may 
be involved in ’fine-tuning' the surge, rather than being 
essential for its initiation. The results presented here are 
consistent with the hypothesis that P-enhancement of the 
surge via stimulatory 5HT systems may involve reduced 
activity of EOP neurones.
As outlined earlier, increased 5HT activity in the MPO was 
interpreted as being representative of a stimulatory 
influence on LHRH neurones. The opiate agonist suppression of 
the LH surge in association with elevated 5HT concentrations 
in the MPO appears to contradict such a conclusion. In the 
earlier discussions, the disparity between the effects of the
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agonists and antagonist on 5HT and LH was attributed to the 
more profound influence of NA on the activity of LHRH 
neurones. However, it is possible that the agonists increased 
5HT activity to stimulate GABA neurones, thus inhibiting the 
surge (Dotti and Taleisnik, 1989), while the antagonist 
activated a direct stimulatory action of 5HT on LHRH 
neurones.
In summary, no clear evidence of 5HT involvement in opiate 
inhibition of the LH surge was provided by the present study. 
However, naloxone-induced elevation of the LH surge amplitude 
may involve antagonism of EOPs, principally at ^-receptors,
to release a stimulatory 5HT input to the LHRH neurones from 
tonic EOP inhibition. It is proposed that such a reduction of 
EOP activity at 5HT neurones may be involved in the 
enhancement of the surge produced by P.
Conclusion
Morphine has long been known to have a profound inhibitory 
influence on the secretion of LH, including the preovulatory 
surge on pro-oestrus; an action mediated by n-opioid
receptors. Conflicting results have been obtained for the 
involvement of k - receptors in opiate suppression of LH 
release, and the possible involvement of a-receptors has not 
been the subject of extensive investigation. The experiments 
reported here provide strong evidence that a heterogeneous 
population of n- and K-receptors are involved in the central
suppression of the LH surge by opiates. Furthermore, some
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evidence is provided that cr-opioid receptors may also be 
involved in the central EOP systems which inhibit LH release.
The effects of the opiates on NA activity in the hypothalamic 
nuclei suggest that they may inhibit the LH surge by 
activating an inhibitory action of NA in the preoptic-tuberal 
pathway, in addition to the well-established inhibition of 
stimulatory NA inputs to the LHRH system. The activation of 
this inhibitory NA influence appears to involve a 
heterogeneous population of ji-, k- and a-opioid receptors.
The naloxone-induced enhancement of the LH surge amplitude 
may involve activation, principally through antagonism at jt-
receptors, of a stimulatory 5HT input to LHRH neurones in the 
MPO and ME. There is less convincing evidence which suggests 
that a stimulatory DA system projecting to the MPO may also 
be involved in the mediation of the naloxone-enhancement of 
the LH surge.
RECOMMENDATIONS FOR FURTHER STUDY
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In the experiments presented here, opiate suppression of the 
preovulatory LH surge by a mixed population of receptors has 
been clearly demonstrated. Furthermore, some evidence is 
provided which indicates that these opioid receptors may be 
located on monoamine neurones which project to the LHRH 
neurones of the preoptic-tuberal pathway. To further 
investigate the above findings, acute central administration 
of the opiates could be used. To this end, indwelling 
intracranial cannulae could be placed (under anaesthesia) to 
allow for ICV administration of drugs to conscious, 
unrestrained animals. Such a method of administration would 
provide for the deposition of drugs in predominantly 
hypothalamic loci, without the possible unintentional 
ablation of neurones within, or projecting to, the 
hypothalamus itself. Again, various doses would be 
administered at 12.30h on pro-oestrus to find the minimum 
amount of a particular drug which could successfully alter 
the magnitude of the preovulatory LH surge. This would be 
determined by withdrawal of serial blood samples throughout 
the morning and early evening of pro-oestrus to measure 
circulating LH levels.
To elucidate the possible involvement of hypothalamic 
monoamines in the mediation of the effects of the opiates, 
drugs would be administered as above (at the minimum 
effective dose), and the animals decapitated at 14.30h. The 
brains would be removed and the MPO and ME isolated as 
described earlier. The monoamine contents of these two nuclei 
would then be determined by HPLC-ECD. To further investigate
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the opioid receptor subtypes involved, specific antagonists 
of each subtype could be co-administered with their 
respective agonists, and the effects on LH secretion, and 
monoamine activity in the hypothalamus, determined.
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